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Wilson disease protein (WLNP) is a P1b-type ATPase crucial for maintaining
copper homeostasis in humans.

Mutations in this protein result in the autosomal

recessive disorder Wilson disease, a condition characterized by copper accumulation in
the liver and brain. WLNP provides copper for incorporation into cuproproteins and
exports excess copper into the bile for excretion. There are six metal-binding domains
(MBDs) in WLNP, found within the first 650 amino acids of this 1,465 amino acid
protein. Though each MBD has a different amino acid sequence, all MBDs possess a
similar ferredoxin fold with a conserved hydrophobic core and a MXCXXC metalbinding motif.
The manner in which the six MBDs communicate with each other and how they
affect other cytosolic-facing domains of WLNP is not understood. There is a long linker
between the fourth and fifth MBDs that provides spatial separation between the first four
and the last two MBDs. To better understand how the first four MBDs function, I
pursued a detailed biophysical characterization of these domains.

Strikingly, when

MBD4 is expressed by itself, it is highly resistant to both chemical and thermal
denaturation: 50% of its structure is retained in 5.9 M guanidine hydrochloride (GuHCl)
and it has a melting temperature of 78˚C. In contrast, when MBDs1-3 are expressed

together as a single protein, 50% of its structure is retained at 2.3 M GuHCl and the
melting temperature is 58˚C. Furthermore, the unusual stability of MBD4 is preserved
when it is expressed in a protein construct that contains all four MBDs (MBDs1-4). In
MBDs1-4, denaturation by GuHCl produced a double sigmoidal curve in which the
second sigmoid correlated with that of MBD4 while the first one correlated with MBDs13.

MBD4 also influenced the thermal denaturation of MBDs1-4, albeit in a more

complicated manner.

MBDs1-4 did not display a thermal unfolding transition and

instead underwent a structural rearrangement that resulted in soluble aggregation.
Though the extreme conditions that MBD4 can withstand are never experienced in vivo,
the enhanced stability of this domain may play a role in its ability to serve as a primary
target of copper acquisition.
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CHAPTER 1
COPPER HOMEOSTASIS

1.1

Eukaryotic Copper Requirements
Copper is an essential trace metal that is required by all eukaryotes. It is used as a

catalytst and structural cofactor in proteins that have a wide range of functions, including
superoxide detoxification, iron metabolism, energy production, and neurotransmitter
production (Table 1.1) (1–4). Another important class of copper-containing protein
transport copper around the cell to specific destinations. These proteins are known as
metallochaperones, examples of which are shown in Table 1.2.
Copper is acquired through diet and is primarily found in liver, shellfish, mushrooms,
nuts, and seeds. An adult human contains about 110 mg of copper, making copper one of
the most abundant inorganic trace metals in the body, after iron and zinc (5, 6).

Table 1.1: Some copper containing enzymes in humans and their functions.
Protein
Ceruloplasmin
Cytochrome c oxidase
Cu/Zn superoxide
dismutase (SOD)
Dopamine βhydrolase
Hephaestin
Lysl oxidase
Tyrosinase

Function
Iron metabolism; oxidixes Fe(II) to Fe(III),
which is transported by transferrin
Final enzyme in the mitochondrial electron
transport chain
Antioxidant protection; catalyzes the
dismutation of superoxide to hydrogen
peroxide and dioxygen
Oxygenates dopamine to produce
norepinephrine
Iron metabolism; helps dietary iron cross the
small intestine into the blood
Connective tissue formation; crosslinks
collagen and elastin
Involved in melanin synthesis

1

Reference
(2)
(7)
(8)

(9)
(2)
(10)
(11)

Table 1.2: Human metallochaperones and copper pumps.
Protein
CCS (copper
chaperone
for SOD)
COX17

Function
Metallochaperone; transports Cu(I) to SOD

Reference
(12)

Metallochaperone; transports Cu(I) to Sco1 and
COX11for insertion into mitochrondrial cytochrome c
oxidase

(13)

HAH1
(ATOX1)

Metallochaperone; transports Cu(I) to either Menkes
protein or the Wilson disease protein

(14)

Menkes
protein

ATPase pump; embedded in the membrane of most nonliver cells; helps to control the absorption of dietary
copper; also pumps Cu(I) to the interior of the transGolgi network for incorporation into cuproproteins;
helps to remove excess Cu(I)
ATPase pump; embedded in the membrane of the transGolgi network in hepatocytes; pumps Cu(I) from the
cytosol to the interior of the trans-Golgi network for
incorporation into cuproproteins; helps to remove excess
Cu(I)

(15)

Wilson
disease
protein

1.2

(16)

The Need for Copper Homeostasis
While copper is necessary for vital processes and for normal growth and

development, excess or unligated copper is toxic. Consequently, copper levels must be
carefully regulated to ensure that adequate copper is available to meet biological demand
while avoiding the hazards that copper poses.
The danger that copper presents comes from the same feature that makes copper a
valuable enzymatic cofactor – its ability to participate in redox reactions. Unligated
copper can produce reactive oxygen species (ROS) which have been linked to cellular
aging, protein and lipid oxidation, DNA/RNA damage, and cancer (17–19).
2

A

particularly potent ROS, the hydroxyl radical, is created when Cu(I) catalyzes the Fenton
reaction, shown below in Equation 1.1 (17).

[Equation 1.1]

Another way that copper can damage cells is by displacing other metals from their
binding sites in proteins. Cu(II) is near the top of the Irving-Williams series and can
displace weaker binding ions such as iron (20) and zinc (21) from proteins (22).
Unligated copper poses the greatest threat; consequently, cells have developed
strategies to minimize this. These strategies include the use of metallochaperones to bind
copper as soon as it enters the cell and ferry it to its destination as well as meticulously
regulating intracellular copper levels to prevent copper excess. Additionally, glutathione
binds copper and offers another form of cellular protection (23, 24). As a result of this
careful orchestration, the unligated copper concentration is quite low; Rae et al. have
shown that there is less than 1 atom of free copper in the yeast cells (25), and this value
is expected to be similar in human cells.
Copper’s importance as a cofactor in enzymes stems from its ability to cycle
between two states – Cu(I) and Cu(II). The redox potential of both of these forms of
copper are biologically accessible, with the specific redox potential being determined by
the nature of the microenvironment created by the protein at the metal-binding site, the
identity of the specific ligands that are supplied by the protein, and the environment the
protein is in. Cu(I) can be readily oxidized during redox reactions and is typically ligated
by softer ligands such as the sulfur atoms in cysteine and methionine. Cu(II), on the
3

other hand, can be readily reduced during redox reactions; this form of copper prefers the
oxygen atoms in the side chains of aspartate or glutamate or the imidazole nitrogen of
histidine. Cu(I) and Cu(II) have different geometries, with Cu(I) favoring trigonal planar
and Cu(II) favoring square planar or square pyramidal geometry. Enzymes that have
copper cofactors must be able to adapt to the different geometries favored by the cuprous
and cupric ions that are formed during the various stages of the redox reaction (26).

1.3

Copper Movement in Eukaryotes
Copper movement is carefully orchestrated to ensure that the demand for copper is

met while preventing excess and unligated copper from accumulating in the cell. This
encompasses the use of copper metallochaperones to bind copper upon its entering the
cell and transferring it to specific destinations as well as the removal of excess copper
from the cell before the cell’s chelation capacity is reached (27, 28).
Absorption of dietary copper occurs in the small intestine (29). Copper enters the
enterocytes through Ctr1, an integral membrane protein that is 190 amino acids long. It
contains several distinct regions, including three transmembrane domains (with a MX3M
motif present in the second transmembrane region), a cluster of cysteines and histidines
in the intracellular C-terminal domain and a methionine rich, extracellular N-terminal
domain (30). Experiments using x-ray crystallography, cryo-electron microscopy and
2D crystallography have revealed that Ctr1 is functionally active as a homotrimer, with a
cone-shaped pore at the center of the trimer through which Cu(I) traverses the membrane
and enters the cell (31, 32). Ctr1 does not transfer Cu(II).

As extracellular copper is

usually present as Cu(II), it requires reduction prior to being transported by Ctr1. A
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recently identified family of reductases known as Steap proteins reduce cupric ions at the
brush border of enterocytes, enabling the entry of Cu(I) into the cell via Ctr1 (33).
Upon entry into the cell, copper is acquired by various metallochaperones that
transport the copper to specific cellular destinations. The exact mechanism by which the
metallochaperone itself acquires the copper is not presently known.

Protein-protein

interactions between the metallochaperone and Ctr1 may facilitate the transfer of copper,
or perhaps a small ligand like glutathione acts as an intermediary between Ctr1 and the
metallochaperone, as Maryon et al. have suggested (34).
metallochaperones have been identified in humans.

At present, three

One metallochaperone, CCS,

transports copper to SOD (28). Another metallochaperone, COX17, is located in the
mitochondria and transfers copper to Sco1 and COX11; Sco1 donates copper to the CuA
site in the cytochrome c oxidase (CCO) complex while COX11 donates copper to the
CuB site (28).
elucidated.

How copper is transported to the mitochondria has not yet been

A third metallochaperone is HAH1, which transports copper to Wilson

disease protein (WLNP) and Menkes protein (27, 35).

Wilson disease protein is

expressed in the liver, brain, kidney, and mammary glands while Menkes protein is
expressed in all other tissue (36). A diagram of copper movement in hepatocytes is
shown in Figure 1.1.
Wilson disease protein and a related protein, Menkes protein, are located in the
membrane of the trans-Golgi network where secreted cuproproteins acquire copper prior
to being exported. Under basal conditions, these PIB-type ATPases accept copper from
HAH1 and pump it across the membrane into the interior of the trans-Golgi network by
hydrolyzing ATP; this is discussed in greater detail in Section 1.4. In hepatocytes,
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copper is incorporated into the multi-copper ferroxidase ceruloplasmin which is then
secreted into the bloodstream. Despite containing over 95% of the copper that is found in
the plasma, however, ceruloplasmin does not appear to play in pivotal role in copper
metabolism; mice lacking ceruloplasmin do not display abnormal copper absorption or
excretion (37). Under conditions of copper excess, Wilson disease protein and Menkes
protein translocate to cytosolic vesicles and migrate to the plasma membrane, where they
fuse with it and transport copper from the cell (36, 38). In hepatocytes, the excess copper
is transferred to the bile and excreted. In enterocytes, excess copper is translocated
across the basolateral membrane and enters the blood stream for distribution. Most of the
copper ends up in the liver, as it is the major site of copper homeostasis (39).
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Figure 1.1: Intracellular copper transport in eukaryotes. Copper enters the cell as Cu(I)
through Ctr1, an integral membrane protein. Once in the cell, copper is immediately
acquired by either a small molecular weight ligand or a metallochaperone which then
ferries the copper to a specific cellular destination. (I) The transportation of copper to
the mitochondria has not been elucidated. Once copper enters the mitochondria,
however, it is acquired by the metallochaperone Cox17. Cox17 delivers copper to Sco1
and Cox11, which transfers copper the CuA site in Cox1 or the CuB site in Cox2 in the
CCO complex. (II) HAH1 transports copper to the Wilson disease protein or Menkes
protein that is embedded in the trans-Golgi network (TGN). Under basal copper
conditions, these ATPases pump copper across the membrane into the interior of the
trans-Golgi network (TGN). In response to excess copper, Wilson disease protein and
Menkes protein translocate into vesicles and migrate to the plasma membrane, where
they exports copper from the cell. In enterocytes, copper is released into the blood for
delivery to other tissues. In hepatocytes, the copper goes into the bile duct for excretion.
Copper excretion is impaired in Wilson disease, resulting in the accumulation of copper.
(III) The metallochaperone CCS transports copper to superoxide dismutase (SOD).
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Defects in Menkes protein and Wilson disease protein result in severe diseases
known as Menkes disease and Wilson disease, respectively. In Menkes disease, copper is
not exported from the small intestine, resulting in intestinal copper accumulation and
copper deficiency in all other tissues; this disease is characterized by neurodegeneration,
growth failure, kinky hair, and early death (40, 41). In contrast, Wilson disease results
when copper removal is impaired, resulting in the accumulation of excess copper in the
liver and brain; this disease is characterized by liver cirrhosis as well as psychological
and neurological damage (42).

At present, there is no cure for Menkes disease and

treatment is merely supportive; the disease is often fatal in childhood (43). No cure
presently exists for Wilson disease, though the condition can be managed with copper
chelating drugs, dietary restrictions, and liver transplants (44). The location of the
mutation in the Wilson disease protein determines the severity of the disease, with
mutations in highly conserved regions resulting in a more severe form of the disease (45).

1.4

Wilson Disease Protein

1.4.1

Structural Features
Menkes protein and Wilson disease protein are both heavy metal pumps

belonging to the family of PIB-type ATPases. These ATPases are evolutionary related
among all three domains of life and contain five primary structural domains: the
transmembrane domain (TM-domain), the actuator domain (A-domain) and a large,
cytosolic N-terminal metal-binding domain; two other domains, the phosphorylation
domain (P-domain) and the nucleotide binding domain (N-domain), are collectively
referred to as the ATP-binding domain. A cartoon representation of WLNP is shown in
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Figure 1.2. The mature Wilson disease protein contains 1,465 residues and has a mass of
157 kD while Menkes protein contains 1,500 amino acids and has a mass of 163 kD.
The TM-domain consists of eight helices that function to move copper across the
membrane of the trans-Golgi network. There are several conserved residues in these
helices, including a CPC tripeptide motif in the sixth helix, a YN dipeptide motif in the
seventh helix, and a methionine and serine in the eighth helix; the necessity of some of
the conserved residues have been established by site-directed mutagenesis (46). The
cysteines in the CPC motif are believed to ligate copper as it moves through membrane,
as altering these residues in CopA, the Wilson disease homologue found in E. coli,
abolishes copper transport (47).
The P-domain and the N-domain are together referred to as the ATP-binding
domain. The ATP-binding domain has a dual purpose – to bind and hydrolyze ATP to
provide energy to move copper across the membrane as well as to phosphorylate itself as
part of the catalytic cycle. An aspartate residue that is present in the conserved DKTGT
motif is phosphorylated during the course of the catalytic transfer cycle, which is shown
in Figure 1.3. The A-domain, located between the fourth and fifth transmembrane
helices, dephosphorylates the aspartate residue in the DKTG motif to restore WLNP to its
initial state. A conserved glutamate, found within a TGE tripeptide sequence, assists with
the dephosphorylation.
Wilson disease protein pumps copper across the membrane of the trans-Golgi
network according to the Post-Albers scheme (48, 49), as shown in Figure 1.3. There are
four states that occur during the transport cycle – E1, E1P, E2P, and E2. E1 has a high
copper affinity while E2 has a low copper affinity; phosphorylation is denoted by P.
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Binding of copper to the metal-binding domains triggers a rearrangement that
makes it possible for ATP to bind to the N-domain; the copper then moves to the CPC
motif in the sixth transmembrane helix (E1) (50). The hydrolysis of ATP yields energy
and a phosphate group that is then used to phosphorylate the conserved aspartate residue
in the DKTG motif in the P-domain; the copper is then moved to the metal-binding site
located inside the membrane; this is the E1P state. The E2P state is characterized by the
release of copper into the interior of the trans-Golgi network. To conclude the cycle, the
aspartate is dephosphorylated by the conserved TGE motif in the A-domain, and the
protein is in the E2 state and ready to begin the cycle anew. The A-, N-, and P- domains
experience large relative movements during the catalytic cycle that correlate with the
movement of the transmembrane helices (50).
The foundation for understanding the catalytic transport cycle of Wilson disease
protein comes from studies that have been done on SERCA1a, a PIIA-type ATPase that
transports Ca(II) into the lumen of the sarcoplasmic reticulum by using energy from ATP
hydrolysis (51–53). All P-type ATPases are believed to operate in the same manner as
SERCA1a (54).
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Trans-Gogli Membrane

Figure 1.2: Schematic of the Wilson disease protein and its acquisition of copper. A, P,
and N denote the actuator domain, the phosphorylation domain, and the nucleotide
binding domain, respectively. The transmembrane regions are denoted by “TM” while
the metal-binding domains are denoted by MBD followed by a number. The numbers
between the MBDs indicate the length of the linker between the domains. The MBDs
acquire Cu(I) from HAH1 and transport it to the inside of the trans-Golgi network under
basal conditions. Under conditions of copper excess, WLNP relocates to cytosolic
vesicles and migrates to the cell membrane to export copper from the cell.
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Figure 1.3: Post-Albers scheme of the catalytic cycle of the Wilson disease protein,
adapted from Banci et al. (50). E1 has a high affinity for copper while E2 has a low
affinity.

The N terminal metal-binding domain is comprised of smaller, individual metalbinding domains, each capable of binding one atom of Cu(I) in a distorted linear motif
(55, 56). The number of tandem repeats of the metal-binding domains (MBDs) varies
among species. The yeast homologue, known as Ccc2, has two metal-binding domains,
enabling it to bind only one atom of Cu(I) per domain (57). Human Wilson disease
protein and Menkes protein each possess six metal-binding domain repeats. In rats and
mice, the Wilson disease protein has five metal-binding domain repeats, with the fourth
being omitted based on sequence homology to the human Wilson disease protein (58).
Drosophila melanogaster (fruit fly) contains four metal-binding domains (59) while
Caenorhabditis elegans contains three (60).
12

Though the individual metal-binding

domains all have the same three dimensional structure, a βαββαβ arrangement known as
a ferredoxin fold, the primary structures of the domains are different (58). The NMR
solution structure of the third metal-binding domain of Wilson disease protein is shown
in Figure 1.4 as an example of a ferredoxin fold (61).
A crystal structure does not exist for the intact Wilson disease protein. However, in
2011 the crystal structure of the apo form of CopA, a homolog of Wilson disease protein,
from Legionella pneumophila was determined at a resolution of 3.2 Å (62); a ribbon
diagram of the structure is shown in Figure 1.5. CopA contains one metal-binding
domain, but it position could not be modeled due to its mobility. Some unassigned
electron density permitted researchers to assign the region to a general area, however.
That location is one of the three places suggested by cryo-electron microscopy to be the
location of the metal-binding domain for CopA from Archaeoglobus fulgidus (63),
corroborating the L. pneumophilia model (62).
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Figure 1.4: The NMR solution structure of the third metal-binding domain of Wilson
disease protein, modified from PDB 2ROP. The red α-helices and yellow β-sheets of the
ferredoxin fold are shown. The two side chains of the two metal-binding cysteines,
located in the solvent exposed loop between the first β-sheet and the first α-helix, are
shown as orange sticks (61).
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Figure 1.5: A cartoon model of CopA (apo form) from L. pneumophila, modified from
structure 3RFU from the PDB (62). The actuator, nucleotide binding domain, and
phosphorylation domains are shown in yellow, cyan, and green, respectively. The metalbinding domain is shown as a transparent lavender sphere. Six of the transmembrane
helices are shown in orange while the two helices that form the platform are shown in
red. Copper movement is shown, with the blue boxes denoting the transmembrane
binding sites. In the larger rectangle, the side chains of the cysteines and proline in the
conserved CPC motif are shown in yellow and purple, respectively.
15

The crystal structure of CopA revealed that two of the helices appear to form a
cytosolic platform, shown as red helices in the figure above. This platform may facilitate
the transfer of copper from the metal-binding domains to the copper binding site within
the membrane; upon crossing the membrane, the copper is released into the lumen. One
of the helices, termed MB, is kinked and forms the putative platform. It is proposed that
HAH1 can deliver copper directly to the platform and bypass the metal-binding domains
(62); if this is true, then the metal-binding domains may have more of a regulatory role,
as others have suggested (63–65).
Comparing the sequences of CopA proteins from various species revealed that the
most highly conserved residues were located in the core of the protein, including in the
putative platform area (62); this is shown in Figure 1.6. Using this structure as a
template and mapping the features of WLNP onto it, Gourdon et al. observed that
mutations in the highly conserved core region give rise to more serious forms of Wilson
disease. Several mutations occur near the phosphorylation site in the P-domain. The
most common mutation, H1089Q, occurs in the ATP-binding pocket of the N-domain
while the most common mutation in Asian populations, R778L, occurs near the platform
entry site; several other mutations are also located near the platform, underscoring the
importance of this region (45).
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Figure 1.6: Conservation of residues among CopA proteins (62). The blue mesh shows
the believed location of the metal-binding domain. The most conserved regions are
located near the platform, indicated by the arrow. Using this structure as a template to
construct a model of WLNP revealed that the most damaging mutations are located in the
heavily conserved regions, particularly the platform area. Used by permission of Nature
Publishing Group.

The presence of multiple metal-binding domains in the N-terminal region has
prompted considerable interest, particularly with understanding why humans have six.
Linkers of various lengths connect the metal-binding domains, providing an inherent
separation between the metal-binding domains that may be significant. The lengths of
the linker regions in human Wilson disease protein are shown in Figure 1.2. There is
speculation that the domains are not all functionally equivalent and some may have more
of a regulatory role (63–65).
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Attempts to recombinantly express and purify large quantities of full length
Wilson disease protein or Menkes protein have not been successful to date, owing to the
difficulties inherent with expressing large transmembrane proteins.

Consequently,

researchers have instead focused on expressing and characterizing individual domains
and combinations of domains, such as the MBD4 (66), MBD3-4 (61), or the actuator
domain (50) of Wilson disease protein and MBD3 (67) or the actuator domain (50) of
Menkes protein. By studying the structure and function of its constitutive domains,
researchers hope to understand how the intact proteins function.

1.4.2

Copper Acquisition by the Metal-Binding Domains
One aspect of WLNP that has garnered a lot of focus is the MBDs, particularly

with regard to delineating the mechanism by which copper is transferred between the
MBDs and from HAH1 to the MBDs. By studying the copper binding affinities of the
MBDs and HAH1, X-ray crystal structures of HAH1 complexed with various metals, and
titrations of the MBDs with either copper loaded HAH1 or other copper loaded MBDs,
researchers have learned about copper transfer and the driving forces behind copper
movement.

HAH1 is comprised of 68 amino acids that are arranged in the same

βαββαβ motif possessed by each metal-binding domain in WLNP. The similarity in
structure between the chaperone and the target protein is a noticeable feature of proteins
involved in copper homeostasis. The copper binding CXXC motif in HAH1 is located in
the solvent accessible loop between the first β-sheet and α-helix, the same location as in
WLNP (68). HAH1 acquires Cu(I) after import into the cell and transports it to WLNP
(16).
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Determining the copper affinities of HAH1 and the MBDs has proven
challenging, with different techniques and different ligands yielding different absolute
values that vary over several orders of magnitude (69–71).

One reason for the

discrepancy is the limitations of the method chosen. The best way to obtain accurate
values is to perform competition experiments in the presence of the protein using small
ligands with known formation constants. This is non-trivial, because the small ligand
needs to have an affinity for copper close to that of the protein and thereby buffer the
‘free’ copper in solution. Recent developments have led to the synthesis of new ligands
that meet these criteria (72). Using the Cu(I) chelators BCS and BCA, Xiao et al.
reported Cu(I) apparent dissociation constants (reported as logKD’) for HAH1 and
WLN5-6 to be -17.4 and -17.6, respectively (71). Both of these proteins bind copper
with high affinity, yet are also able to transfer copper efficiently. Future experiments are
planned to attain greater accuracy and understanding of copper binding to these types of
sites (71–73).
Copper transfer from HAH1 to constructs of either single or multiple MBDs has
been monitored using NMR. In 2006, Achila et al. examined the acquisition of copper by
the two MBDs that are closest to the transmembrane region – WLN5-6 (66). When
apoWLN5-6 was titrated with Cu(I)-HAH1, neither complex formation between the two
proteins nor copper exchange was observed. In contrast, when apoWLN5-6 was titrated
with Cu(I)-WLN4, partial copper transfer did occur, first to MBD6 and then to MBD5,
though no complex formation was detected. The same study also found that titrating
apoWLN4 with Cu(I)-HAH1 led to both copper transfer and the detection of an adduct
that was in fast exchange on the NMR timescale. Additionally, the researchers found that
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titrating apoWLN2 with Cu(I)-HAH1 also resulted in the formation of an NMRobservable adduct, though it was formed in smaller amounts than the adduct that was
formed with WLN4. Furthermore, apoWLN5-6 behaved as a unit in solution.
WLN3-4 was investigated by Banci et al., who found that the MBDs rotated
independently of each other in solution (61). Titration of apoWLN3-4 with Cu(I)-HAH1
led to the formation of an NMR-observable complex with MBD4 that was in fast
exchange; no complex formation was detected for MBD3, however, and MBD3 did not
acquire copper.
While the studies with constructs of double MBDs yielded important evidence as
to how copper transfer occurred, it remained to be answered whether or not the behavior
of these truncated constructs accurately reflected what occurs in the intact metal-binding
domain of WLNP. The above results were consistent with other studies that showed that
interaction (74).
In 2009 Banci et al. reported on the interaction of WLN1-6 with Cu(I)-HAH1
(75). In contrast to previous studies, this one reported that each of the six MBDs could
acquire copper from Cu(I)-HAH1.

Additionally, MBDs 1, 2, and 4 formed NMR-

observable complexes, as evidenced by shifts in the backbone amides chemical shifts; the
complex formation between Cu(I)-HAH1 and MBDs 2 and 4 were in agreement with
what was previously reported (61, 66). The authors confirmed that MBDs 3, 5, and 6
acquired copper directly from HAH1 and not from intramolecular copper transfer from
other MBDs by mutating the cysteines in the CXXC motifs to alanine in domains 1, 2,
and 4. Titrating this mutated construct, which was unable to bind copper in the mutated
domains, with Cu(I)-HAH1 still resulted in the transfer of copper to MBDs 3, 5, and 6.
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As no complex formation was observed, this indicated that the exchange was slow on the
NMR timescale. Unfortunately, the NMR solution structure for WLN1-6 could not be
determined; the construct contained 633 residues, had limited solubility, and degraded
significantly over 48-72 hours, thereby complicating efforts at determining a structure.
A study done on the structural and dynamic properties of apo and Cu(I)WLN4-6
yielded results that were not in complete agreement with the above studies (76).
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relaxation experiments performed on both apo and Cu(I)WLN4-6 indicated that there was
no large change in the dynamic properties of the protein upon copper binding. The
domains tumbled independently of each other, with even MBDs 5 and 6 showing slight
flexibility. This contrasted with the more rigid dimer that these two domains possessed
when they were in a construct comprised only of MBDs 5 and 6 (i.e. WLN5-6) (66).
Additionally, the study on WLN4-6 found that apoWLN4-6 interacted with apoHAH1
even in the absence of copper or in low amounts of copper, with domain 4 showing the
most chemical shifts; the authors suggested this meant that the transfer of copper from
HAH1 to WLN4 is driven by favorable protein-protein interactions that occur even in the
absence of copper. This supposition is supported by the fact that WLN4 is an acidic
domain with a theoretical pI of 3.81 (preceding and succeeding linkers not included)
while HAH1 is a basic protein with a theoretical pI of 7.5. Favorable interactions
between an acidic face of WLN4 with a basic face of HAH1 could help to align the
copper binding sites and facilitate copper transfer; a potential model of this is shown in
Figure 1.7. From these results, Fatemi et al. suggest the copper transfer is driven by the
motional freedom of the MBDs that is afforded by the linkers as well as favorable
protein-protein interactions between both HAH1 and the MBDs and between the MBDs.
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Additionally, the studies done on WLN4-6 were done at 35ºC while the other studies
were done at 25ºC, which may account for some of the extra movement seen in WLN4-6
that was not present in other constructs.
The above studies show that it is important to consider the role of individual
MBDs within the context of the intact N-terminal region. The studies all agree that
MBD4 is the most likely of all domains to form an NMR-observable complex with Cu(I)HAH1, however.
The mechanism of copper transfer from HAH1 to WLN4 was the subject of lab
colleague Brian Zeider’s dissertation project (77). Part of his work focused on trapping
the proposed 3-coordinate intermediate that forms between Cu(I)HAH1-WLN4 during
copper transfer and delineating whether all cysteines in the CXXC motifs played a role in
ligating copper. To achieve this, each of the four metal-binding cysteines in HAH1 and
WLN4 were mutated one at a time to alanine, i.e. C12A HAH1, C15A HAH1, C15A
WLN4 and C18A WLN4. Each mutated protein was enriched in
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N, then

titrated with the unlabeled, non-mutant partner and copper, in a 1:1:1 ratio. Through the
analysis of chemical shift variations and tumbling times, it was determined that both
metal-binding cysteines in WLN4 are required to form an NMR-observable complex
while only C12 from HAH1 was required (77). The observation that the C15 in HAH1 is
not observed in a complex with WLN4 by NMR correlates with a computational study
done on the proposed mechanism of copper transfer from HAH1 to WLN4 (78). This
study reported that one of the most energetically favorable 3-coordinate intermediates
that could form would include both cysteines in WLN4 and C12 in HAH1; the other
energetically favorable intermediate is the one that initially forms when C15 from WLN4
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both cysteines in HAH1 formed the initial 3-coordinate intermediate. After overcoming
the 39.7 kJ /mol activation barrier, the intermediate with both cysteines in WLN4 and
C12 in HAH1 is formed. Then C12 is released from the complex, finalizing the transfer
of copper to WLN4, as depicted in Figure 1.8 below. This potential model of copper
transfer is consistent with the intermediate complex that is found in yeast homologs,
where C15 of Atx1 and C13 and C16 of Ccc2a provide the ligands to Cu(I) (79).
Intramolecular copper transfer from one metal-binding domain to another has also
been documented between single domain constructs in vitro, with Cu(I)-WLN1 being
able to transfer copper to apoWLN4 and vice versa (80). This strengthens the argument
that copper can be moved from one MBD to another prior to being moved across the
membrane.
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Figure 1.7: Potential interaction between WLN4 and HAH1 (81). WLN4 has an acidic
face that can interact with a basic face on HAH1. This interaction would bring the metalbinding cysteines (yellow spheres) of WLN4 and HAH1 into close proximity, thereby
facilitating the transfer of copper. Used with permission of Springer.

Figure 1.8: Diagram of a potential mechanism of copper transfer from HAH1 to WLN4.
While other potential 3-coordinate intermediates are possible, NMR studies have shown
that the intermediate shown above dominates (77).
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1.4.3

Regulation
The activity of Wilson disease protein is regulated by two means – copper levels

and phosphorylation. These two factors determine the protein’s localization, i.e. whether
it is in the trans-Golgi network or in vesicles.
Under basal or low copper levels, Wilson disease protein is localized to the transGolgi network where it pumps copper across the membrane and into the lumen for
incorporation into ceruloplasmin and other cuproproteins. When copper levels exceed
biological demand and threaten to overwhelm the chelation capacity of the cell, Wilson
disease protein translocates into vesicles and migrates to the plasma membrane; once
there, the vesicles fuse with the plasma membrane and export copper out of the cell (30).
In the liver, excess copper is exported into bile and excreted from the body. Mutations in
the Wilson disease protein can prevent proper trafficking and interfere with the ability to
excrete copper, resulting in the accumulation of copper in the body (82, 83). Since the
liver is the primary site of copper metabolism, most of the copper accumulates there.
Phosphorylation of specific serine residues also plays a role in the regulation and
localization of Wilson disease protein (84–86). Wilson disease protein exhibits a basal
level of phosphorylation under basal copper levels. An increase in copper levels triggers
a kinase mediated phosphorylation of other serine residues, resulting in the Wilson
disease protein migrating from the trans-Golgi network to vesicles. Four serine residues
become phosphorylated in response to elevated copper levels. Two of these serines
(Ser478 and Ser481) are located in the linker region between metal-binding domains 3
and 4, another (Ser1121) is located in the nucleotide-binding domain and one (Ser1453)
is located at the C-terminal tail (85).

Protein kinase D is essential for phosphorylating

these residues (86). Additionally, mutating the cysteines in the CXXC motif of metal25

binding domain 6 prevents the protein kinase D mediated phosphorylation of Wilson
disease protein, thereby preventing its ability to translocate into

vesicles (86).

Consequently, this metal-binding domain plays a pivotal role in the proper functioning of
Wilson disease protein.

1.5

Research Objectives
The role of the first four metal-binding domains of Wilson disease protein has not

been clearly elucidated. Metal-binding domains 1, 2, and 4 have been shown to form
NMR observable complexes with the copper metallochaperone HAH1, which suggests
that one of the roles for these domains is to acquire copper. On the other hand, other
experiments have pointed to a more regulatory role for the first four metal-binding
domains Deletion of the first four metal-binding domains does not alter the catalytic
phosphorylation of WLNP, but it does increase the sensitivity of WLNP to copper.
Lower copper levels are able to activate the truncated WLNP (64). Activation by lower
levels of copper suggests that the first four metal-binding domains may affect the access
of copper to metal-binding sites that are located outside of the N-terminal region, such as
the platform area. Additionally, catalytic phosphorylation of Wilson disease protein was
observed even when the first five metal-binding domains are deleted (87).
Several studies have shown that WLNP can function with only the sixth metalbinding domain (64, 88). Since the linker between the fifth and sixth metal-binding
domains is only 8 residues long and NMR data on a construct of WLN5-6 showed that
they tumbled as a single unit, it is likely that the fifth and sixth metal-binding domains in
WLNP function together. Additionally, the long linker between the fourth and fifth
metal-binding domains provides a large spatial separation that may enable the first four
26

metal-binding domains to function independently from the fifth and six metal-binding
domains. Whether or not the first four metal-binding domains function independently
from each other, like beads on a string, or cooperatively has not yet been elucidated and
was the subject of this dissertation.
Taking all of this into consideration led to the identification of research objectives for
this dissertation. The goal was to understand the structure and stability of the first four
metal-binding domains of human Wilson disease protein.

The structure was

characterized using gel filtration chromatography, laser light scattering, and NMR
spectroscopy. Stability was analyzed by CD in conjunction with thermal and GuHCl
denaturation.

The results of these experiments were expected to lead to a greater

understanding of the role of the first four metal-binding domains of WLNP. In turn, this
would lead to a greater understanding of WLNP function and the reason certain domains
are favored sites for copper acquisition.

The study would also lead to a greater

appreciation of how mutations impair the functioning of WLNP.
A small secondary project investigated the effect of pH and Hg(II) binding on the
association state of the copper metallochaperone HAH1. Gel filtration chromatography
was used to characterize the association state. This project was part of a larger project
that was done with Dr. Pecoraro and his group from the University of Michigan. Hg(II)
was used as a mimic for Cu(I) because it is amenable to several spectroscopic techniques
that Cu(I) is not. This study was undertaken with the hope of observing changes in the
coordination state of Hg(II) as pH changed. Such changes may reflect the changes in
coordination that Cu(I) undergoes when it is being transferred from HAH1 to WLNP and
may provide a model of copper transfer.
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CHAPTER 2
MATERIALS AND EXPERIMENTAL METHODS

2.1

Introduction
This chapter details the chemical and biological supplies used for conducting this

research, as well as the techniques used for the preparation of the plasmids, and the
expression, purification, and characterization of the resulting proteins.

2.2

Reagents and Instrumentation
The specialty chemical and biological reagents used are itemized in the tables

below. Commonly used reagents, such as buffers and salts, were of molecular biology
grade or better.

Information on the instrumentation, including model number and

applications, are also provided.

2.2.1

Chemical and Biological Reagents
The reagents shown below were used in this research. Separate tables have been

provided for chemical and biological reagents.
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Table 2.1: Chemical reagents used. The purity of the reagents is given, when available.
Chemical reagent
15

N-Ammonium Chloride

Copper Standard for ICP-AES
Deuterium Oxide
DSS
d12-EDTA
13
C-Glucose
Guanidine Hydrochloride
Indium Standard for ICP-AES
MEM Vitamins
Nitric Acid (Trace Metal Grade)
Tetrakis(acetonitrile)copper(I)
Hexafluorophosphate

Part
Number
NLM-4671
SC194-100
453366
DLM-32
DLM-414
CLM-1396
G3272
IAA-049
25-020-CI
A509212
346276
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Manufacturer

Purity

Cambridge Isotopes

99%

Fisher Scientific
Sigma-Aldrich
Cambridge Isotopes
Cambridge Isotopes
Cambridge Isotopes
Sigma-Aldrich
Ultra Scientific
Mediatech
Fisher Scientific
Sigma-Aldrich

>99%
>99%
≥99%

>99%

Table 2.2: Biological reagents and kits used in this research.
Biological Reagent / Kit
BCA Protein Assay Kit
Benzonase
Bio-Rad Protein Assay Reagent
BL21(DE3) Competent Cells
BugBuster® Reagent
DNA Ladder (100 bp)
DNA Ladder (1 kb)
Gel Filtration Markers Kit for Protein
Molecular Weights 6.5-66 kD
KOD Hotstart Polymerase Kit
Low Molecular Weight Gel Filtration
Calibration Kit
MinElute PCR Purification Kit
Novablue Competent Cells
pET32Xa/LIC Vector Kit
QiaPrep® Spin Miniprep Kit
QuikChange II Site-Directed
Mutagenesis Kit
Rainbow Protein Markers (Full Range)
Rosetta™(DE3) Competent Cells
XL-10 Gold Competent Cells

Part Number
23225
E1014
500-0006
69450
70584-4
N3231S
N3232S
MWGF70

Manufacturer
Thermo Scientific
Sigma-Aldrich
Bio-Rad
EMD Millipore
EMD Millipore
NEB
NEB
Sigma Aldrich

71086-3
17-0442-01

EMD Millipore
Amersham Biosciences

28004
69825-4
70072
27106
200521

QIAGEN
EMD Millipore
EMD Millipore
QIAGEN
Agilent Technologies

RPN800E
70954-3
200517-4

GE Healthcare
EMD Millipore
Agilent Technologies
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2.2.2

Instrumentation
The instruments summarized in Table 2.3 were utilized during the course of this

research. The columns used with the ÄKTA FPLC are shown in Table 2.4.

Table 2.3: Instruments used.
Instrument

Manufacturer

ÄKTA FPLC

GE Lifesciences

CD
Spectropolarimeter
Minicycler
Thermocycler
NMR (located at the
University of Notre
Dame, South Bend,
IN)
NMR (located at the
University of
Chicago, Chicago,
IL)
Refractometer

Jasco

Shaker / Incubator
UV-VIS
Spectrophotometer

MJ Research
Bruker

Model / Part
Use
Number
Part Number: 18Protein
1900-26
Purification
Model Number: J-815 Circular Dichroism
Experiments
Model Number: PTCPCR
150
AVANCE II, 800
NMR Experiments
MHz

Varian

Unity Inova 600 MHz

1H-15N HSQC
Experiment of
WLN4 at 80ºC

Bausch and
Lomb

Abbe 3L

New Brunswick
Scientific
Beckman

Unknown

Determining the
Concentration of
GuHCl Solution
Bacterial Culture
Growth
Plasmid and
Protein
Quantitation

Model Number: DU7400
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Table 2.4: Columns used for the purification of the WLN constructs. All part numbers
are from GE Healthcare.
Column
HisPrep FF 16/10

Part Number
28-9365-51

Resin
Ni Sepharose 6 Fast
Flow

HiLoad 26/60
Superdex 75 pg
HiLoad 16/60
Superdex 200 pg
HiPrep 26/10
Desalting
Column
Superdex 75 HR
10/300

17-1070-01

Superdex 75 Prep
Grade
Superdex 200 Prep
Grade
Sephadex G-25
Superfine

2.3

17-1069-01
17-5087-01

17-1047-01

Superdex 75, 13 μm

Use
Purification of Fusion
Proteins and Subsequent
Digests
Gel Filtration After
HisPrep
Gel Filtration After
HisPrep
Buffer Exchange

Determination of Apparent
Molecular Weight

Summary of Plasmids and Protein Constructs
This section contains a summary of all of the plasmids and protein constructs used

in this research.

2.3.1

Plasmids Containing Portions of the Wilson Disease Protein
Multiple plasmids were used in this research, though all were based on the pET-

32Xa/LIC vector. Table 2.5 shows the name of each plasmid and the amino acids in the
human Wilson Disease protein (WLNP) for which it codes; the residue numbering is
based on the Copper transporting ATPase 2 isoform A [homo sapiens], NCBI accession
number NP_000044. The protein constructs are referred to as “WLN” followed by the
metal-binding domain they contain. For example, WLN1-2 is a construct comprised of
the first two metal-binding domains.
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Table 2.5: Plasmid names and the metal-binding domains they contained.
Plasmid Name
pET32-WLN1-2
pET32-WLN1-3
pET32-WLN1-4
pET32-WLN1-6
pET32-WLN4
pET32-WLN1-4
G333R

Residues of
WLNP
57-213
57-327
57-429
57-633
356-429
57-429

Comment
First two metal-binding domains
First three metal-binding domains
First four metal-binding domains
All six metal-binding domains
Fourth metal-binding domain
Identical to pET32-WLN1-4, except for a
glycine to arginine mutation at residue 333
(located between the third and fourth metalbinding domains)

WLN1-2 Amino Acid Sequence
GVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQGSATVKYVPSVVCL
QQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQSCVSSIE
GKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFEAAIKSK
MBD1, MBD2, Linker region
157 amino acids
16,958 Daltons
Figure 2.1: The amino acid sequence of WLN1-2. The different metal-binding domains
(MBDs) are indicated by different colored fonts, as detailed above.

WLN1-3 Amino Acid Sequence
GVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQGSATVKYVPSVVCL
QQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQSCVSSIE
GKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFEAAIKSKV
APLSLGPIDIERLQSTNPKRPLSSANQNFNNSETLGHQGSHVVTLQLRIDGMHC
KSCVLNIEENIGQLLGVQSIQVSLENKTAQVKYDPSCTSPVALQRAIEALPPGNF
KVSL
MBD1, MBD2, MBD3, Linker regions
272 amino acids
29,382 Daltons
Figure 2.2: The amino acid sequence of WLN1-3. The different metal-binding domains
(MBDs) are indicated by different colored fonts, as detailed above.
41

WLN1-4 and WLN1-4 G333R Amino Acid Sequences
GVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQGSATVKYVPSVVCL
QQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQSCVSSIE
GKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFEAAIKSKV
APLSLGPIDIERLQSTNPKRPLSSANQNFNNSETLGHQGSHVVTLQLRIDGMHC
KSCVLNIEENIGQLLGVQSIQVSLENKTAQVKYDPSCTSPVALQRAIEALPPGNF
KVSLPDGAEGSGTDHRSSSSHSPGSPPRNQVQGTCSTTLIAIAGMTCASCVHSIE
GMISQLEGVQQISVSLAEGTATVLYNPAVISPEELRAAIEDMGFEASVVSE
MBD1, MBD2, MBD3, MBD4, Linker regions
374 amino acids
39,783 Daltons (WLN1-4)

38,868 Daltons (WLN1-4 G333R)

Figure 2.3: The amino acid sequence of WLN1-4 and WLN1-4 G333R. The underlined
glycine residue (G) was mutated to arginine (R) in the construct WLN1-4G333R. The
different metal-binding domains (MBDs) are indicated by different colored fonts, as
detailed above.

WLN1-6 Amino Acid Sequence
GVATSTVRILGMTCQSCVKSIEDRISNLKGIISMKVSLEQGSATVKYVPSVVCL
QQVCHQIGDMGFEASIAEGKAASWPSRSLPAQEAVVKLRVEGMTCQSCVSSIE
GKVRKLQGVVRVKVSLSNQEAVITYQPYLIQPEDLRDHVNDMGFEAAIKSKV
APLSLGPIDIERLQSTNPKRPLSSANQNFNNSETLGHQGSHVVTLQLRIDGMHC
KSCVLNIEENIGQLLGVQSIQVSLENKTAQVKYDPSCTSPVALQRAIEALPPGNF
KVSLPDGAEGSGTDHRSSSSHSPGSPPRNQVQGTCSTTLIAIAGMTCASCVHSIE
GMISQLEGVQQISVSLAEGTATVLYNPAVISPEELRAAIEDMGFEASVVSECST
NPLGNHSAGNSMVQTTDGTPTSVQEVAPHTGRLPANHAPDILAKSPQSTRAVA
PQKCFLQIKGMTCASCVSNIERNLQKEAGVLSVLVALMAGKAEIKYDPEVIQP
LEIAQFIQDLGFEAAVMEDYAGSDGNIELTITGMTCASCVHNIESKLTRTNGITY
ASVALATSKALVKFDPEIIGPRDIIKIIEEIGFHASLAQ
MBD1, MBD2, MBD3, MBD4, MBD5, MBD6, Linker regions
578 amino acids
61,505 Daltons
Figure 2.4: The amino acid sequence of WLN1-6. The different metal-binding domains
(MBDs) are indicated by different colored fonts, as detailed above.
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WLN4 Amino Acid Sequence
GTCSTTLIAIAGMTCASCVHSIEGMISQLEGVQQISVSLAEGTATVLYNPSVISPE
ELRAAIEDMGFEASVVSE
MBD4
74 amino acids
7,589 Daltons
Figure 2.5: The amino acid sequence of WLN4. The sole metal-binding domain is
indicated in orange. Neither the preceding nor succeeding linker regions were included
in this construct.

2.3.2

HAH1 Plasmid
The DNA sequence that coded for the full length human HAH1 protein (68 amino

acids) was inserted into the pET-11d vector using a series of overlapping primers by Dr.
David Huffman. Relative to the native HAH1 sequence, the pET-11d construct contained
an extra alanine residue at the beginning (MAP); the sequence is shown in Figure 2.6
below. The pET-11d vector contained no fusion or affinity tags.

HAH1 Amino Acid Sequence
MAPKHEFSVDMTCGGCAEAVSRVLNKLGGVKYDIDLPNKKVCIESEHSMDTL
LATLKKTGKTVSYLGLE
69 amino acids
7,472 Daltons
Figure 2.6: The amino acid sequence of HAH1.

2.4

Construction of Plasmids, Protein Expression, and Protein Purification
This section discusses how the plasmids were constructed, the conditions under

which the proteins were expressed, and the purification schemes used to purify the WLN
constructs and HAH1.
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2.4.1

Preparation of the pET32-WLN1-2, pET32-WLN1-3, pET32-WLN1-4, and
pET32-WLN1-4 G333R Plasmids
The plasmids shown in Table 2.5 all originated from a plasmid that contained all

six metal-binding domains (WLN1-6), subcloned into the pET-32Xa/LIC vector by Dr.
Joshua Muia at Western Michigan University (1). The pET-32Xa/LIC vector contains a
thioredoxin tag to enhance solubility and expression of the desired protein; it also
contains a His6 tag (6 histidines in a row) to assist with purification. The vector map for
this plasmid is shown in Figure 2.7. A cartoon of the resulting fusion proteins, in which
thioredoxin (TRX) was expressed at the amino terminus and a WLN construct at the
carboxy terminal, is shown in Figure 2.8. A TEV site was inserted into the WLN1-6
plasmid after the fusion tags (thioredoxin and His6 tag) and just upstream of the first
metal-binding domain, for removal of the fusion tags following protein purification.
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Figure 2.7: The vector map of the pET-32Xa/LIC plasmid (EMD Millipore, Technical
Bulletin 186VM).

Figure 2.8: Diagram of the WLN protein constructs, which were expressed as fusion
proteins with thioredoxin (TRX). The His6 tag is shown in red font, and the TEV
cleavage site is shown in purple font. TEV protease cleaves between the glutamine and
glycine residues.
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For all of the plasmids in Table 2.5 except WLN4, site directed mutagenesis was
used to insert a stop codon at the appropriate place in the pET32-WLN1-6 plasmid to
produce the desired protein construct (i.e. a stop codon at the end of metal-binding
domain 2 produced the WLN1-2 plasmid). Site directed mutagenesis was performed by
using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). The
primers used to incorporate the mutations were designed based on the parameters
outlined in the manufacturer’s instruction guide (Agilent Technologies, Publication
Number 200521-12) included with the mutagenesis kit.

These parameters included

having a primer length of 25-45 bases that terminated in one or more C or G bases,
incorporating the mutation in the middle of the primer (with 10-15 bases of correct
sequence on either side), a GC content≥ 40%, and a melting temperature T m ≥ 78ºC (Tm
= 81.5 +0.41(%GC) - 675/N - %mismatch, where N is the primer length and the %GC
and %mismatch are whole numbers). The primers, summarized in Table 2.6 below, were
synthesized by Integrated DNA Technologies, Inc. (Coralville, Iowa). Prior to use, the
lyophilized primers were resuspended in autoclaved, deionized water (18.2 MΩ•cm) at a
concentration of 200 μM; working solutions of 10 μM were then prepared using the same
sterile water. The primers were stored at -20°C pending usage.
The pET32-WLN1-4 plasmid was prepared by Dr. Joshua Muia and Sun Hwa
Lee at Western Michigan University by using the same procedure as outlined in the
above paragraph (1). The primers used to prepare this plasmid are shown in Table 2.6.
Insertion of the stop codon was achieved using mutagenic primers and PCR. The
contents of each PCR reaction are shown in Table 2.7. The PCR was performed in a
thermocycler using the conditions shown in Table 2.8. Mineral oil (30 µL) was overlaid
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on top of each reaction after the addition of the polymerase. After PCR was completed,
DpnI (10 U) was added to the PCR tube, and it was incubated at 37ºC for one hour to
degrade the template plasmid. Subsequently, an aliquot of the PCR product was run on a
0.8% agarose gel in order to verify the presence of a plasmid with the expected size of
7.8 kilobases (kb). Staining of the DNA was achieved by incorporating 0.5 μg/mL of
ethidium bromide into the agarose gel before it was poured.

Digesting the plasmid with

BglII (20 U) and BamHI (30 U) yielded two fragments of the proper approximate size
when run on an agarose gel: the pET-32Xa/LIC vector (5.8 kb) and the WLN1-6 gene
insert (~1.78 kb).

Note that all of the plasmids discussed in this section contain the

WLN1-6 gene insert; the different constructs were achieved by incorporating a stop
codon at the appropriate place in the DNA sequence. Consequently, the sizes of both
fragments produced from the double digest were the same for all of these plasmids.
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Table 2.6: The mutagenic PCR primers used to prepare the plasmids discussed above.
The text in bold denotes the stop codon that was introduced. The underlined text
indicates the mutation responsible for the conversion of glycine to arginine at position
333. The melting temperatures (Tm) listed were calculated according to the formula
discussed in the preceding text.
Primer Name

Length

WLN1-2 Stop
Forward
WLN1-2 Stop
Reverse
WLN1-3 Stop
Forward
WLN1-3 Stop
Reverse

36

Tm
(ºC)
81.4

36

81.4

45

93.7

45

93.7

WLN1-4 Stop
Forward
WLN1-4 Stop
Reverse
WLN1-4 G333R
Forward
WLN1-4 G333R
Reverse

37

78.1

37

78.1

33

81.4

33

83.5

Sequence (5’-3’)
GAA GCT GCC ATC AAG AGC TAA
GTG GCT CCC TTA AGC
GCT TAA GGG AGC CAC TTA GCT CTT
GAT GGC AGC TTC
CCA CCT GGG AAT TTT AAA GTT TCT
CTT TGA GAT GGA GCC GAA GGG
CCC TTC GGC TCC ATC TCA AAG
AGA AAC TTT AAA ATT CCC AGG
TGG
GCT TCA GTC GTT TCT GAA TGA TGT
TCT ACT AAC CCT C
GAG GGT TAG TAG AAC ATC ATT
CAG AAA CGA CTG AAG C
GAT GGA GCC GAA AGG AGT GGG
ACA GAT CAC AGG
CCT GTG ATC TGT CCC ACT CCT TTC
GGC TCC ATC

Table 2.7: PCR reaction contents for site directed mutagenesis.
Component
10x Reaction Buffer
pET32-WLN1-6 (10 ng/µL)
Forward Primer (10 μM)
Reverse Primer (10 μM)
dNTP Mix (2 mM)
Quik Change Solution
Sterile Water
Pfu Ultra HF DNA Polymerase (2.5 U/µL)
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Volume (µL)
5
1
1
1
1
3
38
1

Table 2.8: PCR thermocycler conditions. The fourth segment was not part of the PCR
cycle, but was included in the program to keep the reaction cool if the PCR product was
not immediately used after completion of the program.
Segment
1
2

Number of Cycles
1
12

3
4

1
1

2.4.2

Temperature (ºC)
95
95
60
68
68
4

Time
3 minutes
50 seconds
50 seconds
7 minutes 50 seconds
7 minutes 50 seconds
24 hours

Preparation of the pET32-WLN4 Plasmid
The pET32-WLN4 plasmid was constructed using PCR to amplify the fourth

metal-binding domain from the pET32-WLN1-6 plasmid. Ligation independent cloning
was then used to insert the fourth metal-binding domain into the pET-32Xa/LIC vector
(2, 3). KOD Hotstart Polymerase and the WLN4 primers listed in Table 2.9 were used
for the amplification; these primers also incorporated a TEV restriction site into the
plasmid to facilitate cleavage of the fusion protein.

The primers were designed to

incorporate the requisite 5’ sequences for the insertion of the PCR insert into the pET32
vector (EMD Millipore, Technical Bulletin 184-1).
The contents of the PCR reaction tube and the thermocycler conditions are shown
below in Table 2.10 and Table 2.11, respectively. Mineral oil (30 µL) was overlaid on
top of each reaction after the addition of the polymerase. Following PCR, the product
was purified using the MinElute PCR Purification Kit from QIAGEN. An aliquot of the
purified product was then run on a 1.2% agarose gel to determine if the PCR was
successful. Visualization of the DNA revealed a band between 200 & 300 bases; the
expected size of the PCR product was 284 bases. The PCR product was purified using
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MinElute PCR Purification Kit from QIAGEN. Quantitation of the PCR product was
achieved by running an aliquot on a 1.2% agarose gel and comparing the intensity of the
band to that of the 100 bp standard ladder.

Table 2.9: The PCR primers used to amplify the fourth metal-binding domain. The text
in bold denotes the vector specific sequences required for ligation independent cloning
while the underlined text denotes the TEV protease restriction site. The melting
temperatures listed were supplied by the Integrated DNA Technologies, Inc.
Primer Name

Length

WLN-4 Forward

45

Tm
(ºC)
69.1

WLN-4 Reverse

51

67.9

Sequence (5’-3’)
GGT ATT GAG GGT CGC GAG AAC CTT
TAT TTC CAG GGC ACA TGC AGT
AGA GGA GAG TTA GAG CCT CAT
TCA GAA ACG ACT GAA GCC TCA AAT
CCC ATG

Table 2.10: PCR reaction contents for preparing the WLN4 plasmid.
Component
10x Reaction Buffer
pET-32Xa/LIC-TEV-WLN1-6 (10 ng/µL)
Forward Primer (10 μM)
Reverse Primer (10 μM)
dNTP Mix (2 mM)
Magnesium Sulfate (25 mM)
Sterile Water
KOD Hotstart DNA Polymerase (1 U/µL)

50

Volume (µL)
5
1
1.5
1.5
5
3
32
1

Table 2.11: PCR thermocycler conditions. The fourth segment was not part of the PCR
cycle, but was included in the program to keep the reaction cool if the PCR product was
not immediately used after completion of the program.
Segment
1
2

Number of Cycles
1
30

4

1

Temperature (ºC)
95
95
58
70
4

Time
2 minutes
20 seconds
30 seconds
30 seconds
24 hours

The purified PCR product was then inserted into the pET-32Xa/LIC vector using
the pET-32Xa/LIC vector kit from EMD Millipore. This vector kit utilized ligation
independent cloning (LIC) to directionally insert genes into the vector without
performing restriction enzyme digests and ligation reactions (2, 3). Instead, the PCR
products are designed to incorporate 5’ sequences that are complementary to the DNA
sequence of the vector. T4 DNA polymerase was used to create the requisite vector
compatible overhangs in the PCR product; the vector and the PCR product were then
annealed, and the plasmid was used to transform Novablue® cells (EMD Millipore).
After PCR, 10 μL (0.2 picomoles) of purified PCR product was combined with 2
μL of 10x T4 DNA polymerase buffer, 2 μL of dGTP (25 mM), 1 μL of DTT (100 mM),
4.6 μL of nuclease free water, and 0.4 μL of T4 DNA Polymerase (2.5 U/ μL). This
mixture was incubated at 22°C for 30 minutes in the thermocycler followed by a 5 minute
incubation at 75°C to inactivate the T4 DNA polymerase. Annealing of the vector and
the PCR product was performed by mixing 3 μL of the above described T4 DNA
Polymerase treated PCR product with 1 μL of pET-32Xa/LIC vector and incubating the
mixture for 5 minutes at 22°C. Subsequently, 1.25 μL of EDTA (25 mM) was added,
followed by another 5 minute incubation at 22°C.
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2.4.3

Transformation of Bacterial Cells for Plasmid Propagation
The plasmids described in Sections 2.4.1 and 2.4.2 were propagated in E. coli.

Two different strains of cells were used: XL-10 Gold Ultracompetent Cells (Agilent
Technologies) were used for the plasmids that were produced using site-directed
mutagenesis while Novablue® competent cells (EMD Biosciences) were used for the
pET-32-WLN4 plasmid. The transformation procedures used for the two different cell
lines differed slightly.
The XL10-Gold Ultracompetent Cells were transformed as follows. An aliquot of
cells (5 μL) was thawed on ice for 5 minutes before 0.5 μL β-ME was added. The cells
were then incubated on ice for 10 minutes, with gentle swirling occurring every 2
minutes. Afterwards, 3 μL of the DpnI treated DNA was added, and the cells were
incubated on ice for 30 minutes. The cells were next heat shocked at 42ºC for 10 seconds
to facilitate plasmid entry into the cells. Following a 2 minute recovery on ice, 100 μL of
SOC media (20 g/L tryptone, 5 g/L yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 10 mM MgSO4, 10 mM glucose, pH7.0) that had been warmed to 37ºC was
added. The cells were then incubated in a 37ºC shaker (250 rpm) for 1 hour. Afterwards,
all of the cells were plated on a pre-warmed LB-agar plate (10 g/L tryptone, 10 g/L NaCl,
5 g/L yeast extract, 15 g/L agar) that contained 100 μg/mL carbenicillin and incubated
upside down for 16-18 hours at 37ºC in a gravity convection oven.
Novablue® competent cells were transformed according to the following
procedure. An aliquot of cells (20 μL) was thawed on ice for 5 minutes before 2 μL of
the annealed plasmid mixture was added. The cells were incubated on ice for 5 minutes,
then heat shocked at 42ºC for 15 seconds. Following a 2 minute recovery on ice, 80
μL
of SOC media (pre-warmed to 37ºC) was added. The cells were grown in a shaker
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maintained at 37ºC and 250 rpm for 1 hour. All of the cells were then plated onto a prewarmed LB-agar plate that contained 100 μg/mL carbenicillin. The plate was incubated
in a gravity convection oven for 16-18 hours.
Further propagation of the plasmids was achieved by inoculating multiple 5 mL
cultures of LB media (10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract) containing
either 100 μg/mL carbenicillin or 100 μg/mL ampicillin with cells from a single colony
from the plates. The cultures were incubated in a 37ºC shaker (250 rpm) for 8-10 hours,
and then centrifuged at 13,000 rpm for 5 minutes. The supernatant was discarded, and
the pellet was either immediately subjected to plasmid purification or stored at -20ºC
until processed.
The plasmids were purified using the QiaPrep® Spin Miniprep Kit from
QIAGEN, according to the manufacturer’s instructions included with the kit (QiaPrep®
MiniPrep Handbook, Second Edition, December 2006).

Following purification, the

plasmids were quantitated by measuring the absorbance at 260 nm, using a Beckman DU7400 UV-Vis Spectrometer. Aliquots of the plasmids were then sent to Retrogen (San
Diego, CA) for sequencing. All plasmids were stored at -20ºC.

2.4.4

Protein Expression
Two different media were used to grow the bacteria. Specific media was chosen

based on the particular experiment for which the protein would be used. Unlabeled
proteins were required for most experiments, and these proteins were produced in LB
media. Proteins being studied with NMR required enrichment with either 15N, or 13C and
15

N; M9 minimal media supplemented with the appropriate precursors was used to

prepare these proteins.
53

2.4.4.1 Transformation of Rosetta™ 2 (DE3) Cells for Protein Expression
Regardless of the type of liquid media used to grow the cultures and express the
protein, a transformation was required to introduce the appropriate plasmid into the
bacteria. This transformation procedure was the same, regardless of the type of media
used subsequently.
Rosetta™ 2(DE3) cells were used to express the proteins encoded by the plasmids
described in Sections 2.32 and 2.4.1-2.4.2. This BL21 derivative was selected because it
is supplemented with tRNAs for 7 codons (AGA, AGG, AUA, CUA, GGA, CCC, and
CGG) that are infrequently used by E. coli but commonly found in eukaryotes (EMD
Millipore, Technical Bulletin TB009); the WLN1-4 and WLN1-4 G333R constructs
contained all 7 rare codons.
Transformation of Rosetta™ 2(DE3) cells was performed according to the
manufacturer’s procedure that was supplied with the cells (EMD Millipore, Technical
Bulletin TB009); a summary of this procedure follows. A 5 μL aliquot of cells was
removed from -80ºC and thawed on ice for 5 minutes. Between 10-20 ng of plasmid (in a
volume of 1-2 μL) was added to the cells, followed by gentle swirling every 2 minutes
during a 10 minute incubation on ice. The cells were then heat shocked for 15 seconds at
42ºC followed by a 2 minute recovery on ice. After the addition of 80μL of SOC media
(pre-warmed to 37 ºC), the cells were placed in a 37ºC shaker (250 rpm) for 1 hour. All
of the cells were then plated on an LB-agar plate that contained 100 μg/mL carbenicillin
or 100 μg/mL ampicillin and 34 μg/mL chloramphenicol. The plate was then incubated
in a 37ºC oven for 16-20 hours.
Both carbenicillin/ampicillin and chloramphenicol were used to maintain the
correct genotype; the plasmid conferred resistance to carbenicillin/ampicillin and the
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Rosetta™ 2(DE3) cells conferred resistance to chloramphenicol. Carbenicillin is a more
stable analogue of ampicillin that is less resistant to degradation by β-lactamase and is
also more stable as the pH decreases. Sometimes cells will lose the plasmid containing
the protein to be expressed (the plasmid also contains the gene conferring antibiotic
resistance) if all of the antibiotic degrades in the culture during growth. Plasmid loss was
not observed here, and both antibiotics were used interchangeably for cultures grown in
LB media. For producing the isotopically enriched proteins, only carbenicillin and not
ampicillin was used in the cultures. Additionally, chloramphenicol was not used for
expressions done in minimal media; this was done to reduce the stress on the bacteria.

2.4.4.2 Non-labeled Protein Expression
Non-isotopically labeled proteins were used for all experiments not involving
NMR. These proteins include WLN1-2, WLN1-3, WLN1-4, WLN1-6, WLN4, WLN1-4
G333R, and HAH1. These proteins were expressed by Rosetta™ 2 (DE3) cells that were
grown in LB media containing 100 μg/mL carbenicillin or 100 μg/mL ampicillin and 34
μg/mL chloramphenicol.
Starter cultures were prepared by inoculating cells from a single colony into 5 mL
of LB media. The cultures were placed in 37ºC shaker (250 rpm) for 8-10 hours before
being used to inoculate a 50 mL LB culture, which was then placed in the 37ºC shaker
(250 rpm) and grown for 8-10 hours.
Protein expression was done in a 2.8 L flask that contained 500 mL of media; this
ratio of media volume to flask volume provided adequate aeration for the bacteria. The
media was inoculated with an aliquot from the 50 mL culture and incubated in the 37ºC
shaker (250 rpm) until reaching an OD600 of 0.6-0.8. Protein expression was initiated by
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the adding IPTG to a final concentration of 1 mM. The cells were induced for either 4-5
hours at 37ºC or 16-18 hours at room temperature (~22ºC), depending on the availability
of the shakers and time constraints. Since the thermostat on the shaker was unable to
reliably maintain a temperature < 26ºC, the room temperature inductions were done by
keeping the lid of the shaker open and exposing the shaker to the lab atmosphere. The
temperature of the lab remained fairly constant at ~22 ºC during the course of the
inductions.
Following induction, the cells were harvested by centrifugation at 5,000 rpm for
15 minutes at 4ºC. The cell pellets were either immediately lysed to extract the proteins
or stored at -20ºC pending purification.
2.4.4.3 15N and

13

C,15N Labeled Protein Expression

13

C,15N labeled versions of WLN1-2 and WLN4 were prepared for

multidimensional NMR experiments;

15

N labeled WLN4 was also prepared as well. In

order for the appropriate isotopic labels to be incorporated into the proteins, M9 minimal
media was supplemented with

15

N-ammonium chloride to incorporate

15

glucose to incorporate 13C. The recipe for this media is shown in Table 2.12.
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N and

13

C-

Table 2.12: Recipe for M9 minimal media. The final volume was adjusted to one liter
using deionized water (18.2 MΩ•cm).
Reagent
M9 Stock Solution (5x)
MgSO4 (1 M)
CaCl2 (1 M)
MEM Vitamin Mix (100x)
13
C-glucose (or unlabeled glucose)
15
N-ammonium chloride

Amount / Liter of media
200 mL
1 mL
0.3 mL
10 mL
2g
1g

The M9 stock solution (5x) was prepared by dissolving 15g KH2PO4, 42.5g
Na2HPO4 · 2H2O, and 2.5g NaCl in a total volume of 1 L of deionized water (18.2
MΩ•cm). This solution was autoclaved and then stored at room temperature. All other
reagents were sterile filtered using a 0.2 μm polyethersulfone membrane (Pall
Corporation, Part Number 4602) prior to being added to the media. Deionized water
(18.2 MΩ•cm) was autoclaved and used as a diluent for the minimal media. To ensure
adequate aeration, 500 mL of media was used in 2.8 L flasks.
A new transformation was performed each time labeled protein was prepared; the
transformation procedure is described in Section 2.4.4.1. Using bacteria to express
isotopically labeled protein required several intermediate cultures to acclimate the
bacteria to the harsher conditions imposed by the minimal media and
15

13

C-glucose and

N-ammonium chloride, as bacteria directly transferred to this media from an LB-agar

plate would be unlikely to grow. A series of cultures was prepared, as shown in the
Figure 2.9 below. All of the cultures in this figure were grown in a shaker that was
maintained at 37ºC and 250 rpm; carbenicillin (100 μg/mL) was used in all cultures.
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5 mL LB

•Inoculated with cells from a single colony
•Grown 8-10 hours

5 mL M9

•Unlabeled glucose and ammonium chloride
•Inoculated with 5 μL of previous LB culture
•Grown 10-12 hours

5 mL M9

•13C-glucose and 15N-ammonium chloride
•Inoculated with 20 μL of previous culture
•Grown 10-12 hours

•13C-glucose and 15N-ammonium chloride
•Inoculated with 5-10 μL of previous culture
30 mL M9 •Grown overnight (12-16 hours)

Figure 2.9: The series of starter cultures grown to express 15N and 13C, and 15N labeled
proteins. If only 15N labeling was required, then unlabeled glucose was used in lieu of
the 13C-glucose.

The entire 30 mL culture was then used to inoculate 500 mL of M9 media that
contained the appropriately labeled precursors. These large scale cultures were grown in
a shaker at 37ºC until the OD600 reached between 0.6-0.8.

Protein expression was

initiated with the addition of IPTG (1 mM, final concentration), and the temperature was
reduced to room temperature (~22ºC) by keeping the lid of the shaker open. After 16
hours, the cells were pelleted by centrifugation at 5,000 rpm for 15 minutes at 4°C. If the
proteins were not immediately extracted from the pellets, then the pellets were stored at 20°C.
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2.4.5

Protein Extraction and Purification
All of the proteins expressed in Section 2.4.4 were purified using the same

purification steps. An ÄKTA FPLC was used in conjunction with the first four columns
shown in Table 2.4.

Extraction of the proteins occurred immediately prior to

purification.

2.4.5.1 Extraction of the WLN Constructs
Prior to purifying the proteins, they first had to be extracted from the cell pellets.
If the pellets were frozen, they were thawed at room temperature on the bench for 15-25
minutes before proceeding. Bugbuster® (EMD Millipore) was used to chemically disrupt
the cell membranes and release the soluble protein from the cells; 5 mL of this reagent
was used for every 1g of cell pellet, as specified by the manufacturer’s instructions (EMD
Millipore, Technical Bulletin 245). Benzonase was used to reduce the viscosity of the
Bugbuster®/protein solution and increase protein extraction by degrading DNA and RNA;
1 μL of benzonase was used for every 5 mL of Bugbuster®. The exact concentration of
the benzonase purchased from Sigma varied, though it was guaranteed to be≥ 250 U/μL;
typically, 5-8 μL of benzonase were used per 1 L of cell culture. After resuspending the
cell pellet in the Bugbuster® and benzonase, the solution was incubated on a table top
shaker (50 rpm) at room temperature for 30 minutes. Afterward, the cellular debris was
pelleted by centrifugation at 15,000 rpm at 4°C for 15 minutes. The supernatant was
decanted into a clean tube and centrifuged again under the same conditions to remove any
residual particulates. The supernatant was then decanted into a clean tube and ready for
purification.
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2.4.5.2 Purification of the WLN Constructs
As all of the Wilson disease protein constructs used here were cloned into the
pET-32Xa/LIC vector, they were all expressed as fusion tags containing thioredoxin and
a His6 tag. Consequently, the purification steps were the same for all proteins, with the
only exception being that a Superdex 200 pg (preparative grade) column was used to
purify WLN1-6 instead of the Superdex 75 pg column used for the other, smaller
proteins. The purification scheme is summarized below in Figure 2.10. Protein elution
was monitored at 254 nm for all columns.

HisPrep Column (Cell Lysate)
Desalting Column (Fusion Protein)
TEV Digest
HisPrep Column (TEV Digest)
Superdex 75 pg or Superdex 200 pg (WLN Construct)
Desalting Column (WLN Construct)

Figure 2.10: The purification scheme used to purify the WLN constructs. Shown in
parentheses is the sample that was loaded onto the column; this sample came from the
preceding purification step.
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Before loading the proteins onto the HisPrep column, the column was first
cleaned with 5 column volumes (CV, 1 CV= 20 mL) of Buffer B (50 mM Tris, pH 8.0,
500 mM NaCl, 500 mM imidazole) followed by an equilibration with 5 CVs of Buffer A
(50 mM Tris, pH 8.0, 500 mM NaCl, 30 mM imidazole). The proteins were then loaded
onto the column, and the column was washed with 10 CVs of Buffer A to remove
unbound proteins that did not contain the His6 tag. Elution was achieved using a gradient
of 0-100% Buffer B over 5 CVs. Fractions containing the fusion protein were pooled
following analysis by SDS-PAGE to confirm the presence of the protein.
After the initial HisPrep purification, the proteins were exchanged into TEV
digestion buffer (50 mM Tris, pH 8.0. 0.5 mM EDTA) using a Desalting column, which
was pre-equilibrated with 4 CVs (1 CV = 60 mL) of buffer. Elution was performed
isocratically over 1.2 CVs using the same buffer. The fractions containing the protein
were pooled. Protein quantitation was performed with the BCA assay.
Cleavage of the fusion protein into thioredoxin and the various WLN constructs
was achieved using TEV protease in the presence of 1 mM DTT. A 1:80 mg/mg ratio of
TEV:fusion protein was used.

The digestion proceeded for 14-18 hours at room

temperature, with >90% cleavage occurring after this time, as judged by visual inspection
of a SDS-PAGE gel. Performing the digestion at 37°C was tried to determine if the
digestion time could be shortened, but a significant amount of fusion protein (estimated at
>50%) remained after 8 hours when an aliquot was run on an SDS-PAGE gel.
Following digestion, the WLN constructs were purified from the thioredoxin tag
and the TEV protease using the HisPrep column. The conditions for column cleaning,
equilibration, and elution were the same as those described above, except that only 5 CVs

61

of Buffer A were used to wash the column after loading the digest. Since the His6 tag
was attached only to the thioredoxin tag at this point and not the WLN construct, only the
former would bind to the HisPrep column. Consequently, the WLN constructs would
elute during the 5 CV wash with Buffer A. TEV protease also contained a His6 tag,
enabling it to bind to the HisPrep column. A SDS-PAGE gel was run of the fractions
suspected of containing the WLN constructs, and the appropriate fractions were pooled.
To further purify the WLN constructs, gel filtration chromatography was used.
For WLN1-2, WLN1-3, WLN1-4, WLN1-4 G333R, and WLN4, the Superdex 75 pg
column was used. This column resolves proteins between 3-70 kD (GE Healthcare,
Instructions 71-7127-00-AF). WLN1-6 required the use of a column capable of resolving
larger proteins, specifically a Superdex 200 pg column (capable of resolving proteins
between 10-600 kD). The Superdex columns were equilibrated with 2 CVs (1 CV =320
mL for the Superdex 75 pg column and 120 mL for the Superdex 200 pg column) of gel
filtration buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 10 mM DTT, 10 mM EDTA).
Elution was done isocratically with gel filtration buffer over 1.2 CVs. SDS-PAGE was
used to determine which peaks contained the WLN constructs as well as the relative
purity. After pooling the appropriate peaks, the sample was stored at -80°C for at least 3
days.

Storing the proteins in the presence of 10 mM EDTA was determined to

significantly decrease the degradation observed with several of the WLN constructs,
particularly WLN1-2. The exact mechanism by which the EDTA inhibited the protein
degradation was not determined.
The final step in the purification process was exchanging the proteins into
phosphate buffer (50 mM, pH 7-7.5) using the Desalting column, which was equilibrated
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with 4 CVs (1 CV = 60 mL) of buffer. The protein was eluted isocratically over 1.2 CVs.
The fractions containing the protein were pooled, the volume reduced to 2-4 mL, and the
protein quantitated using either the BCA assay (Pierce, Rockford, IL) with BSA
standards or the Bradford Assay (Bio-rad, Hercules, CA) with IgG standards (4, 5). The
protein was aliquoted into 0.5 mL portions and frozen at -80°C pending use.
At several stages in the purification process, the volume of the protein needed to
be reduced. This was done by using an Amicon Ultrafiltration Cell, equipped with either
a 3 kD or 10 kD MWCO membrane composed of regenerated cellulose (EMD Millipore,
Part Numbers PLBC04310 and PLGC04310, respectively). Note that the filters used for
the Amicon Cell are treated with glycerol.

While this compound would not have

adversely affected most of the experiments done in this study, it would pose a significant
problem with the samples used for NMR, because it contains NMR observable protons.
Consequently, a more stringent cleaning procedure was used for membranes that would
be exposed to proteins being analyzed by NMR. The glycerol was removed by running
50 mL of 1 M NaCl through the membrane, followed by 150 mL of sterile, deionized
water. For non-NMR destined samples, the membranes were rinsed with 100 mL of
sterile, deionized water.

2.4.5.3 Metallation of the WLN Constructs
Copper loading of the WLN constructs was done in vitro in an anaerobic chamber
(Vac Atmosphere Company) following purification. The constructs were diluted to 1-8
μM using degassed 50 mM sodium phosphate buffer (pH 7.5) / 150 mM NaCl in a 50 mL
Amicon ultrafiltration device that was equipped with either a 3 or 10 kD MWCO
membrane. DTT was added to a final concentration of 1 mM, and the constructs were
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reduced (with stirring) for 30 minutes. A slightly substoichiometric amount of copper(I),
in the form of tetrakis(acetonitrile)copper(I) hexafluorophosphate, was slowly added to
the constructs dropwise over the course of 10-15 minutes. A substoichiometric amount of
copper was used because protein precipitation was observed when stoichiometric or
excess copper was added to the multi-domain constructs. After the addition of the
copper, the protein was allowed to continue stirring for 30 minutes to allow the copper to
bind. Unbound copper and DTT was then removed either by purifying the protein on a
PD-10 desalting column (part number 17-0851-01, GE Healthcare) or by using the
Amicon device to reduce the volume and then adding fresh buffer and reducing the
volume again (total of three times) .
Copper loading was quantitatively determined by using inductively coupled
plasma atomic emission spectroscopy (ICP-AES). A Perkin Elmer Optima 2100DV ICPAES instrument was used for this analysis. A series of copper standard solutions were
prepared and used to construct a calibration curve. Indium was added as an internal
standard to both the copper standard solutions and the protein solutions. The analysis
was done by graduate students in the laboratory of Dr. Carla Koretsky at Western
Michigan University.

2.4.5.4 Extraction and Purification of HAH1
HAH1 was extracted from the cells using the freeze-thaw method to disrupt the
cell membrane and release the cellular contents. Pellets were frozen in liquid nitrogen for
five minutes, then thawed in cool water for 15 minutes; this cycle was repeated two more
times (for a total of three freezing and three thawing cycles). Following the end of the
final thaw, 20 mL of extraction buffer (20 mM MES, pH 5.5, 1 mM EDTA, 5 mM DTT)
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was added per liter of culture. The pellet was resuspended in the buffer by placing it on a
platform shaker for one hour, followed by centrifugation at 15,000 rpm for 15 minutes.
Following centrifugation, the supernatant was loaded onto two ion exchange
columns that were set up in tandem: a DEAE sepharose column (GE Healthcare)
followed by a CM sepharose column (GE Healthcare).

The columns had been

equilibrated with 10 CVs (1 CV = 60 mL for each column) of binding buffer (20 mM
MES, pH 6). The order of the columns and the pH of the binding buffer were selected to
take advantage of HAH1’s isoelectric point, which is ~7.5. In the binding buffer, HAH1
had a slight positive charge and bound to the CM column. Many of the other proteins in
the supernatant were either negatively charged at pH 6 and bound to the DEAE column
(the first column) or were hydrophobic and not retained by either column. After the
supernatant was loaded, 10 CVs of binding buffer were run through the columns to
remove unbound proteins. The DEAE column was then removed, and HAH1 was eluted
from the CM column using a linear gradient of 0-100% elution buffer (20 mM MES, pH
6, 1 M NaCl) over 8 CVs. Aliquots of the peaks were run on an SDS-PAGE gel, and the
fractions containing HAH1 were pooled. Further purification was achieved by using a
Superdex 75 26/60 column with 50 mM sodium phosphate, pH 7.5, 150 mM NaCl buffer.
The relevant fractions were combined, concentrated, and aliquoted into 0.5 mL portions
that were frozen at -80°C pending use.

2.5

Biophysical Characterization
Several different techniques were used to characterize the WLN constructs,

including high resolution gel filtration, laser light scattering, circular dichroism,
differential scanning calorimetry, and nuclear magnetic resonance spectroscopy.
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2.5.1

High Resolution Gel Filtration on the WLN Constructs
High resolution gel filtration (HRGF) was used to determine the apparent

molecular weight of the WLN constructs. In gel filtration chromatography, analytes are
injected onto a column and eluted isocratically.

In contrast to other modes of

chromatographic separation, there is no chemical interaction between the column and the
analyte in gel filtration chromatography. Instead, separation is achieved on the basis of
the analyte’s ability to the physically access the porous beads and diffuse inside them.
Smaller and more globular molecules are better able to access the pores than larger
molecules and therefore have a greater distance to traverse before reaching the end of the
column. Consequently, smaller molecules elute at greater volumes (i.e. they take more
time to travel the greater distance) than larger molecules, which are precluded from
entering the pores by their size. Globular proteins elute at volumes consistent with their
actual molecular weight while proteins that are elongated (i.e. more ellipsoid) elute at
volumes consistent with higher molecular weight proteins (6).
Protein standards from calibration kits were injected onto a Superdex 75 HRGF
10/300 column, which optimally separates proteins between 3-70 kD. A calibration
curve was constructed by plotting the partition coefficient (Kav) against the logarithm of
the molecular weight. Kav was calculated with Equation 2.1 below, where Vc is the
geometric column volume (23.5 mL), Ve is the elution volume, and V0 is the void volume
(GE Healthcare, Technical Bulletin 18-102218-AK).

𝐾𝑎𝑣 =

𝑉𝑒 − 𝑉0
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𝑉𝑐 −𝑉0

[2.1]

V0 is the volume at which an analyte will elute if it is completely excluded from entering
the space inside the porous beads because it is too large; blue dextran, a polymer of 2,000
kD, was used for this purpose. After plotting the points, a linear trend line was fitted to
the curve using Microsoft Excel 2007. The equation of the trend line was then solved for
the molecular weight of the protein (the inverse log of x), since Kav (y) was known.
The lyophilized proteins from the calibration kits were resuspended in gel
filtration buffer (50 mM sodium phosphate, pH 7.0, 150 mM NaCl, 10 mM DTT) to
concentrations between 10-20 mg/mL; details of the standards are shown in the table
below. Different combinations of the standards were used depending on their availability
at the time of analysis; four standards were used for each analysis. Between 0.1-0.4 mg
of each protein standard and WLN construct (in a volume of 100 μL) were injected onto
the column after it had been equilibrated with 2 CVs of buffer. Each protein was eluted
isocratically with 1.2 CVs of buffer. The WLN constructs were diluted with gel filtration
buffer prior to injecting onto the column, and fresh DTT was added (10 mM final
concentration) to ensure that the proteins were reduced. At least two injections of each
protein standard and WLN construct were performed, and the average elution volume
was used to calculate Kav. The elution volume was taken from the peak apex, which was
found using the Unicorn software (version 3.21.02) that was provided with the ÄKTA
FPLC.
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Table 2.13: The protein standards used to construct the calibration curves for HRGF.
Protein
Aprotinin
Cytochrome c
Ribonuclease A
Carbonic Anhydrase
Ovalbumin
Albumin

Molecular Weight (Daltons)
6,500
12,400
13,700
29,000
43,000
66,000

HRGF can also be used to monitor the formation of complexes between proteins
(7–9). This technique was used to investigate whether an interaction was occurring
between WLN1-3 and WLN4, as results from circular dichroism experiments on WLN14 suggested that WLN1-3 and WLN4 were interacting. If an interaction was occurring
between the constructs, the presence of a species with a mass approximately equal to that
of WLN1-4 might be observable.
Equimolar amounts (100 μM) of both constructs were incubated in 500 μL of 50
mM sodium phosphate buffer, pH 7.5. No DTT was added (in case the interaction was
mediated by a disulfide bond) and the sample was left at room temperature for 24 hours.
Aliquots (100 μL) were injected onto the Superdex 75 HRGF column after 1, 5 and 24
hours. For comparative purposes, WLN1-3, WLN1-4, and WLN4 were also run on the
column to verify their elution volumes. The same gel filtration buffer (without DTT,
however), equilibration and elution volumes, and flow rate that were described above
were used.

2.5.2

Gel Filtration Analysis of the Association State of HAH1
Gel filtration chromatography was used to investigate the influence of pH and

Hg(II) binding on the association state of HAH1. A Superdex 75 HiLoad 16/600 column
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was used in conjunction with one of three different buffers: pH 7.5 and 8.5 buffers
contained 100 mM sodium phosphate, 200 mM sodium chloride, 1 mM TCEP, and the
pH 9.4 buffer contained 100 mM CHES, 200 mM sodium chloride, 1 mM TCEP. TCEP
was included in the buffer in order to prevent the oxidation of cysteines at elevated pH, as
oxidation could result in the formation of HAH1 dimers. The gel filtration studies were
conducted at 4̊C (the FPLC was in a ref rigerator), necessitating that the buffers be
prepared (at room temperature) such that they would have the appropriate pH at 4˚C.
Prior to each injection (0.5 mL), the column was equilibrated with 1 CV (~120 mL) of
buffer using a flow rate of 1 mL/min. Samples were eluted isocratically with 1.1 CV of
buffer and a 1 mL/min flow rate. The elution volume of each protein was considered to
be the peak apex, which was found using the Unicorn Software.
A mixture of protein standards (aprotinin, ribonuclease A, carbonic anhydrase,
and ovalbumin, see Table 2.13 for details) was analyzed with each of the three buffers.
The mixture contained between 0.75-1 mg of each protein in a volume of 0.5 mL.
Duplicate injections were made for both the protein standards HAH1, and the average
elution volume was used for the calculations. At each pH, a calibration curve was
constructed from the standards using the procedure discussed in the previous section; this
curve was used to calculate the apparent molecular weights of apo- and Hg(II)HAH1 at
each pH.

2.5.3

Light Scattering
Light scattering (LS) is an analytical technique that can be used to determine

several important biophysical characteristics of a protein, including the hydrodynamic
radius (RH), the radius of gyration (Rg), the molecular weight, and the shape. This non69

invasive technique requires small amounts of protein (~100-300 μg, depending on the
molecular weight of the protein) and yields the oligomerization state of the sample (10).
There are two types of light scattering techniques: static and dynamic. Both
techniques take advantage of the fact that molecules in solution scatter light in a manner
that is dependent on their size and shape; the scattering intensity is also influenced by the
Brownian movement of the particles (11). The primary difference between these
techniques is the time scale.

Dynamic light scattering (DLS) operates on the

microsecond timescale and measures the rapid fluctuations in the intensity of scattered
light that occurs in a small volume of solution; the RH and translational diffusion
coefficient are two values that can be extracted from this technique.

In contrast, static

light scattering (SLS) operates on the second timescale, and the intensity of the scattered
light over this time is averaged (i.e. the system being studied is static, not dynamic);
consequently, the transient fluctuations in scattered light that are observed in DLS are
absent in SLS.

The molecular weight of the molecule, Rg, and the second virial

coefficient (A2) can be calculated from SLS data.
DLS takes advantage of the fact that rapid fluctuations in the intensity of scattered
light reflect the diffusion rate of the particles, i.e. the Brownian motion (11). This
diffusion rate, known as the translational diffusion coefficient (D), is a variable in the
autocorrelation function; D is calculated from the raw data through curve fitting. The
autocorrelation function describes how the signal intensity changes with time and
indicates the likelihood that the same signal intensity will be encountered at some later
time. Since this likelihood decreases with time, the autocorrelation curve takes the form
of an exponential decay curve.

Once D is known, the Stokes-Einstein Equation
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(Equation 2.2) can be solved for RH. In this equation, k is the Boltzmann constant, T is
the temperature, D is the translational diffusion coefficient, and η is the solvent viscosity.

𝐷=

𝑘𝑇

6𝜋𝜂𝑅𝐻

[2.2]

The foundation of SLS is that the amount of light scattered by a sample is directly
proportional to the product of the sample concentration and the sample’s weight-average
molar mass (11).

Zimm’s formalism of the Rayleigh-Debye-Gans model for the

scattering of light by a dilute polymer solution, shown below in Equation 2.3,
established this correlation (11, 12). In this model, K*c/R(θ) is plotted against sin2 (θ/2)
and the data is fit to an equation in the form of sin2 (θ/2). The molar mass is given by the
y-intercept while the radius of gyration is given by the slope. The radius of gyration is
the root mean square distance to the particle’s center of gravity. If the concentration of
the sample as it elutes from the gel filtration column can be independently determined,
then Equation 2.3 can be solved by ASTRA software (Wyatt Technology, Santa
Barbara, CA) using the Deybe model. A refractive index detector is frequently used to
measure the concentration.
𝐾∗𝑐

𝑅(𝜃)

=

1

𝑀𝑊∙𝑃(θ)
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+ 2𝐴2 𝑐

[2.3]

Table 2.14: Definition of the variables used in Equation 2.3.
Variable
K*

Description
An optical parameter that is equal to 4π2n2(dn/dc)2/(I04NA)

c

The sample concentration (g/mL)

R(θ)

The excess intensity of scattered light at angle θ

MW

The weight-average molar mass

P(θ)

The angular dependence of the scattered light

A2

The second virial coefficient (measures sample/solvent interaction)

NA

Avogadro’s number

I0

Wavelength of scattered light in a vacuum (cm)

The amount of light that is scattered is dependent on the sample’s polarizability:
the more polarizable the sample, the greater the intensity of the scattered light. This is
accounted for by dn/dc, where dn is the change in the refractive index and dc is the
change in concentration.
DLS and SLS analyses on WLN1-2, WLN1-3, and WLN1-4 were done at the
Keck Foundation Biotechnology Resource Facility at Yale University by facility
personnel. The samples were injected onto a Superdex 75 HRGF column (WLN1-2) or a
Superdex 200 HRGF (WLN1-3 and WLN1-4) that was connected to an Agilent 1200
HPLC (Agilent Technologies, Wilmington, DE). The column effluent was monitored by
three detectors: an OPTILAB rEX Refractive Index Detector (Wyatt Technology, Santa
Barbara, CA), a DAWN-HELEOS Light Scattering Detector, and a Waters 996
Photodiode Array Detector (Waters Corporation, Milford, MA). The buffer was 50 mM
HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA and 1 mM DTT; a flow rate of 0.75
mL/min was used for the Superdex 75 column while a flow rate of 0.5 mL/min was used
for the Superdex 200 column. Chemstation software (Agilent Technologies, Wilmington,
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DE) controlled the HPLC and collected the UV-Vis data from the PDA while ASTRA
software (Wyatt Technology, Santa Barbara, CA) controlled the other two detectors.
All samples submitted for analysis were between 4.8-5 mg/mL in 50 mM sodium
phosphate buffer, pH 7.5. Prior to injection onto the column, the samples were filtered
through a 0.22 μm Durapore membrane ( UFC30GVNB, EMD Millipore) to remove
particulates. The filtrates were then diluted to a concentration of 2.5-3 mg/mL using the
gel filtration buffer, and 0.35 mL of each sample was injected.
The weight average molar mass for each construct was calculated across the entire
peak and was determined using the ASTRA software (version 5.4.3.10) and the Debye
model (10). Bovine serum albumin and trypsin inhibitor were used to normalize the
intensity of the scattered light 90° to the sample cell. The hydrodynamic radius of each
construct was calculated using ASTRA software in conjunction with the LS data taken in
2 second slices.

2.5.4

Circular Dichroism
The phenomenon of circular dichroism (CD) is observed when optically active

molecules differentially absorb left- and right-handed circularly polarized light.

In

proteins, the peptide bond is a chromophore and absorbs circularly polarized light in the
far UV region (190-260 nm).

Maximum absorption of light occurs at specific

wavelengths and is determined by the geometry of the peptide bond. Consequently,
different secondary structural elements absorb circularly polarized light at unique
wavelengths. Peptide bonds in α-helices have negative peaks at 222 and 208 nm and a
positive peak at 193 nm while peptide bonds in β-sheets have a negative peak at 218 nm
and a positive peak at 195 nm; bonds found in random coils have a negative peak at 195
73

nm (13–15). The negative peaks at 222 nm in α-helices and 218 nm in β-sheets are due
to the n→π * transition of the peptide bond while the negative peak at 208 nm in α-helices
and the positive peak at 195 in β-sheets are attributed to the π →π* transition (13–15).
CD experiments were performed using a Jasco J-815 Spectropolarimeter. The
temperature was regulated by a Peltier Thermostated Cell Holder (Jasco, PTC-423) that
was cooled with a water pump. Prior to use, the instrument was purged with nitrogen
(high purity grade) for 15 minutes at 15 psi to removed oxygen, as the high voltage
produced when running the instrument generates ozone that damages the optics. The
same flow rate of nitrogen was maintained while the instrument was in use.
Two types of CD experiments were performed: one at fixed temperature and
scanning wavelength, and the other at scanning temperature and fixed wavelength. The
former was used to monitor the denaturation of the WLN constructs by guanidine
hydrochloride (GuHCl), and the latter was to monitor the thermal denaturation of the
constructs. The different experiments utilized different cuvettes and data acquisition
parameters.
GuHCl unfolding for all constructs was performed on samples that contained 1020 μM protein, 5 mM phosphate buffer (pH 7.5), and concentrations of GuHCl ranging
from 0-~7M. A series of samples was prepared of each protein that contained the same
amount of protein and buffer, but varying amounts of GuHCl.

The maximum

concentration of GuHCl that could be attained depended on the concentration of both the
protein and GuHCl stock solutions as well as the requisite final protein concentration. A
CD signal of at least ~-30 millidegrees (mdeg) at 222 nm was desired for each sample
that contained no GuHCl (i.e. 0 M GuHCl), and the concentration of protein required to
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generate this signal varied among the constructs, with smaller constructs requiring higher
concentrations. Samples were equilibrated at room temperature for 2 hours before the
CD spectra were recorded.
Spectra were collected from 190-260 nm, with a scanning rate of 100 nm/min, a
data pitch of 0.1 nm, a bandwidth of 1 nm, and a digital integration time of 1 second.
Three scans were accumulated during each run, with the final spectrum being an average
of the three scans. The samples were placed in a 1 mm rectangular quartz cuvette, which
was rinsed three times with filtered deionized water between samples. The temperature
was held constant at 25°C.
The 8 M GuHCl stock solution was prepared by weighing the appropriate amount
of GuHCl into a 50 mL conical tube and diluting to the requisite volume with deionized
water. Since GuHCl is hygroscopic, however, a more accurate means of determining the
concentration was required. This was achieved by measuring the refractive index of the
GuHCl solution and water on a Bausch and Lomb Abbe 3L refractometer. Equation 2.4
was then used to calculate the exact molarity of the solution, where ΔN is the difference
in the refractive index between the GuHCl solution and water (16).
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦) = 57.147Δ𝑁 + 38.68Δ𝑁 2 − 91.60Δ𝑁 3

[2.4]

The raw CD signal (mdeg) was converted to units of mean residue molar
ellipticity ([θMRW], a unit commonly used for reporting the ellipticity of proteins. This
unit specifies the ellipticity for protein residues instead of entire proteins and is useful for
comparing proteins of different sizes. Equation 2.5 was used to convert mdeg to mean
residue ellipticity; θ is the CD signal in mdeg, CMR is the mean residue concentration
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(CMR = molar protein concentration * number of residues), and l is the path length of the
cuvette in centimeters. The unit for [θ]MRW is deg * cm2 * dmol-1.

[𝜃]𝑀𝑅𝑊 =

100 × 𝜃

[2.5]

𝐶𝑀𝑅 × 𝑙

Several thermodynamic parameters were calculated from the GuHCl unfolding
°
), the m value, and the
curves, including the free energy of unfolding (ΔGH
O

°
concentration midpoint (Cm). ΔGH

2

2O

is the free energy of unfolding extrapolated back to

zero denaturant (details given below); a positive value indicates that the folded protein is
more stable than the unfolded one. The m value reflects the amount of the protein’s
surface area that is exposed to the solvent upon denaturation and shows how the free
energy of unfolding is dependent upon the concentration of the denaturant (17). The Cm

is the denaturant concentration at which 50% of the protein is folded and 50% unfolded.
These parameters were all determined by fitting the curve of denaturant concentration
versus the CD signal at 222 nm to either a two- or three- state equation.
In a two-state unfolding mechanism, a protein exists in either the native (N) state
or the denatured state (D). The transition from the native to the denatured state is
governed by an equilibrium constant, KND, as shown in Equation 2.6 below. At low
concentrations of denaturant, the native state is favored. As the denaturant concentration
increases, the forces that stabilize the protein’s structure are disrupted and the protein
begins to unfold. At the highest concentration of GuHCl (~7 M), the protein is assumed
to be completely unfolded. The observed CD signal at any concentration of GuHCl
results from a linear combination of the amount of protein that is in the fully native state
and the fully denatured state; any intermediates that form during denaturation exist
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transiently and accumulate to negligible levels. A two-state unfolding mechanism is
indicated by a sigmoidal curve when the denaturant concentration versus the CD signal at
222 nm is plotted.

[2.6]

Curves that displayed an apparent two-state unfolding mechanism were analyzed
as follows. For any concentration of guanidine hydrochloride [GuHCl], the free energy
of unfolding associated with the transition of the protein from its native to a denatured
state was assumed to vary according to Equation 2.7 (18). In this equation, ∆𝐺𝐻°

𝟐𝑂

is the

free energy of unfolding extrapolated back to zero denaturant and m is the slope of a plot
of ΔG versus [GuHCl].
°
ΔG = ΔGH
− m[GuHCl]
2O

[2.7]

Since the observed CD signal (Sobs) results from the linear combination of the
fraction of the protein that in its native form (fN) and the fraction that is denatured (fD),
then Equation 2.8 results,

Sobs = SN fN + SD fD
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[2.8]

where SN is the signal of the native protein (i.e. at 0 M GuHCl) and SD is the signal of the
fully denatured protein (the highest [GuHCl] that was used in each experiment, ~7 M).
As all of the protein is either in the native or denatured form, fN + fD =1. Taking into
account that ΔG = -RT ln(fN/fD), Equation 2.9 can be written (19); R is the gas constant
and T is the temperature.

𝑆𝑜𝑏𝑠 =

𝑆𝑁 +𝑆𝐷 𝑒
1+𝑒

−(∆𝐺𝐻 𝑂 −𝑚[𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇
2

−(∆𝐺𝐻 𝑂 −𝑚[𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇
2

[2.9]

Proteins that displayed a sigmoidal curve when the [GuHCl] was plotted against
the CD signal were considered to unfold via an apparent two-state model. The data were
fit to the above equation using IGOR Pro 6 (Wavemetrics, Portland, OR), permitting the
determination of 𝛥𝐺𝐻° 𝑂 , and the m value. Fitting the data to IGOR’s built in sigmoid
2

function was used for determining Cm.

In a three-state unfolding pathway, a stable intermediate (I) is formed as the
protein transitions from its native (N) to a denatured state (D). As Equation 2.10 below
shows, the transitions from N  I and I  D each have their own equilibrium constants,
KNI and KID, respectively. Both transitions also have their own ΔG and m values,
ΔGNI and mNI and ΔGID and mID, respectively. A plot of denaturant concentration
vs. CD signal for a protein that unfolds via a stable intermediate has a double sigmoidal
curve.

Proteins displaying such a curve were considered to unfold via an apparent 3-

state model and were analyzed as discussed below.
K N I

N

KID

I

D
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[2.10]

The accumulation of an intermediate requires a more complex equation to fit the
curve. The equation, shown on the following page as Equation 2.11, is similar to
Equation 2.9 but contains parameters to account for the presence of the intermediate. SN,
SD , R, and T have the same definitions as they did in the two-state model. ΔGNI and
mNI and ΔGID and mID were calculated using the above equation. The concentration
midpoints for the NI and ID transitions were found by using Equation 2.12, where
xhalf1 and xhalf2 were the first and second transitions, respectively.

The other

parameters in this equation did not correspond to any values of interest. Both equations
were fit to the curves using IGOR Pro 6.
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𝑆𝑜𝑏𝑠
=

𝑆𝑁 + 𝑆𝐼 𝑒𝑥𝑝{−(∆𝐺𝑁→𝐼 − 𝑚𝑁→𝐼 [𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇} + 𝑆𝐷 𝑒𝑥𝑝{−∆𝐺𝑁→𝐼 − 𝑚𝑁→𝐼 [𝐺𝑢𝐻𝐶𝑙]}𝑒𝑥𝑝{−(∆𝐺𝐼→𝐷 − 𝑚𝐼→𝐷 [𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇}
1 + 𝑒𝑥𝑝{−(∆𝐺𝑁→𝐼 − 𝑚𝑁→𝐼 [𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇} + 𝑒𝑥𝑝{−∆𝐺𝑁→𝐼 − 𝑚𝑁→𝐼 [𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇}𝑒𝑥𝑝{−∆𝐺𝐼→𝐷 − 𝑚𝐼→𝐷 [𝐺𝑢𝐻𝐶𝑙])/𝑅𝑇}

𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒 𝑅𝑒𝑠𝑢𝑙𝑡 = 𝑏𝑎𝑠𝑒 + (𝑚𝑎𝑥1)(1 + exp {−(𝑥𝑥 − 𝑥ℎ𝑎𝑙𝑓1)/𝑟𝑎𝑡𝑒1})
𝑅𝑒𝑠𝑢𝑙𝑡 = (𝑚𝑎𝑥2)/(1 + exp {−(𝑥𝑥 − 𝑥ℎ𝑎𝑙𝑓2)/𝑟𝑎𝑡𝑒2})
𝑓(𝑥𝑥) = 𝑟𝑒𝑠𝑢𝑙𝑡

[2.11]

[2.12]
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Thermal unfolding studies were done on the WLN constructs as well. In these
experiments, the temperature varied while the wavelength remained constant. Unfolding
was monitored from 25-97°C, with a gradient of 2°C/min. Upon reaching 97°C, that
temperature was held for 3 minutes before the sample was cooled according to the same
gradient and the cooling spectra collected. For both the forward and reverse gradients,
the band width was 1 nm and the data integration time was 1 second. A small stir bar
was added to the cuvette, and the sample was stirred continuously during the experiment.
The CD signal was monitored at 222 nm, as α-helices absorb maximally at this
wavelength, and each metal-binding domain is known to possess two α-helices. The
samples contained 3-7 μM protein and 5 mM phosphate buffer. Higher concentrations of
the smaller constructs were required to attain the minimally desired signal of ~-30 mdeg.
A 1 cm rectangular quartz cuvette was used. No buffer blank was used. The melting
temperatures (Tm) were calculated using the Spectra Manager software (version 2.08.01)
that was supplied with the instrument.

2.5.5

Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was used to determine the melting

temperature (Tm) of apo WLN1-4 and apo and Cu(I)-WLN4.

This analysis was

performed by personnel at the Biophysics Core at the University of Colorado-Denver
Anschutz Medical Campus. These proteins were analyzed by DSC because a thermal
unfolding transition was not observed by CD for WLN1-4 and Cu(I)WLN4. ApoWLN4
was analyzed as well for both verification of the Tm determined by CD and as a reference
for comparison of the DSC determined Tm for Cu(I)-WLN4.
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In DSC, the heat capacity (Cp) of a sample and a reference cell is measured as a
function of increasing temperature. If the sample undergoes a phase transition (i.e. melts
or unfolds), then its heat capacity will change relative to the heat capacity observed in the
reference cell, which contains the buffer blank. This change in heat capacity is indicated
by a peak in the plot of temperature versus Cp; the area of the peak is equal to the
enthalpy change associated with the phase transition.
A MicroCal VP-DSC (GE Healthcare) instrument was used for the analysis. A
temperature gradient of 1°C/min, from 20-110°C, was applied. The instrument was
controlled using the VPViewer software supplied by the manufacturer. Data analysis was
performed using the Microcal Origin software package.
Apo and Cu(I)-WLN4 were each run once. The sample cell was loaded with 0.5
mL of protein (both proteins were 1 mg/mL in 50 mM sodium phosphate buffer, pH 7.5)
while the reference cell was loaded with 0.5 mL of 50 mM sodium phosphate buffer, pH
7.5.
Multiple concentrations of apoWLN1-4 were analyzed by DSC: 0.1 mg/mL, 0.25
mg/mL, 0.5 mg/mL, and 1 mg/mL. As with the WLN4 samples, 0.5 mL of WLN1-4 in
50 mM sodium phosphate buffer, pH 7.5, was loaded into the sample cell while 0.5 mL
of 50 mM sodium phosphate buffer, pH 7.5 was loaded into the reference cell. A 1
mg/mL solution was used initially, but the protein precipitated during the course of the
thermal gradient.

The diluted solutions were then tried in an attempt to find a

concentration that produced a clearly discernible signal without precipitating. Each of
the different concentrations was run once, from 20-110°C with a temperature gradient of
1°C/min.
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Prior to submitting the samples for DSC analysis, the copper content of the
proteins was determined using ICP-AES (see Section 2.4.5.3 for details). The proteins
were quantitated using the BCA assay.

2.5.6

Nuclear Magnetic Resonance Spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy is a powerful technique that can

be used to evaluate the structure and dynamic properties of proteins in solution. Single
proteins as well as protein-protein interactions can be studied with this non-invasive
technique (20–22) Proteins being studied by NMR must be enriched in NMR active
isotopes, i.e.

13

C and/or

15

N; large proteins > 40kD are also frequently enriched with

deuterium (2H) as well. This enrichment is achieved by expressing proteins in minimal
media supplemented with the appropriately labeled feedstock. The procedures used for
expressing the labeled proteins studied in this research as discussed in Section 2.4.4.3.
All of the NMR data was collected using a Bruker AVANCE II 800 MHz NMR
that was equipped with a cryoprobe. This NMR, located at the Lizzadro Magnetic
Resonance Research Center at the University of Notre Dame (South Bend, IN), was
operated with assistance from facility personnel.
All proteins were analyzed in buffers comprised of 50 mM sodium phosphate, pH
7.5, 10 mM d12-EDTA, and 5% D2O. The protein concentration varied according to the
particular WLN construct, as shown in Table 2.15 below.

While high protein

concentrations are desirable, the proteins had a propensity to aggregate over time at
elevated concentrations; consequently, lower concentrations had to be used in order to
preserve the sample integrity. As a buffer with high conductivity negatively influences
the signal to noise ratio when using a cryoprobe, sodium chloride was not used in the
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samples to stabilize higher protein concentrations (23).

Two (2D) and three (3D)

dimensional experiments were performed on WLN4 and WLN1-4. These experiments
were run in succession, and samples frequently had to be exchanged for new ones after
two to three days due to protein aggregation. A summary of the experiments that were
run on the various WLN constructs are shown in Table 2.15.
The non-copper loaded forms of all proteins were analyzed, with the copper
content being determined by ICP-AES as discussed in the previous section. The protein
concentration was determined for WLN1-2 and WLN1-4 using the BCA assay while
WLN4 was quantitated using the Bio-rad Assay. Thin wall NMR tube rated for 1000
MHz (part number 542-PP-8, Wilmad-Lab Glass) were used in all experiments. For
experiments performed at temperatures other than 25°C, an external standard of 10 μM
sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) was used to reference the chemical
shifts. The acquisition parameters varied according to the specific experiment being run.
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Table 2.15: Summary of NMR experiments done with WLN1-2, WLN1-4, and WLN4.
Protein Construct
C,15N WLN4 (100 μM)

13

Experiment
H-15N HSQC

1

HNCACB

CΒCA(CO)NH

HNCA

C,15N WLN1-2 (200 μM)

1

H-15N HSQC

C,15N WLN1-4 (300 μM)

1

H-15N HSQC

13

13

Comment
Collected at 25°C, 37°C, and 50°C
Correlates the amide proton and the
amide nitrogen of i
Collected at 37°C
Correlates N and HN of i with Cβ
and Cα of i and i-1
Collected at 37°C
Correlates N and HN of i with Cβ
and Cα of i-1
Collected at 37°C
Correlates N and HN of i with Cα of
i and i-1
Collected at 25°C
Correlates the amide proton and the
amide nitrogen of i
Collected at 25°C
Correlates the amide proton and the
amide nitrogen of i

The backbone resonance assignment of WLN4 was achieved by walking through
the Cα chemical shifts and linking stretches of amino acids that were sequentially
adjacent.

Three experiments were run to collect the requisite data to perform the

sequential walking: a 1H-15N HSQC, which showed all correlations between N(i) and
HN(i), a HNCACB, which showed all correlations between N(i), H-N(i) with Cα and Cβ
of i and i-1 and a CBCA(CO)NH, which showed all correlations between N(i), H-N(i)
with Cα and Cβ of i-1 (24, 25). (Figure 2.11 below shows the structure of a generic
dipeptide, with the name of each particular atom indicated.)
Since the CBCA(CO)NH showed only the Cα and Cβ from i-1 while the
HNCACB showed the Cα and Cβ from both i and i-1, the Cα and Cβ associated with a
specific NH could be discerned. This made it possible to group atoms into spin systems,
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which could then be linked to other spin systems through sequential walking. These short
sequences were then mapped onto the full sequence of WLN4 using CARA, a computer
program developed by Rochus Keller and Dr. Kurt Wüthrich at The Swiss Federal
Institute of Technology in Zurich, Switzerland (www.cara.nmr.ch). NMR spectra were
processed with the NMRPipe Program with the assistance of Dr. Blair Szymczyna.

Figure 2.111 Diagram of a generic dipeptide with each atom labeled. Various NMR
experiments detect specific atoms of either the i residue and/or the i-1 (preceding) residue
in a protein.

2.6

Summary
This chapter discussed the materials, reagents, and instruments used in the course

of this research. The procedures used to prepare the pET32-WLN1-2, pET32-WLN1-3,
pET32-WLN1-4 G333R, and pET32-WLN4 plasmids were detailed. Also discussed
were the expression of the labeled and non-labeled protein constructs as well as their
subsequent purification. Finally, the biophysical techniques used to characterize the
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protein constructs were described.

These techniques included high resolution gel

filtration, laser light scattering, circular dichroism, differential scanning calorimetry, and
nuclear magnetic spectroscopy.
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CHAPTER 3
PLASMID PREPARATION, PROTEIN EXPRESSION, AND PURIFICATION OF
THE WLN CONSTRUCTS

3.1

Introduction
Protein constructs comprised of single or multiple metal-binding domains of

human Wilson disease protein have been amenable to expression in E. coli (1–7). While
the single domain constructs are often readily expressed without the use of solubility tags,
many of the multiple metal-binding domain constructs are better expressed as fusions
with proteins (solubility tags) such as thioredoxin, maltose binding protein, or glutathione
S-transferase. The benefits of expressing the metal-binding domains as fusion proteins
instead of by themselves include an increased protein yield and better solubility (i.e. they
are less likely to be found in inclusion bodies). Affinity tags such as a His6 tag (i.e. six
histidines in a row) are also frequently incorporated into these fusions to provide a
convenient means of purification.
This chapter discusses the preparation of the plasmids containing the WLN
constructs as well as the expression and purification of the proteins.

3.2

Plasmid Preparation
The Quik Change II XL Site-Directed Mutagenesis Kit was used to create the

pET32-WLN1-2, pET32-WLN1-3, and pET32-WLN1-4 G333R plasmids. Details of the
primers, PCR parameters, and reagent information can be found in Sections 2.2. and
2.4.1-2.4.2. The pET32-WLN1-2 and pET32-WLN1-3 plasmids were created by using
the mutagenesis kit to insert a stop codon in the appropriate location in the pET32WLN16 plasmid, which codes for all six metal-binding domains. For example, the pET3291

WLN1-2 plasmid was produced by inserting a stop codon after the end of the second
metal-binding domain in the pET32-WLN1-6 plasmid while the pET32-WLN1-3 plasmid
was produced by inserting a stop codon after the end of the third metal-binding domain.
The pET32-WLN1-4 G333R plasmid was created by using the same site directed
mutagenesis kit to introduce a guanine to adenine mutation in the pET32-WLN1-4
plasmid; this missense mutation resulted in a glycine to arginine substitution at position
333, which is located in the linker region between the third and fourth metal-binding
domains. Following mutagenesis, the plasmids were used transformed into XL-10 Gold
cells (Agilent Technologies); the transformation procedure can be found in Sections
2.4.3. The plasmids were propagated by using cells from single colonies to inoculate 5
mL of liquid LB media that contained 100 μg/mL carbenicillin; multiple 5 mL cultures
were prepared.

The cells were pelleted after 8-10 hours of growth (in a shaker

maintained at 37°C, 250 rpm) by centrifugation at 15,000 rpm in a tabletop centrifuge.
After purification using Qiagen’s QiaPrep® Spin Miniprep Kit, the plasmids were
digested with BglII (20 U) and BamHI (30 U) and run on a 0.8% agarose gel to verify the
presence of the expected fragments. As shown in Figure 3.1 below, all three of the
plasmids contained the expected fragment sizes of 5800 bp (pET-32Xa/LIC vector) and
1,731 bp (the WLN1-6 insert). Note that all of the plasmids constructed here contain the
same 1,731 bp insert, although the plasmids express different proteins. This is because
the plasmids were constructed by inserting a stop codon at the appropriate position
instead of cloning only the desired metal-binding domains into the pET-32Xa/LIC vector.
After verification of the correct fragment sizes by agarose gel electrophoresis, the
plasmids were quantitated by measuring their absorbance at 260 nm and sent for
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sequencing at Retrogen (San Diego, CA). The plasmids with the correct sequence were
stored at -20°C and used for future experiments.

Figure 3.1: Agarose gel (0.8%) of the pET32-WLN1-2, pET32-WLN1-3, and pET32WLN1-4 G333R plasmids that were digested with BamHI (30 U) and BglII (20 U). The
lane contents were as follows: 1) 1 kb markers (New England Biolabs), 2) pET32WLN1-2, 3) pET32-WLN1-3, 4) pET32-WLN1-4 G333R. The ~1.7 kb fragment in lanes
2-4 is the WLN1-6 insert, the ~5.8 kb fragment is the pET-32Xa vector, and the band at
~7.5 kb is undigested plasmid.

The pET32-WLN1-6 plasmid used as the template DNA was graciously provided
by a fellow lab member, Dr. Joshua Muia. The pET32-WLN1-4 plasmid used as the
template DNA to prepare the pET32-WLN1-4 G333R mutant was prepared by Dr.
Joshua Muia and Sun Hwa Lee. Since the pET32-WLN1-6 plasmid was engineered with
a TEV cleavage site (ENYLFQG), all the plasmids prepared using this plasmid as the
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template DNA contained this site as well; these included all of the plasmids discussed
above.
These plasmids expressed the WLN constructs as fusion proteins with
thioredoxin (TRX) located at the N-terminal of fusion, as shown in Figure 2.8. The
fusion proteins also contained a His6 tag located between the thioredoxin tag and the
metal-binding domains.
The pET32-WLN4 plasmid was created by using KOD Hotstart DNA Polymerase
to amplify the fourth metal-binding domain in the pET32-WLN1-6 plasmid. The primers
were designed to incorporate a TEV protease restriction site into the plasmid sequence.
Though the pET-32Xa/LIC vector possesses a Factor Xa cleavage site (IEGR), using
Factor Xa to cleave fusion proteins has proven problematic for other members of this lab.
Factor Xa is expensive, and in order to get a high level of cleavage, many units of
enzyme were required.

Additionally, this enzyme apparently produces non-specific

cleavage in the fusion proteins, as evidenced by the presence of protein bands with
unexpected sizes on SDS-PAGE gels (data not shown). In contrast, TEV protease is a
much cheaper protease (it can be produced in-house) that has not shown any evidence of
non-specific cleavage. Consequently, the decision was made to incorporate the TEV
restriction site into the pET32-WLN4 plasmid and avoid using the Factor Xa cleavage
site.
Following PCR, the PCR product was then cloned into the pET-32Xa/LIC vector
using ligation independent cloning. Details on the primers, PCR parameters, reagents,
and ligation into the pET-32XA/LIC vector can be found in Sections 2.2. and 2.4.1-2.4.2,
respectively. After ligation, the plasmid was used transformed into XL-10 Gold cells
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(Agilent Technologies), as discussed in Section 2.4.3. The plasmid was propagated by
using cells from single colonies to inoculate 5 mL of liquid LB media that contained 100
μg/mL carbenicillin or ampicillin.

Multiple colonies were screened by inoculating

multiple 5 mL aliquots of LB, each with cells from a single colony. After 8-10 hours of
growth at 37°C in a shaker (250 rpm), the cells were pelleted by centrifugation at 15,000
rpm in a tabletop centrifuge. Subsequently, the plasmids were purified using QIAGEN’s
QiaPrep® Spin Miniprep Kit. An aliquot of the plasmids were digested with BglII (20 U)
and BamHI (30 U) and run on a 1.0% agarose gel to verify the presence of the expected
fragments, as shown in Figure 3.2 below. The size of the pET-32XaLIC vector was
5800 base pairs while the size of the WLN4 insert is 284 base pairs. Quantitation of the
plasmid was done by measuring the absorbance at 260 nm. Multiple plasmids were
submitted to Retrogen (San Diego, CA) for DNA sequencing. Plasmids with the correct
sequence were kept and stored at -20°C.
As with the plasmids constructed above, the pET32-WLN4 plasmid expressed
WLN4 as a fusion protein with thioredoxin located at the N-terminal, followed by a His6
tag. A diagram of the fusion protein is shown in Figure 2.8.
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Figure 3.2: Agarose gel (1%) of the pET32-WLN4 plasmid digested with BamHI (30 U)
and BglII (20 U). The lane contents were as follows: 1) 100 bp markers (New England
Biolabs), 2) pET32-WLN4 digest 3) 1 kb marker (New England Biolabs).

3.3

Protein Expression
All protein expression was done in Rosetta™ 2(DE3) cells. This BL21 derivative

was selected because it contained tRNAs for 7 codons that are uncommonly used by E.
coli but frequently used by eukaryotes (EMD Millipore, Technical Bulletin TB009). The
pET32-WLN1-4 and pET32-WLN1-4 G333R plasmids contained all of these codons
while the plasmids of the smaller WLN constructs had fewer.
The transformation procedure used for inserting the plasmids into Rosetta™
2(DE3) cells was discussed in Section 2.4.4.1. Briefly, 5 μL of cells were transformed
using 10-20 ng of plasmid DNA. Following a one hour incubation with SOC media in a
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37°C shaker, the cells were plated onto an LB-agar plated that contained either 100
μg/mL carbenicillin or ampicillin and 34 μg/mL chloramphenicol. The plates were then
incubated in a 37°C oven for 16-18 hours, after which time 50-75 colonies were typically
produced.

3.3.1

Expression of Non-labeled Proteins
LB media was used for the production of non-labeled proteins, which was used in

all experiments except those involving NMR. The procedure used for growing and
expressing the proteins is detailed in Section 2.4.4.2. In summary, a 5 mL starter culture
was grown using cells from a single colony on the LB-agar plate. This culture was used
to inoculate 50 mL of LB; the 50 mL culture was then used to inoculate 500 mL of LB.
After the OD600 of the 500 mL culture reached between 0.6-0.8, protein expression was
induced by the addition of IPTG (1 mM final concentration). To maintain adequate
aeration, only 500 mL of LB was contained in a 2.8 L flask. Total culture volumes of
either 1 or 2 liters were grown simultaneously. The cultures were all grown in a shaker
maintained at 37°C and 250 rpm. Protein expression was done at either 37°C for 4 hours
or room temperature (~22°C) for 16 hours. As the thermostat on the shaker could not
reliably sustain temperatures < 25°C, the lid on the shaker was kept open during these
inductions to maintain the temperature. The temperature of the lab remained constant
during the course of the inductions. Anecdotal evidence collected during this research
project suggested that longer induction times at lower temperatures produced more
recombinant protein. Intensive studies were not done to confirm this, however. For
production of non-labeled proteins, the two temperatures were used interchangeably,
depending of the availability of the shaker and time constraints.
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Following induction, the cultures were centrifuged at 5,000 rpm for 15 minutes at
4°C to produce a cell pellet. If protein purification did not begin immediately, then the
cell pellet was frozen at -20°C. A 1 L culture typically produced ~5-7 g of wet pellet.

3.3.2

Expression of 15N and 13C,15N Labeled Proteins
The procedure used to express single labeled (15N) and double-labeled (13C, 15N)

proteins was discussed in detail in Sections 2.4.4.3. The cultures were all grown at 37°C
while protein expression occurred at room temperature (~22°C) for 14-16 hours. A 1 L
culture of singly/doubly labeled protein typically produced ~ 5-6 g of wet pellet.
An initial induction study was performed at two temperatures, 22°C and 37°C, in
order to determine the optimal temperature for protein expression in minimal media. For
this experiment, unlabeled glucose and ammonium chloride was used in the M9 minimal
media. WLN1-4 was expressed in the induction studies. Cultures were grown to an
OD600 between 0.6-0.8 at 37°C and induced with IPTG (1 mM, final concentration).
Aliquots (1 mL) were taken at the time points indicated in Figure 3.3. The amount of
protein loaded onto the gels was normalized for all samples based on the OD600 recorded
for each aliquot.
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Figure 3.3: Temperature induction study of WLN1-4 grown in minimal media
containing unlabeled precursors. The lane contents were as follows: 1) Amersham Full
Range Rainbow Markers, 2) 22°C, 0 hr, 3) 22°C, 4.5 hr, 4) 22°C, 5.5 hr, 5) 22°C, 6.5 hr,
6) 22°C, 7.5 hr, 7) 37°C, 4.5 hr, 8) 37°C, 5.5 hr, 9) 37°C, 6.5 hr, 10) 37°C, 7.5 hr, where
the time listed is the number of hours after induction that the sample was collected. No 0
hr sample for the 37°C induction was run on the gel due to an insufficient number of
lanes; previous induction studies indicated that there was no induction at 0 hr (data not
shown). The TRX-WLN1-4 fusion protein (58 kD) is shown within the red oval. A
12.5% acrylamide gel was used; staining was done using 0.1% Coomassie Blue R-250.

As indicated in the gel above, the induction performed at 22°C yielded higher
levels of TRX-WLN1-4 than the induction done at 37°C. Consequently, 22°C was
selected as the induction temperature for expressing the label proteins.
Further induction tests were run using WLN1-4 in order to determine the optimal
induction time for protein expression in minimal media that contained labeled precursors.
In order to gauge the effect of the labeled supplements on the induction time, two
different media were used: M9 with

13

C-glucose and

15

N ammonium chloride and LB

media (used as a positive control, since this relatively nutrient rich media was conducive
to optimal protein expression). Culture growth, induction, and sampling were done the
same way as described for the temperature study above. Again, the amount of protein
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loaded onto the gels below was normalized for all samples. The gels run on the induction
test samples are shown below in Figures 3.4-3.5.

Figure 3.4: Time course induction study at 22˚C for the expression of WLN1-4 in
minimal media that contained 13C-glucose and 15N-ammonium chloride. The lane
contents were as follows: 1) Amersham Full Range Rainbow Markers, 2) 0 hr, 3) 10 hr,
4) 14 hr, 5) 21 hr, 6) 24 hr, 7) 37 hr, and 8) 44 hr, where the time listed is the number of
hours after induction that the sample was collected. The TRX-WLN1-4 fusion protein (58
kD) is shown within the red rectangle and appeared to run at a slightly higher molecular
weight than usual. This anomaly was attributed to a problem with the gel, as the
standards also ran oddly. A 12.5% acrylamide gel was used; staining was done using
0.1% Coomassie Blue R-250.
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Figure 3.5: Time course induction study at 22˚C for the expression of WLN1-4 in LB
media. The lane contents were as follows: 1) Amersham Full Range Protein Standards, 2)
0 hr, 3) 4 hr, 4) 8 hr, 5) 20 hr, 6) 24 hr, where the time listed is the number of hours after
induction that the sample was collected. The band highlighted with the red oval is TRXWLN1-4; the mass of this fusion protein is 58 kD. A 12.5% acrylamide gel was used;
staining was done using 0.1% Coomassie Blue R-250.

In the M9 media supplemented with labeled precursors, maximal protein
expression is reached at 14 hours and appeared to remain constant for up to 44 hours,
which suggested that the protein was not being degraded during the extended induction
times. Predictably, the LB culture reached maximum protein expression the soonest, at 8
hours, and the protein levels remained constant for up to 24 hours. Based on the results
of these studies, induction of the singly/doubly proteins was performed at 22°C for
between 14-16 hours.
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3.4

Protein Extraction and Purification

3.4.1

Protein Extraction
The same procedure was used to extract the proteins from the cell pellets,

regardless of the specific construct or labeling. This procedure, described in Section
2.4.5.1, was performed immediately prior to protein purification.

3.4.2

Protein Purification
The same purification scheme, described in Section 2.4.5.2 was used to purify all

constructs, regardless of the specific construct or labeling. The same columns were used
with all constructs, with the exception of the one used for gel filtration; WLN1-6 used a
Superdex 200 pg column while the other constructs used a Superdex 75 pg column.

HisPrep Column (Cell Lysate)
Desalting Column (Fusion Protein)
TEV Digest
HisPrep Column (TEV Digest)
Superdex 75 pg or Superdex 200 pg (WLN Construct)
Desalting Column (WLN Construct)
Figure 3.6: The purification scheme used to purify the WLN constructs. Shown in
parentheses is the sample that was loaded onto the column; this sample came from the
preceding purification step.
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During the initial purification step, the cell lysate was loaded onto the HisPrep
column. Since only proteins containing a His6 tag should have been bound to this
column, there was only one peak produced on the chromatogram. The apex of this peak
typically occurred at ~25% Buffer B for all constructs. A representative chromatogram is
shown in Figure 3.7. All of the fractions in the peak were combined and exchanged into
TEV digestion buffer for cleavage of the fusion protein with TEV protease.

Figure 3.7: A representative chromatogram of the purification of the fusion proteins
from the cell lysates using the HisPrep column. The first peak contained proteins that did
not bind to the column and were removed during the wash with Buffer A. The second
peak was the fusion protein that eluted during the gradient.

A 1:80 TEV protease:fusion protein ratio produced >95% cleavage after 16 hours
at room temperature, as estimated from SDS-PAGE gels (data not shown). No
promiscuity was observed with this enzyme. The TEV protease recognition site is
EQNLYFQG, with the protease cleaving between the residues in bold (8).
As a result, all the WLN constructs that began with the first metal-binding domain
contained an amino terminal glycine that was not part of the native protein sequence.
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The WLN4 construct also began with glycine, but first amino acid in the metal-binding
domain is a glycine (the preceding linker was not included in the construct). Separation
of the WLN constructs from the thioredoxin tag and the TEV protease was achieved by
using the HisPrep column. Since the WLN constructs lacked a His6 tag, they eluted
during the wash with Buffer A. Both the TEV protease and the thioredoxin tag possessed
a His6 tag and were bound to the column when the digest was loaded; they were
subsequently eluted in a single peak during the gradient. A representative chromatogram
is shown in Figure 3.8 below.

Figure 3.8: A representative chromatogram of the purification of the TEV digest of the
fusion proteins on the HisPrep column. The first peak contained the WLN construct,
which eluted during the wash with Buffer A. The second peak, containing the thioredoxin
tag and the TEV protease, eluted during the gradient.

Gel filtration chromatography was used to further purify the WLN constructs after
the initial purification of the digest on the HisPrep column. The column used depended
on the construct being purified: a Superdex 200 pg was used for WLN1-6 while a
Superdex 75 pg was used for the other constructs. The proteins were eluted isocratically
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from the columns using gel filtration buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 10 mM
EDTA, 10 mM DTT). The volume at which each construct eluted was determined by its
apparent molecular weight, with the larger constructs being eluted at smaller volumes.
Typically, the chromatogram for each construct contained a major peak (the WLN
construct) and one or more smaller peaks (impurities). An overlay of the constructs
purified using the Superdex 75 pg column is shown in Figure 3.9 below.

A

chromatogram of WLN1-6 that was purified using the Superdex 200 pg column is shown
in Figure 3.10.

Figure 3.9: An overlay of the chromatograms for the constructs purified using the
Superdex 75 pg column. The elution volume of each construct (taken from the peak apex)
was: 238 mL for WLN4, 216 mL for WLN1-2, 184 mL for WLN1-3, and 171 mL for
WLN1-4. The UV absorption at 254 nm was monitored and is shown on the y-axis as
milli-Absorbance Units (mAU).
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Figure 3.10: A chromatogram of WLN1-6 that was purified using a Superdex 200 pg
column. This construct eluted at 73 mL. The noisy baseline was due to lamp problems on
the FPLC.

The final stage of purification involved exchanging the constructs into 50 mM
phosphate buffer, pH 7-7.5. This was performed using the same Desalting column that
was used to exchange the fusion protein into TEV digestion buffer.
All constructs, except WLN4, were quantitated using the BCA assay; that
construct was quantitated using the Bio-rad Bradford Assay. WLN4 proved unresponsive
to the BCA assay, necessitating the use of an alternate assay.
For cultures grown in LB media, ~12-20 mg of purified WLN construct was
obtained per liter of culture. Cultures grown in M9 media supplemented with either 15Nammonium chloride and unlabeled glucose or

13

C-glucose and

15

N-ammonium chloride

typically yielded ~12-15 mg of purified WLN construct per liter of culture.
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Figure 3.11: SDS-PAGE Gel of various WLN constructs. The lane contents were as
follows: 1) Amersham Full Range Protein Standards, 2) WLN1-6, 3) WLN1-4, 4)
WLN1-3, and 5) WLN1-2. The molecular weights for the WLN constructs were 61.4 kD,
39.7 kD, 29.3 kD, and 16.9 kD, respectively. A 12.5% SDS-PAGE gel was used;
staining was done with 0.1% Coomassie R-250.
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Figure 3.12: SDS-PAGE Gel of WLN4. The lane contents were as follows: 1)
Amersham Full Range Protein Standards, and 2) WLN4. The molecular weight of WLN
4 was 7.5 kD. A 10% NuPAGE Bis-Tris gel from Invitrogen was used; staining was
done with 0.1% Coomassie R-250.

3.5

Summary
Four plasmids that contained different combinations of the N-terminal metal-

binding domains were prepared: pET32-WLN1-2, pET32-WLN1-3, pET32-WLN1-4
G333R, and pET32-WLN4. The first two plasmids were prepared using site directed
mutagenesis to insert a stop codon at the appropriate location in the pET32-WLN1-6
plasmid, resulting in constructs with the appropriate number of metal-binding domains.
The third plasmid was also created using the same site directed mutagenesis kit to
introduce a guanine to adenine mutation, which resulted in a missense mutation and the
conversion of a glycine residue to an arginine residue; pET32-WLN1-4 was used as the
template plasmid. The pET32-WLN4 plasmid was prepared by using PCR to amplify the
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fourth metal-binding domain from the pET32-WLN1-6 plasmid and inserting it into the
pET-32Xa/LIC vector; KOD Hotstart DNA Polymerase was used for the PCR
amplification.
All proteins were expressed using Rosetta™ 2(DE3) cells. LB media was used to
grow most of the cultures, since non-isotopically labeled protein was required for most
analyses. Proteins that were singly (15N ) or doubly (13C, 15N) labeled were prepared by
adding the appropriately labeled precursors to M9 minimal media.
Induction tests were performed to optimize the time and temperature for
production of the labeled proteins.

Based on these results, the expression of the

singly/doubly labeled proteins was done at 22°C for 14-16 hours while the expression of
the triply labeled protein was done for 24 hours at 22°C.
All of the protein constructs, regardless of their labeling, were purified using the
same chromatographic steps: HisPrep column, Desalting column, HisPrep column,
Superdex 75 pg or Superdex 200 pg, and Desalting column.

The proteins were

quantitated using either the BCA or Bradford assay and stored at either -20°C or -80°C
until needed.
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CHAPTER 4
THE BIOPHYSICAL CHARACTERIZATION OF THE WLN CONSTRUCTS

This chapter discusses the results of the biophysical analysis of the various WLN
constructs. The techniques used to characterize the constructs included high resolution
gel filtration, light scattering, circular dichroism, differential scanning calorimetry, and
nuclear magnetic resonance spectroscopy.

4.1

High Resolution Gel Filtration
High resolution gel filtration (HRGF) was used to determine the apparent

molecular weights of WLN1-2, WLN1-3 and WLN1-4. This technique was also used to
investigate a possible interaction between WLN1-3 and WLN4. A Superdex 75 HRGF
10/300 column, which fractionates proteins between 3-70 kD, was used for these
analyses.

Information on the operational parameters used with the column and the

experimental design of the interaction study can be found in Section 2.5.1.
WLN1-2, WLN1-3, and WLN1-4 were analyzed by HRGF to determine their
apparent molecular weights. A calibration curve was constructed by injecting a set of
globular protein standards onto the column and plotting the log of their molecular
weights against their partition coefficients, Kav (see Equation 2.1). Separate calibration
curves were done for WLN1-2 and WLN1-3/WLN1-4 because the constructs were
analyzed at different times, and the same protein standards were not available at both
times. Based on the calibration curves, the apparent molecular weights of the constructs
were calculated to be: 19,100 Daltons for WLN1-2, 35,500 Daltons for WLN1-3, and
46,800 Daltons for WLN1-4. These results are summarized in Table 4.1 and 4.2; the
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calibration curves are shown in Figures 4.1 and 4.2.

Table 4.1: Details of the calibration curve that was used to analyze WLN1-2. The
calculated molecular weight derived from the protein sequence is shown in parentheses;
the experimentally calculated molecular weight obtained by using the calibration curve is
shown in bold font. Ve was the average elution volume of at least two injections of the
protein, and Kav was the partition coefficient that was calculated using Equation 2.1.
Protein
Aprotinin
Cytochrome C
Ovalbumin
Albumin
Blue Dextran
WLN1-2
(16,958 Daltons)

Concentration
(mg/mL)
3
2
3
2.5
1

MW
(Daltons)
6,500
12,400
43,000
66,000
2,000,000

Log
MW
3.81
4.09
4.63
4.82
n/a

Ve (mL)
15.39
13.81
10.81
9.85
7.73

Kav
0.49
0.39
0.19
0.13
n/a

2.2

19,100

n/a

12.84

0.32

0.60
0.50
Kav

0.40
0.30
0.20
0.10
0.00
3.70

y = -0.3497x + 1.8177
R² = 0.9998
3.90

4.10

4.30

4.50

4.70

Log MW

Standards

WLN1-2

Linear (Standards)

Figure 4.1: Calibration curve for the data presented in Table 4.1.

112

4.90

Table 4.2: Details of the calibration curve that was used to analyze WLN1-3 and
WLN1-4. The calculated molecular weight derived from the protein sequence is shown
in parentheses; the experimentally calculated molecular weight obtained by using the
calibration curve is shown in bold. Ve was the average elution volume of at least two
injections of the protein, and Kav is the partition coefficient.

Kav

Protein
Aprotinin
Ribonuclease A
Carbonic
Anhydrase
Ovalbumin
BSA
Blue Dextran
WLN1-3
(29,382 Daltons)
WLN1-4
(39,783 Daltons)

0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
3.50

Concentration
(mg/mL)
3.0
3.0

MW
(Daltons)
6,500
13,700

Log MW
3.81
4.14

Ve (mL)
15.04
13.19

Kav
0.47
0.35

3.0
4.0
2.5
0.5

29,000
44,000
66,000
2,000,000

4.46
4.64
4.82
n/a

11.63
10.52
9.51
7.68

0.25
0.18
0.12
n/a

3.2

35,500

n/a

11.00

0.21

3.2

46,800

n/a

10.36

0.17

y = -0.3429x + 1.7721
R² = 0.9987

3.70

3.90

4.10
4.30
4.50
Log of MW (Daltons)

4.70

Calibration Standards

WLN1-3

WLN1-4

Linear (Calibration Standards)

Figure 4.2: Calibration curve for the data presented in Table 4.2.
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4.90

HRGF was used to characterize WLN1-6. Using a Superdex 200 HRGF 10/300
column, a lab colleague, Joshua Muia, determined that the apparent molecular weight of
this construct was ~134 kD; the actual size of the construct was 61.4 kD (1). The
substantial difference between the actual and apparent molecular weight were attributed
to WLN1-6 having a larger hydrodynamic radius (RH) than a globular protein with the
same molecular weight would have (see Section 4.2 for information on the
hydrodynamic radii of the constructs). As a consequence of its increased hydrodynamic
radius, WLN1-6 adopted a more ellipsoid than spherical shape and migrated through the
gel filtration column as a protein with a higher molecular weight would (2).
HRGF data illustrated that the addition of metal-binding domains to the Wilson
disease constructs resulted in decreased elution volumes, which indicated that the
constructs had higher apparent molecular weights and larger hydrodynamic radii than
what would be expected for globular proteins of similar molecular weights. This trend
became more pronounced as more domains were added. It is important to keep in mind
that HRGF reports only on the average state of the protein ensemble and not on the
conformational state of individual protein molecules. Therefore, as more metal-binding
domains were added, the average state of the protein increased.
WLN4 and WLN1-4 G333R were not analyzed by HRGF because the Superdex
75 HRGF 10/300 was unavailable for use after these constructs had been created and
purified.
HRGF was also used to investigate a potential interaction between WLN1-3 and
WLN4, as described in Section 2.5.1. Briefly, equimolar amounts of WLN1-3 and
WLN4 were incubated at room temperature for 24 hours. An aliquot was injected onto
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the Superdex 75 HRGF column after 1, 5, and 24 hours. If an interaction were occurring,
it would be expected that the new species would elute near 9.2 mL, the elution volume
for WLN1-4.
The chromatograms in Figure 4.3 do not show the presence of a species other
than WLN1-3 and WLN4. After 24 hours, a peak at 6.9 mL appeared. This peak eluted
below the void volume (7.7 mL) of the column and was attributed to aggregation of
WLN1-3, as the WLN1-3 peak at 10.1 mL decreased in absorbance. The elution profiles
of WLN1-3, WLN1-4, and WLN4 are shown for reference in Figure 4.4. The lack of an
observed interaction between WLN1-3 and WLN4 could have several causes. WLN1-3
and WLN4 may simply not interact, or interaction may require the linker region that is
between metal-binding domains 3 and 4, which neither the WLN1-3 nor the WLN4
construct possessed.
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35

Absorbance (mAU)

30
10.1 mL

25
20
15
6.9 mL

10

12.6 mL

5
0
-5

0

5

10

15

Volume (mL)
1 hr

5 hr

24 hr

Figure 4.3: HRGF interaction study between WLN1-3 and WLN4. Equal volumes of
the sample containing WLN1-3 and WLN4 were injected at the indicated times. As the
chromatograms show, there is no evidence of a species with an increased apparent
molecular weight at any of the time points. The peak at 6.9 mL in the 24 hour sample
elutes before the void volume of the column and is not considered evidence of an
interaction. That peak is likely due to the aggregation of WLN1-3, since its peak area
and height have decreased at 24 hours. Absorbance was monitored at 254 nm.
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35

Absorbance (mAU)

30
25
10.0 mL
9.2 mL

20
15
10

12.4 mL

5
0
-5

0

5

10

15

Volume (mL)
WLN4

WLN1-3

WLN1-4

Figure 4.4: Elution profiles of WLN1-3, WLN1-4, and WLN4 on the Superdex 75
HRGF column. Equimolar amounts of all proteins were injected. Absorbance was
monitored at 254 nm.

4.2

Light Scattering Analysis
WLN1-2, WLN1-3, and WLN1-4 were characterized by static (SLS) and dynamic

(DLS) light scattering at the Keck Biotechnology Resource Laboratory at Yale
University. The constructs were injected onto a high resolution gel filtration column that
was connected to an OPTILAB rEX Refractive Index Detector, a DAWN-HELEOS Light
Scattering Detector, and a Waters 996 Photodiode Array Detector. ASTRA software
(version 5.4.3.10) was used to calculate the weight-average molar mass and the
hydrodynamic radius (RH) of each construct. The Debye model was used for determining
the weight-average molar masses, and a dn/dc value of 0.175 mL/g was used in this
calculation, as this value was adequate for the analysis of the standard proteins analyzed
with the WLN constructs (3, 4). Figure 4.5 shows the molar mass distribution of WLN12; the trace indicated that there was only one apparent form of WLN1-2 present, i.e. the
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sample was monodisperse. Figure 4.6 shows the molar mass distribution for WLN1-3
and WLN1-4. While the trace for WLN1-4 indicated the presence of a monodisperse
sample, the trace for WLN1-3 indicated the presence of other proteins. Subsequent
analysis of another aliquot of WLN1-3 by SDS-PAGE revealed that the protein had
partially degraded (data not shown). These degraded proteins appeared as a trailing edge
at the back of the peak in the trace, as shown in Figure 4.6; this portion of the peak was
not used for calculating the molecular weight and RH.
The autocorrelation curves for WLN1-2, WLN1-3, and WLN1-4 are shown in
Figures 4.7, 4.8, and 4.9, respectively. Once the translational diffusion coefficient, D,
was determined, the hydrodynamic radius of each construct was calculated by solving the
Stokes-Einstein equation. The hydrodynamic radius is the radius that a hard sphere with
the same translational diffusion coefficient as the protein would have and indicates the
radius of the hydrated protein.
The molecular weights and hydrodynamic radii of the constructs are
summarized in Table 4.3.
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Figure 4.5: Molar mass distribution of WLN1-2 (red trace) injected onto a Superdex 75
HRGF 10/300 column. Trypsin inhibitor (pink trace) and bovine serum albumin (blue
trace) were run for comparative purposes; these globular proteins have molar masses of
20.0 kD and 66.4 kD, respectively. The solid lines denote the UV absorbance at 280 nm
while the dots denote the weight-average molar mass for each 1 second slice.
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Figure 4.6: Molar mass distribution of WLN1-3 (red trace) and WLN1-4 (green trace)
that were injected onto a Superdex 200 HRGF 10/300 column. The asymmetry of the
WLN1-3 peak indicated the presence of other association states and/or other proteins.
Subsequent analysis by SDS-PAGE revealed that the construct had partially degraded
(data not shown). Bovine serum albumin (blue trace), ovalbumin (brown trace) and
carbonic anhydrase (aqua trace) were run for comparative purposes; these globular
proteins have molar masses of 66.4 kD, 42.8 kD, and 29.0 kD, respectively. The solid
lines denote the UV absorbance at 280 nm while the dots denote the weight-average
molar mass for each 1 second slice.
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Figure 4.7: The autocorrelation function for WLN1-2. The translational diffusion
coefficient (D) was calculated as 1.13 ± 0.03 * 10-6 cm2/sec by ASTRA software.

Figure 4.8: The autocorrelation function for WLN1-3. The translational diffusion
coefficient (D) was calculated as 9.61 ± 0.53 * 10-7 cm2/sec by ASTRA software.
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Figure 4.9: The autocorrelation function for WLN1-4. The translational diffusion
coefficient (D) was calculated as 7.11 ± 0.24 * 10-7 cm2/sec by ASTRA software using.

Table 4.3: Summary of the biophysical parameters of the constructs that were
determined by light scattering. The actual MW refers to the MW that was calculated
from the protein sequence. The RH and ASTRA calculated MW were calculated from the
apex of one peak. *WLN1-6 eluted as a polydisperse sample, i.e. multiple peaks were
present. **Data is from the unpublished work of a lab colleague, Ibtesam Alja’afreh.
Construct

WLN1-2
WLN1-3
WLN1-4
WLN4
WLN1-6
WLN3-6

Actual
ASTRA
MW Calculated
(kD)
MW (kD)
16.9
17.0
29.3
29.8
39.7
40.9
7.6
7.6
61.4
66*
61.4
39.1

RH (nm)

Frictional
Ratio

Reference

2.16 ± 0.06
2.54 ± 0.14
3.43 ± 0.11
1.33 ± 0.07
4.09 ± 0.09
3.67 ± 0.12

1.24
1.24
1.50
1.02
1.72
1.63

This work
This work
This work
(5)
(1)
**
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The results summarized in Table 4.3 indicated that there was no difference
between the ASTRA calculated molecular weight and the sequence predicted molecular
weight for WLN1-2, WLN1-3, and WLN1-4. WLN4 was prepared and sent for light
scattering analysis by a lab colleague, Dr. Wilson Okumu (5). The results, also shown in
Table 4.3, indicate that the ASTRA calculated molecular weight and the actual molecular
weight are the same. In contrast to the monodisperse nature of the previous constructs,
WLN1-6 exhibited polydispersity. The ASTRA calculated molecular weight (of the apex
of the main peak) for WLN1-6 (prepared and submitted for analysis by a lab colleague,
Dr. Joshua Muia) was similar to the actual molecular weight (1). The hydrodynamic
radius of WLN1-6 was calculated to 4.09 ± 0.09 nm, which is greater than the 3.4 nm
hydrodynamic radius of bovine serum albumin, a globular protein with nearly the same
molecular weight (1).
The frictional ratio for each construct was calculated using the Dynamics 7
software supplied with the light scattering instrument. A frictional ratio of 1.0 denotes a
perfect sphere; the higher the ratio, the less spherical the protein. The cutoff of the
frictional ratio that describes spherical vs non-spherical proteins is not precisely defined,
but it is usually regarded to be 1.5. Based on this cut-off, the shape of WLN1-6 was
determined to be non-spherical while WLN1-4 was deemed spherical, though it is at the
border of the designation and displays more of a non-spherical shape than WLN1-3. As
the frictional ratios in Table 4.3 indicate, the more domains that were added, the less
spherical the construct became. For comparative purposes, the frictional coefficient for
the purely fibrous protein fibrinogen is 2.3 (6).
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4.3

Circular Dichroism
Stability of the WLN constructs was assessed by using circular dichroism to

monitor denaturation as a function of guanidine hydrochloride and temperature. Analysis
of the data revealed that the constructs have different degrees of stability despite having
the same ferredoxin fold (βαββαβ).

4.3.1

Guanidine Hydrochloride Denaturation
Guanidine hydrochloride was used to denature the protein constructs (apo forms

only) and assess their stability as described in Section 2.5.4. Briefly, a series of samples
(20-40, more samples were prepared for constructs that unfolded via a three-state
pathway) were prepared that contained a fixed protein concentration and a varying
concentration of guanidine hydrochloride.

After equilibrating the samples at room

temperature, a scanning wavelength spectra (200-250 nm) was collected. The CD signal
in mean residue ellipticity (θMRW) at 222 nm was plotted as a function of guanidine
hydrochloride concentration; these curves are shown in Figures 4.10-4.11. The resulting
sigmoidal or double sigmoidal curves were fitted to a two- or three-state model,
respectively, with IGOR Pro 6; these results are shown in the Table 4.4 (7).
WLN1-2 and WLN1-3 unfolded via an apparent two-state mechanism, and the
curves appeared very similar to each with a single, well-defined transition occurring
between ~1.5-3.5 M guanidine hydrochloride. In WLN1-2 there were larger fluctuations
in the CD signal between 0-2 M guanidine hydrochloride than there were for WLN1-3.
The Cm (the concentration of guanidine hydrochloride at which the protein is 50%
denatured) for both constructs was calculated to be 2.47 ± 0.03 M and 2.48 ± 0.03 M
guanidine hydrochloride for WLN1-2 and WLN1-3, respectively. The free energy of
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unfolding for WLN1-2 and WLN1-3 were 16.4 ± 1.4 kJ/mol and 15.2 ± 1.1 kJ/mol,
respectively. The presence of metal-binding domain 3 in WLN1-3 did not significantly
affect stability, as its free energy of unfolding and Cm are very similar to WLN1-2.
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Figure 4.10 A-D: Guanidine hydrochloride denaturation of WLN1-2, WLN1-3, WLN1-4, and WLN4, respectively. The CD signal at
222 nm is plotted.

Figure 4.11: Guanidine hydrochloride denaturation of the mutant WLN1-4 G333R. The
CD signal at 222 nm is plotted.

WLN4 also unfolded via an apparent two-state model and exhibited a single
unfolding transition that occurred between 5-7 M guanidine hydrochloride, with the Cm
calculated to be 5.71 ± 0.02 M guanidine hydrochloride. Prior to ~5 M guanidine
hydrochloride, there were only slight fluctuations in the curve, which emphasized the
extreme stability of the construct. The free energy of unfolding was calculated as 42.9 ±
2.8 kJ/mol.
In contrast to the constructs discussed so far, WLN1-4 had two distinct unfolding
transitions and therefore unfolded via an apparent 3-state model. The first transition
occurred at 2.32 ± 0.02 M guanidine hydrochloride, which is close to the Cm value of
2.48 ± 0.03 M guanidine hydrochloride that was obtained for WLN1-3. The second
transition of WLN1-4 occurred at 5.91 ± 0.1 M guanidine hydrochloride, which is similar
to the Cm value of 5.71 ± 0.02 M guanidine hydrochloride for WLN4.

The free energy

of the unfolding for the first transition was 16.5 ± 1.0 kJ/mol and 38.8 ± 7.2 kJ/mol for
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the second transition, which are similar to the values for WLN1-3 and WLN4,
respectively. Given similarity of the results of WLN-1-4 to those obtained for WLN1-3
and WLN4, WLN1-4 appears to unfold as a result of two independent events – the
unfolding of the first three metal-binding domains (i.e. WLN1-3) and the fourth metalbinding domain (i.e. WLN4).
WLN1-4 G333R, which possessed a mutation in the linker region between the
third and fourth metal-binding domains, unfolded similarly to WLN1-4. An apparent 3state unfolding was observed, with the Cm being 2.35 ± 0.02 M guanidine hydrochloride
and 5.72 ± 0.1 M guanidine hydrochloride for the first and second transitions,
respectively. The free energies of unfolding were 16.0 ± 1.0 kJ/mol and 34.3 ± 6.7
kJ/mol for the first and second transitions, respectively. Since the values for the mutant
are quite similar to the values of WLN1-4, this suggested that the mutation does not
greatly impact the stability. This is consistent with what Banci et al. reported for the
NMR solution structure of WLN3-4 - the disordered linker region between the two metalbinding domains allowed free rotation of the domains (8). A mutation in a disordered
region would not be expected to have a high impact on well-structured regions of a
protein.
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Table 4.4: The denaturation of the Wilson disease protein constructs by guanidine hydrochloride. ΔGH2O is the free energy of
unfolding in the absence of guanidine hydrochloride. m describes the amount of surface area of the protein that is exposed following
denaturation. Cm is the concentration of guanidine hydrochloride in which the protein is 50% denatured. For constructs that followed
a three-state unfolding pathway, the data in the “Second Transition” columns is for the intermediate to denatured portion of the
unfolding (ID) while the data in the previous three columns is for the protein as it moved from the native to intermediate state
(NI). In constructs without a second transition, no intermediate accumulated to appreciable levels and the protein went directly
from its native structure to a denatured form (ND). One curve (containing 20-40 points) was analyzed for each construct and the
standard deviation from the curve fitting is shown.
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Construct
WLN1-2
WLN1-3
WLN1-4
WLN4
WLN1-4 G333R

ΔGH2O
(kJ/mol)
16.4 ± 1.4
15.2 ± 1.1
16.5 ± 1.0
42.9 ± 2.8
16.0 ± 1.0

m1
(kJ/mol * M)
6.6 ± 0.5
6.1 ± 0.4
7.1 ± 0.4
7.5 ± 0.5
6.8 ± 0.4

Cm (M)
2.47 ± 0.03
2.48 ± 0.03
2.32 ± 0.02
5.71 ± 0.02
2.35 ± 0.02

ΔGH2O
(kJ/mol)
N/A
N/A
38.8 ± 7.2
N/A
34.3 ± 6.7

Second Transition
m1
(kJ/mol * M)
N/A
N/A
6.5 ± 1.3
N/A
6.0± 1.2

Cm (M)
N/A
N/A
5.91 ± 0.08
N/A
5.72 ± 0.10

The free energy of unfolding for most proteins is between 20-60 kJ/mol, which is
on the order of a few hydrogen bonds (9). The multi-domain constructs of WLN1-2 and
WLN1-3 were slightly lower than that.

This somewhat low stability may be a

consequence of the fact that these constructs are fragments of a protein and are not
naturally expressed on their own. Adding the fourth metal-binding domain increased the
complexity of the unfolding curve, but the first unfolding transition had a free energy of
unfolding and a Cm that were consistent with WLN1-3, which suggested that WLN1-2
and WLN1-3 may simply be slightly less stable intrinsically.
In contrast to WLN1-2 and WLN1-3, WLN4 displayed a much higher free energy
of unfolding and Cm. Indeed, the Cm of WLN4 is very close to the concentration of
guanidine hydrochloride that is typically used to denature proteins that have been
incorporated into inclusion bodies (10, 11).

Given that each metal-binding domain

possesses the same ferredoxin fold (βαββαβ), it is surprising that the stability of the
fourth metal-binding domain is so much greater than multi-domain constructs.

4.3.2

Thermal Denaturation
The thermal denaturation of apo- and some copper-loaded forms of the constructs

were performed as discussed in Section 2.5.4.

Briefly, 3-5 uM protein in 5 mM

phosphate buffer (pH 7.5) was placed in a 1 cm quartz cuvette that was inserted into a
Peltier device that was connected to a CD instrument. A thermal gradient of 2ºC/min was
used to heat the sample from 25ºC to 97ºC, and the CD signal was monitored at 222 nm;
these curves are shown in Figure 4.12. The melting temperature, Tm, was calculated
using the software supplied with the instrument; each construct was analyzed three times.
The results are shown in Table 4.5 below.
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Figure 4.12: Thermal unfolding curves for the WLN constructs. A representative curve
for each construct is shown.
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Table 4.5: Thermal unfolding of the apo-WLN constructs. The Tm shown is the average
of three trials, ± the standard deviation.
Construct

Tm (ºC)
59.5 ± 1.7

Reversibility
of Unfolding
No

WLN1-2

Comment
Protein precipitated

WLN1-3

58.3 ± 0.6

No

Protein precipitated

WLN4

78.3 ± 0.2

Yes

WLN1-4

No unfolding
transition

N/A

WLN1-4
G333R

No unfolding
transition

N/A

Refolding curve very similar to the
unfolding curve
Protein did not unfold – the minimal
wavelength of absorption changed and
the protein aggregated
Protein did not unfold – the minimal
wavelength of absorption changed and
the protein aggregated

WLN1-2 and WLN1-3 displayed similar melting temperatures and both
irreversibly precipitated after being heated. WLN4 demonstrated high thermal stability
and its melting temperature was 20ºC higher than that of the three domain construct
WLN1-3. Additionally, WLN4 did not precipitate after the thermal gradient and was
able to mostly refold as the reverse gradient was applied, as shown in Figures 4.13 and
4.14.
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Figure 4.13: The thermal unfolding of WLN4 (forward) and the renaturation of the
protein as it was cooled (reverse).

Figure 4.14: CD spectra of WLN4 that was collected prior to the application of the
thermal gradient (green line) and after the application of the reverse gradient, i.e. cooling
it (orange line); both spectra were collected at 25˚C. After being cooled, WLN4 was able
to regain 94.4% of the CD signal at 222 nm that it had at the beginning.

133

Neither WLN1-4 nor its G333R mutant displayed an apparent unfolding
transition. A fluctuation in the CD signal is observed at ~58ºC for both proteins, which
suggested a structural or association state perturbation. A scanning wavelength spectra
collected before and after the thermal gradient indicated that structural rearrangement had
taken place, as shown in Figure 4.15 below; though only the WLN1-4 curve is shown,
WLN1-4 G333R displayed the same wavelength shift. Prior to being heated, WLN1-4
had a MRE minimum at ~222 nm, a wavelength at which α-helices absorb. After the
gradient, however, the MRE at 222 nm increased while the MRE at ~209 nm, a
wavelength at which β-sheets absorb, decreased. Since the thermal denaturation was
monitored at 222 nm, this may explain the slight fluctuation in CD signal that occurred at
around 58ºC - this may have been the temperature at which the structural transition
occurred. After this temperature, the CD signal for WLN1-4 decreases slightly, which is
consistent with the loss of some of the α-helices. The CD signal for the mutant, WLN1-4
G333R, decreased slightly (data not shown).
To verify that the lack of an unfolding transition was in fact reflective of what
would occur in the intact amino terminal of the Wilson disease protein, a construct
comprised of all six metal-binding domains (WLN1-6) was expressed and purified.
When WLN1-6 was heated, there was no apparent melting temperature (see Figure A1 in
the Appendix). Additionally, the scanning wavelength spectra that were taken of the
protein before and after heating were the same as those observed for WLN1-4 and its
mutant (data not shown). Therefore, the thermal behavior of WLN1-4 was representative
of the intact amino terminus of the Wilson disease protein and was not an aberration that
was introduced by truncating this region.
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Figure 4.15: Scanning wavelength spectra of WLN1-4 were collected before and after
the application of the thermal gradient; both spectra were collected at 25ºC. The above
spectra show that the most negative ellipticity shifted from ~222 nm to ~211 nm
following exposure to heat. The mutant WLN1-4 G333R displayed the same wavelength
shift (data not shown).
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Figure 4.16: A chromatogram of WLN1-4 before and after the application of the
thermal gradient. The proteins were injected onto Superdex 200 HRGF column and
eluted using 50 mM sodium phosphate, pH 7.5 / 150 mM sodium chloride at a flow rate
of 0.5 mL/min. In the “Before” sample, WLN1-4 eluted at 19.1 mL while in the “After”
sample it eluted at 10.8 mL.

Another possibility for the lack of an apparent melting point for WLN1-4 and its
mutant is that the proteins are forming soluble aggregates after being heated, and that it
was these aggregates that were resistant to thermal unfolding. This hypothesis was
investigated by analyzing WLN1-4 on a Superdex 200 HRGF column after the protein
had undergone the thermal gradient. As shown in Figure 4.16 above, there was a marked
difference in the elution volume after the protein was heated relative to the elution
volume of the protein prior to being heated. After being heated, WLN1-4 eluted near the
void volume of the column (10.6 mL), which indicated that aggregation had occurred,
though no precipitation was visible to the eye. This is known as soluble aggregation.
WLN1-4 does not have an apparent melting temperature but it did undergo an
apparent structural rearrangement as it was heated. In an attempt to characterize the
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nature of the forces that were contributing to the stability of WLN1-4, sodium chloride
was used to see if the protein could be thermally unfolded. As shown in Figure 4.17, at
concentrations of 75 mM or higher, WLN1-4 did show an apparent melting temperature.
The Tm could not be calculated, however, because the CD signal had not leveled off after
the protein unfolded and before data collection ended at 98ºC.
To verify that an actual unfolding transition had occurred and the decrease in the
CD signal was not due to soluble aggregation, a scanning wavelength spectra was
collected before and after the gradient. As Figure 4.18 shows, the shape of the curve
after WLN1-4 was heated was the same as it was prior to being heated, though the MRE
increased as secondary structure was lost upon heating. The wavelength minima (222
nm) were the same in both curves, unlike when WLN1-4 was unfolded in the absence of
sodium chloride and the wavelength minimum shifted from 222 nm to 211 nm.
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Figure 4.17: The unfolding of WLN1-4 in the presence of various concentrations of
sodium chloride. The same conditions that were used in the previous thermal unfolding
experiments (i.e. thermal gradient, protein and buffer concentration) were used here. The
CD signal was monitored at 222 nm. No visible precipitation was observed after the
gradient.

Figure 4.18: WLN1-4 with 150 mM sodium chloride scanning wavelength spectra
before and after thermal denaturation.
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The ability of WLN1-4 to thermally unfold in the presence of low concentrations
of sodium chloride suggests that electrostatic contacts may play a role in stabilizing
WLN1-4. In this construct, 9.6% of the residues are acidic (aspartic acid and glutamic
acid) and 10.1% are basic (arginine, histidine, and lysine). It is possible that a salt
bridge(s) could be forming between an acidic and basic residue, thereby conferring
structural stability. Since neither an X-ray nor a NMR structure is yet known for WLN14 or WLN1-6, it is not possible to determine what residues in particular may be
interacting. A study by Nilsson et al. showed that the thermal stability of WLN5-6 was
decreased by 30ºC when NaCl was added, which demonstrated that electrostatic contacts
are important in that construct (12). Since the structure of all of the metal-binding
domains is conserved, there may also be electrostatic contacts present in WLN1-4.
Thermally denaturing copper loaded forms of the constructs proved to be
challenging, and it was not possible to obtain consistent melting temperatures. Whether a
single, copper-loaded protein sample was split into two and run successively on the CD,
or two different samples were processed in parallel, or the protein was metallated
immediately prior to unfolding, the melting temperatures varied. Additionally, WLN4
and WLN1-4 were the only constructs that could be consistently metallated; WLN1-2 and
WLN1-3 tended to precipitate upon the addition of copper.
The method used to titrate copper into the proteins differed from the procedure
used to anaerobically metallate the proteins that was outlined in Section 2.4.5.3. The
procedure was modified as discussed below.
An aliquot of WLN1-4 was reduced using TCEP (1 mM) and placed in a 1 cm
cuvette.

Sub-stoichiometric equivalents of copper were titrated in, and a scanning
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wavelength spectra was collected on the CD; see Figure 4.19. After 3.5 equivalents of
copper were added, the thermal gradient was applied. As with the apo-form of WLN1-4,
copper loaded WLN1-4 did not exhibit an apparent melting point; several runs confirmed
this. Additionally, the same spectroscopic shift that apo-WLN1-4 exhibited after being
heated was also present in copper loaded WLN1-4 (Figure 4.19).
WLN4 was titrated with copper in the same manner as WLN1-4 as discussed
above. Copper binding led to a increase in MRE, as shown below in Figure 4.20.
Thermal unfolding of copper-loaded protein was performed several times, but the results
were always inconsistent. This inconsistency may be due to metal induced aggregation
of WLN4.

Figure 4.19: The effect of copper(I) loading on the CD spectra of WLN1-4. The data
was collected at 25ºC using a 1 cm cuvette. The addition of copper results in a less
negative CD signal. This is due to the absorption of the copper-thiolate bonds that absorb
in this region and does not mean that the secondary structure of WLN1-4 is being
decreased. Upon heating, Cu(I)-WLN1-4 exhibited that same shift in minima that apoWLN1-4 did, indicating that soluble aggregation occurred.
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Figure 4.20: Titration of WLN4 with copper. Data was collected in at 25ºC using a 1
cm cuvette. The addition of copper results in a less negative CD signal. This is due to
the absorption of the copper-thiolate bonds that absorb in this region and does not mean
that the secondary structure of WLN4 is being decreased. Consistent unfolding
temperatures for Cu(I)-WLN4 could not be obtained.

The addition of copper to WLN1-4 and WLN4 resulted in an increase of the CD
signal, as indicated in the above figures. This change in CD signal is not due to a
decrease in secondary structure, however, as NMR experiments performed on constructs
of several the metal-binding domains have revealed. In the literature, the addition of
copper to WLN3-4 resulted in the shifting of resonances associated with several residues,
which are predominately within the loops of the metal-binding domains, but the α-helices
and β-sheets were unaffected (13). Additionally, the titration of copper into WLN5-6
revealed that the α-helices and β-sheets were not perturbed, though there were changes
in the copper binding loops (14).
The increase in CD signal observed in Figures 4.19-4.20 is likely due to the
asymmetric nature of the copper binding site once copper is bound. The copper binding
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site is chiral and able to absorb circularly polarized light. Since the CD signal that is
reported by the spectrometer is defined as the difference between the amount of lefthanded circularly polarized light minus the amount of right-handed circularly polarized
light, the increase in CD signal must be due to the copper-binding site absorbing more
right-handed circularly polarized light.
The increase in CD signal upon addition of copper that was observed for WLN1-4
and WLN4 is in contrast to what DiDonato et al. reported for the titration of a construct
comprised of all six metal-binding domains (15). In this study, the researchers found that
the addition of copper led to a more negative CD signal at wavelengths associated with
secondary structure motifs (i.e. 208 and 222 nm), and the authors interpreted this to mean
that the construct was becoming increasingly structured upon binding copper.

The

aforementioned NMR experiments (done after the study by DiDonato) indicated that the
domains did not undergo significant structural rearrangement upon copper binding
(13,14).
The most likely explanation for the discrepancy is that the absorption of CD light
by the copper-thiolate bonds in MBDs were not taken into consideration. As NMR
experiments have convincingly demonstrated that copper binding does not introduce
large scale conformational changes, the changes in CD signal that were observed by
DiDonato et al. must have another explanation. Another possible explanation is that the
the protein DiDonato et al. used for their study was primarily expressed in inclusion
bodies and had to be denatured and refolded prior to use. Perhaps after the protein was
refolded it did not exactly adopt the native conformation. This may have caused minor
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differences in the metal-binding sites that led to observable changes in the CD spectra
upon the addition of copper.

4.4

Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was performed on apo- and copper-

loaded WLN4 and apo-WLN1-4 in order to determine the melting points (Tm) of these
constructs. The analysis utilized a MicroCal VP-DSC (GE Healthcare) instrument and
occurred at the Biophysics Core at the University of Colorado-Denver Anschutz Medical
Campus. These constructs were analyzed by DSC because of difficulties that were
encountered when the thermal denaturation was monitored by CD.
When the thermal denaturation of copper-loaded WLN4 was analyzed by CD, the
melting temperature varied. Two samples that came from the same metallated sample
were run on successive days under the same experimental conditions (a thermal gradient
of 25-95°C, with a 2°C/min ramp rate was used). For one experiment, the melting point
was calculated as 74.5 ± 0.99°C; for the other experiment, it was calculated as 66.7 ±
0.4°C. The reason for this discrepancy was not conclusively determined. A melting
point of 74.5°C was consistent with the melting point of non-copper loaded WLN4 of
~78°C, which was reproducible. Consequently, DSC was used in an attempt to resolve
the ambiguity.
In the case of WLN1-4, this construct did not appear to thermally unfold at
temperatures up to 95°C. Since an aqueous buffer (phosphate) was used as a diluent and
the cuvette did not have a screw cap lid, higher temperatures could not be used without
boiling the sample and evaporating the water. This obstacle was alleviated by DSC
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because the sample cells were pressurized and the particular DSC instrument used here
could reach temperatures of up to 110°C.
An aliquot of WLN4 was loaded with copper according to the procedure outlined
in Section 2.4.5.3. ICP-AES was used to determine the copper content of all samples
prior to their submission for analysis. The copper content of the metallated WLN4 was
77.4% while the copper content of the non-metallated WLN4 was 1.4%. When analyzed
by DSC, the non-copper loaded WLN4 exhibited an endothermic peak in the thermogram
at 84.5°C and an exothermic peak at 107°C. The endothermic peak was expected and the
temperature at the apex of this peak represented the Tm of the protein; the exothermic
peak was attributed to protein aggregation; as no aggregation was visibly apparent when
the cuvette was examined post-run, the aggregation must have been soluble. In contrast,
no unfolding transition was observed for the copper-loaded WLN4, as neither an
endothermic nor an exothermic peak was produced.

No precipitation was visible after

the experiment, but soluble aggregates may have formed; if this were the case, then these
aggregates may have been resistant to thermal denaturation. The thermograms of noncopper and copper-loaded WLN4 are shown in Figures 4.21 and 4.22, respectively.
The melting temperature for apo-WLN1-4 could not be determined.

As the

endotherms in Figure 4.23 show, there was concentration dependent aggregation that
occurred at protein concentrations ≥ 0.5 mg/mL. One possible source of this aggregation
was the WLN1-4 was being partially denatured and the denatured proteins were
aggregating; if this were the case, then higher protein concentrations would produce
transitions at lower temperatures since more protein would be available to be denatured;
this was what was observed for apo-WLN1-4 (GE Healthcare, Differential Scanning
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Calorimetry: Theory and Practice, Technical Bulletin 28-9870-36 AA).

Lower

concentrations of apo-WLN1-4 (0.1 and 0.5 mg/mL) did not generate sufficient signal for
a transition to be observed.

Consequently, a melting temperature could not be

determined for apo-WLN1-4.

Figure 4.21: The thermogram showing the thermal denaturation of apoWLN4; the
temperature in ºC is shown on the x-axis, and the heat capacity (cal/ºC) is shown on the
y-axis. WLN4 (1 mg/mL) was loaded in the sample cell, and 50 mM sodium phosphate,
pH 7.5 was loaded into the reference cell. A thermal gradient from 20-110°C with a
1°C/min ramp rate was applied. The buffer thermogram was not subtracted from the
WLN4 thermogram because to the significant baseline difference between the two
baselines (buffer baseline not shown here). Consequently, the enthalpy of denaturation
could not be calculated. The significant difference between the two baselines was likely
due to incomplete buffer exchange of WLN4. No protein precipitation was observed
following the thermal gradient. Only one run of DSC was performed.
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Figure 4.22: The thermogram showing the thermal denaturation of copper-loaded
WLN4; the temperature in ºC is shown on the x-axis, and the heat capacity (cal/ºC) is
shown on the y-axis. Copper-loaded WLN4 (1 mg/mL) was loaded in the sample cell,
and 50 mM sodium phosphate, pH 7.5 was loaded into the reference cell. The same
thermal gradient described in the previous figure was used for this sample. As with the
non-metallated WLN4 sample, there was a significant difference between the
thermograms of the buffer blank and copper-loaded WLN4; this difference was attributed
to incomplete buffer exchange of WLN4 following metallation. The buffer thermogram
was not subtracted from the WLN4 thermogram for this reason. There was no unfolding
transition observed. No protein precipitation was observed following the thermal
gradient. Only one run of DSC was performed.
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Transition indicating aggregation

Temperature of aggregation changes with concentration

No aggregation at concentrations
<0.5mg/mL but not enough protein to give
sufficient signal

Figure 4.23: The thermogram of apo-WLN1-4. The temperature in ºC is shown on the
x-axis, and the heat capacity (cal/ºC) is shown on the y-axis. Various concentrations of
apo-WLN1-4 were loaded into the sample cell while 50 mM sodium phosphate, pH 7.5
was loaded into the reference cell. The same thermal gradient described in the previous
figures was used for this sample, but no melting point could be determined. At
concentrations high enough to yield a signal, the protein aggregated (≥ 0.5 mg/mL);
lower concentrations produced insufficient signal for analysis.

4.5

NMR

4.5.1

1

H-15N HSQCs of WLN1-2 and WLN1-4

1

H-15N HSQC spectra were collected on

13

C and

15

N isotopically enriched

samples of apoWLN1-2 and apoWLN1-4 using a Bruker AVANCE II 800 MHz NMR, as
discussed in Section 2.5.6. The spectra were overlaid and are shown below in Figure
4.24. Both proteins display well dispersed resonances, which is indicative of a folded,
non-aggregated protein.
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Figure 4.24: 1H-15N HSQC overlay of apoWLN1-2 (shown in red) and apoWLN1-4
(shown in blue). Both spectra display well dispersed resonances, indicative of a folded
protein. The intra-protein overlapping peaks between 7.9-8.5 ppm are found in regions of
proteins that are not in α-helices or β-sheets, i.e. the linkers and loops. WLN1-2
contained 157 residues and WLN1-4 contained 374 residues.

The overlaid spectra showed that many of the apoWLN1-2 resonances are either
on top of or very near to resonances in apoWLN1-4. This indicates that WLN1-2 has a
similar structure in WLN1-4 as it does when it is by itself.

The least amount of signal

overlap between the two spectra occurs in the lower left quadrant, from 8.7-10 ppm on
the x-axis and 123-134 ppm on the y-axis. The identity of these residues is not known
because the resonances were unable to be assigned for either WLN1-2 or WLN1-4.
However, resonances within this region are found in β-sheets. The shifting of resonances
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indicates that the residues involved in one (or more) β-sheet(s) change positions slightly
when WLN1-2 is expressed as part of WLN1-4.

4.5.2

1

H-15N HSQC of WLN4 at Different Temperatures

1

H-15N HSQC spectra were collected on

13

C and

15

N isotopically enriched

samples of apoWLN4 at 25˚C, 37˚C, and 50˚C using a Bruker AVANCE II 800 MHz
NMR, as discussed in Section 2.5.5. Two 3-dimensional experiments, the HNCACB and
the HN(CO)CACB, were collected at 37˚C. These experiments, which correlated the N
and HN of i with Cα and Cβ of i and i-1 and the Cα and Cβ of i-1, respectively, were
necessary to assign the resonances in the 1H-15N HSQC.
The 1H-15N HSQCs from 25˚C and 50˚C are overlaid in Figure 4.23. At both
temperatures, the resonances are well dispersed, indicating that the protein is folded and
not aggregated. The thermal stability of WLN4 that was observed by CD was verified by
the 1H-15N HSQC at 50˚C, which indicated no denaturation or aggregation. In fact, the
peak resolution was better at 50˚C than at 25˚C; this was due to the faster tumbling time
of the protein. The melting temperature of apoWLN4 that was calculated by using CD
was 78.3 ± 0.2˚C, and the unfolding curve (Figure 4.23) displayed little change in CD
signal below 60˚C. This NMR data further establishes the thermal stability of WLN4.
The 1H-15N HSQC at 37˚C is shown with the peak assignment in Figure 4.26; the
amino acid sequence of WLN4 is shown in Figure 2.5. Of the 74 amino acids in WLN4,
9 non-proline residues were unable to be located in the HSQC (there are two prolines in
the sequence: Pro50 and Pro55); the unassigned peaks were the first three amino acids
(Gly1, Thr2, and Cys3) and the loop containing the metal-binding loop (Cys15, Ala16,
Ser17, Cys18, Val19, and H20). The metal-binding loop, which contains Cys15 and
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Cys18, is flexible, and the residues in that region could not be assigned with the 3D
spectra that were collected. An enlarged view of the center of the spectra of Figure 4.26
is shown in Figure 4.27. A list of the 1H, 15N, and 13C resonances is in Table A1 in the
Appendix.
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Figure 4.25: 1H-15N HSQC of apoWLN4, recorded at 25˚C (red) and 50˚C (black). At both temperatures show sharp, well dispersed
resonances, indicative of a folded protein. At 50˚C, the resolution increased as the tumbling time increased, resulting less overlapping
peaks. Additionally, 50˚C WLN4 exhibited no signs of aggregation or denaturation. The thermal stability observed here is consistent
with the CD results indicated that the construct did not unfold until at mesophilic temperatures.
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Figure 4.26: 1H-15N HSQC of apoWLN4 with peak assignment.
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Figure 4.27: An enlarged view of a portion of Figure 4.26.

4.6

Summary
This chapter discussed the biophysical characterization of the WLN constructs

using HRGF, laser light scattering, circular dichroism, differential scanning calorimetry,
and NMR.
HRGF results indicated that the constructs were globular, as they eluted at
volumes consistent with their molecular weights. The hydrodynamic radii and frictional
ratios were calculated from light scattering experiments and confirmed the globular
nature of the constructs. As more domains were added to the constructs, the frictional
ratio increased and the constructs were no longer perfectly spherical, as was expected due
to the increasing size of the constructs.
The stability of the constructs was assessed by using guanidine hydrochloride and
thermal denaturation in conjunction with circular dichroism. The results revealed that
metal-binding domain four is highly resistant to denaturation by these methods, as it
retained 50% of its structure at 5.9 M GuHCl and at 78.3ºC. WLN1-2 and WLN1-3
displayed similar properties to each other, unfolding at 2.5 M GuHCl and ~55ºC. In
contrast to the other constructs, the GuHCl unfolding of WLN1-4 occurred via a threestate unfolding pathway; the first transition coincided with that of WLN1-3 and the
second transition coincided with that of WLN4.

Additionally, a thermal unfolding

transition was not observed for WLN1-4; instead, a structural rearrangement occurred
during heating which resulted in soluble aggregation. The addition of 150 mM NaCl to
WLN1-4 resulted in thermal denaturation, though the melting point could not be
calculated due to insufficient data points that could be collected after the unfolding
transition. The ability of WLN1-4 to thermally denature in the presence of NaCl suggests
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that electrostatic contacts are important in stabilizing this construct; as no structure for
the construct is available, these contacts cannot be determined. When copper was titrated
into the constructs, the MRE at 222 became less negative. As NMR experiments of
WLN3-4 and WLN5-6 have clearly established that no loss of secondary structure occurs
upon the addition of copper, there must be another explanation. One possibility is that the
change in CD signal is due to the introduction of a chiral site that created when copper
binds to the construct and this site absorbs circularly polarized light in the far-UV region;
if more right-handed circularly polarized light were absorbed, then this would explain the
decrease in the CD signal.
DSC was used to determine the melting temperatures of apo- and Cu(I)-WLN4,
and apo-WLN1-4. The melting temperature of apo-WLN4 was ~84.5ºC, similar to the
value that was calculated by using CD (77.9˚C).

Cu(I)-WLN4 did not display an

unfolding transition, and this may have been due to the presence of soluble aggregation;
the melting temperature for metallated constructs varied wildly when CD was used, and
that may have been due to soluble aggregation. No transition point was detected for apoWLN1-4 for temperatures up to 110ºC, though a small endothermic peak was visible; this
peak was probably the result of soluble aggregation.
1

H-15N HSQCs were collected for WLN1-2, WLN1-4, and WLN4. The spectrum

of WLN1-2 overlaid well with the spectrum of WLN1-4, indicating that in the context of
WLN1-4, WLN1-2 adopted largely the same structure as it did when it was expressed by
itself. This could suggest that WLN1-2 is not interacting with the third and fourth metalbinding domains in the absence of copper. Decreased signal overlap in the lower lefthand region in Figure 4.24 was observed, indicating that residues involved in β-sheets
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have slightly different positions in WLN1-2 and WLN1-4.

1

H-15N HSQCs collected at

25˚C and 50˚C revealed that WLN4 retained its structure at elevated temperatures and did
not aggregate, which corroborated the thermal stability that CD experiments indicated.
Triple resonance experiments collected at 37˚C permitted the assignment of 63 of the 74
amide resonances in the 1H-15N HSQC (collected at 37˚C).
This research revealed the unexpected chemical and thermal stability of WLN4.
One explanation of WLN4’s stability may be its hydrophobicity. As Table 4.6 below
shows, WLN4 is the most hydrophobic domain – it is nearly twice as hydrophobic as the
next most hydrophobic domain, WLN1. The large number hydrophobic forces likely
stabilize the domain and make it resilient to GuHCl denaturation as well as thermal
denaturation. Another biophysical parameter, the alipathic index, is also shown in the
table below. This value indicates the relative volume of the protein that is occupied by
alanine, isoleucine, leucine, and valine; larger values are correlated with higher
thermostability (16). The aliphatic index value for WLN4 was in the lower half of the
values of the six metal-binding domains, suggesting that it should be less thermostable.
WLN3 has the highest aliphatic index, suggesting that it should have the highest melting
point. In the context of WLN1-3, however, the presence of WLN3 did not result in a
higher melting point than that of WLN1-2, as both WLN1-2 and WLN1-3 unfolded at
nearly the same temperature (59.5˚C and 58.3˚C, respectively). WLN3 has a very low
hydropathic value of 0.077, indicating that it is only slightly hydrophobic.
Perhaps the hydrophobic nature of WLN4 also plays a role in its thermal stability.
Though WLN4 is the most hydrophobic, it is also the most acidic, with a theoretical pI of
3.93. There are 9 acidic residues, and many of these are clustered together on the surface
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to form a negatively charged patch (Figure 1.7). This patch, predicted to interact with a
basic patch on HAH1, helps to solubilize WLN4. The low pI greatly enhanced the
solubility of WLN4, and during this research, it was frequently concentrated to 1 mM
with no precipitation.

Table 4.6: Biophysical parameters of the metal-binding domains. These values were
computed by using the ProtParam tool on the ExPASy website
(http://web.expasy.org/protparam/). The metal-binding domains did not include either
the preceding or succeeding linker.
The GRAVY value (Grand Average of
Hydropathicity) is calculated by summing the hydropathicity values for all of the amino
acids using the Kyte-Doolittle scale; positive values are hydrophobic and negative values
are hydrophilic. The aliphatic index is the relative volume occupied by alanine,
isoleucine, leucine, and valine residues in a protein; a higher value is correlated with
greater thermostability.
Metal-binding domain

Theoretical pI

GRAVY

Aliphatic Index

1

7.86

0.338

100.00

2

8.71

-0.169

98.61

3

6.72

0.135

113.61

4

3.93

0.579

105.69

5

4.53

0.236

105.69

6

5.51

0.251

110.00

1-2

8.26

96.11

0.046

1-3

8.36

97.39

-0.074

1-4

5.81

92.22

-0.064

WLN4 does display thermal stability that is reminiscent of a protein from a
thermophilic organism while MBDs1-3 seem more mesophilic in origin. For example,
the melting temperature of Cold Shock Protein B (CspB) was determined for two
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different organisms - one was a mesophile, Bacillus subtilus, and the other was a
thermophile, Thermus thermophilus. Both proteins contained 67 amino acids, but the
melting temperature CspB from T. thermophilus was 86˚C while it was 54˚C from B.
subtilus (17).
A study that analyzed the sequences of mesophilic and thermophilic proteins
found that both classes of proteins have similar hydrophobicities and compactness;
additionally, both have similar polar and non-polar contributions to the surface area as
well as main chain and side chain hydrogen bonds (17). Thermophilic proteins had more
side chain – side chain bonds and salt bridges, however, and also contained more
arginines and tyrosines and fewer cysteines and serines (17).
To see if side chain–side chain bonds played a role in the thermal stability of
WLN4, the solution structures of WLN3 and WLN4 (the linker region was not included)
using PyMol and VMD (http://www.ks.uiuc.edu/Research/vmd/) to look for side chain side chain bonds and salt bridges, respectively. There is only a solution structure for
WLN3-4 (PDB ID 3ROP) and not for the domains 3 and 4 separately. The solution
structure of WLN3-4 was used to obtain the structures of domains 3 and 4 by themselves.
No striking differences between the two domains were observed. Additionally, WLN4
does not contain more arginines and tyrosines than other MBDs nor fewer cysteines and
serines, so the thermal stability cannot be rationalized that way.
The metallochaperone HAH1 also contains a ferredoxin fold and has had its
thermal and GuHCl stability reported in the literature. In one study, the melting
temperatures of apo and Cu(I)-HAH1 have been reported as 74˚C and 92˚C, respectively;
the unfolding of both apo- and Cu(I)-HAH1 was reversible (18). In that study, the
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samples contained 20 mM Tris, pH 7.5 and 150 µM DTT and the CD signal was
monitored at 220 nm. In another study the same authors reported that the thermal
stability of apo- and Cu(I)-HAH1 was 68˚C and 71˚C, respectively; the unfolding was
reversible (19). In the second study, the samples contained 20 mM Tris, pH 7.5 and 1
mM DTT; the CD signal was again monitored at 220 nm.

The difference in melting

temperatures may be due the formation of an intermoleclar disulfide bond at elevated
temperatures; a high [DTT] would prohibit the disulfide bond from forming, resulting in
a lower melting temperature.

These thermal unfolding conditions were similar to those

used in this dissertation project: the CD signal was monitored at 222 nm and the samples
were buffered at pH 7.5 with 5 mM phosphate. For the research reported in this
dissertation, DTT was not used. The GuHCl unfolding of both apo- and Cu(I)-HAH1
was reported to be two-state (19). The presence of Cu(I) increased the stability of HAH1,
with the Cm for apo and Cu(I) forms calculated as 1.8 ± 0.1 M and 2.3 ± 0.1 M,
respectively (20). The free energy of unfolding increased from 14.5 ± 0.6 kJ/mol to 16.7
± 0.7 kJ/mol in the apo- and Cu(I)- forms (19).
The sequence of HAH1 (see Figure 2.6) was also analyzed by ProtParam tool on
the ExPASy website (http://web.expasy.org/protparam/). The aliphatic index value was
87.54, the GRAVY value was -0.123, and the predicted pI is 6.70.. If the aliphatic index
is the primary basis for thermostability, then the expected melting temperature would be
quite low. Additionally, HAH1 displays a negative GRAVY value, indicating that it is
hydrophilic. This GRAVY value is in sharp contrast to the GRAVY value of WLN4,
which is 0.576 (hydrophobic). While both apo-HAH1 and apoWLN4 have the same
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ferredoxin fold, nearly the same melting temperatures and display reversible unfolding,
the domains have different biophysical characteristics.
Another copper containing human protein that displays high thermal stability is
copper-zinc superoxide dismutase (SOD1). When mature, SOD1 contains one atom each
of copper and zinc as well disulfide bond that dimerizes that makes a homodimer; in this
form, the melting point is >90˚C (20). When SOD1 lacks the both metal ions as well as
the disulfide bridge, it exists as a monomer and the melting temperature drops to 42˚C;
adding the disulfide bridge (without the metals) dimerizes SOD1 and increases the
melting temperature to ~52˚C (21). SOD1 does not contain a ferredoxin fold. Instead,
each subunit contains an eight-stranded, antiparallel, Greek-key-β-barrel motif as well as
several loops; one of the loops contains the metal-binding sites for both metal ions (22).
In SOD1, the high thermal stability is linked to the binding of the copper and zinc ions, as
in their absence SOD1 has a very low melting temperature. In contrast, both HAH1 and
WLN4 have high melting temperatures even in the absence of copper.
Sequence alignment of the six MBDs was performed used Clustal Omega
(https://www.ebi.ac.uk/Tools/msa/clustalw2/) and appears in Figure 4.28. WLN4 does
not appear to possess any readily apparent differences in amino acid sequence that would
explain why this domain has such high stability. Discounting the highly conserved
metal-binding region (residues 10-16 in the figure), there are 9 residues that are fully
conserved among all six MBDs. Additionally, another 12 residues have highly similar
properties (e.g. bulky, hydrophobic amino acids like valine or isoleucine appear in all
MBDs at position 8) while an additional 4 residues have weakly similar properties (e.g. a
small hydrophobic residue like alanine or a bulkier β-branched amino like valine appears
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in position 67 in all MBDs.)

Of the 72 amino acids that appear in the sequence

alignment, 16 are fully conserved, 12 are strongly conserved, and 4 are weakly
conserved; this amounts to 32 residues or 44.4% of the amino acids in the MBDs. The
remaining 40 amino acids are not conserved among the MBDs.
The research presented in this dissertation regarding the stability of WLN4 has
not appeared in the literature. While the extreme conditions that this domain can tolerate
do not exist the cell, the remarkable stability that WLN4 possesses may play a role in its
ability to function as a primary site of copper acquisition.

4.7

Future Work
The research presented in this dissertation revealed the remarkable chemical and

thermal stability of WLN4. This surprising stability exists both when WLN4 is expressed
by itself and when it is expressed as part of WLN1-4, which suggests that the stability is
important for the function of WLN4 within the N-terminal metal-binding domain.
To continue investigations in this area, there are several avenues of research that
could be considered. One avenue would be to examine the effect of copper binding on
the stability of WLN4. Another avenue would be to confirm the chemical and thermal
stability of the copper metallochaperone HAH1, since previous studies gave conflicting
data (18,19). As WLN4 is one of the preferred sites of copper acquisition from HAH1, it
would be interesting to see if HAH1 possesses the same stability. A third avenue of
research would be to determine either a NMR solution structure or X-ray crystal structure
for WLN1-4. A complete structural description of WLN1-4 provide insight into how the
metal-binding domains are arranged and would aid in understanding their role in WLNP.
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Figure 4.28: Sequence alignment of the 6 MBDs. The sequences were aligned using Clustal Omega. Amino acids are color coded as
follows: red – small and hydrophobic (AVFPMILW), blue – acidic (DE), magenta – basic (RK), Green – hydroxyl, sulfhydryl, amino,
and glycine (STYHCNGQ). The symbols below the line denote consensus, with “*” denoting a fully conserved residue, “:” denoting
conservation between residues with very similar properties, and “.” denoting conservation between groups with weakly similar
properties. A dash represents a gap in the sequence. The same sequences that were analyzed for Table 4.6 were aligned here.
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CHAPTER 5
THE EFFECTS OF PH AND HG(II) BINDING ON THE ASSOCIATION STATE
OF HAH1

This chapter discusses the HRGF study that was done in order to determine the
effect of pH and Hg(II) binding on the association state of the copper metallochaperone
HAH1.

The study was performed as part of a collaboration with Professor Vincent

Pecoraro and his group at the University of Michigan and included
199m

Hg PAC experiments.

199

Hg NMR and

The goal of the study was to better characterize the

coordination environment of Hg(II) in HAH1 as a function of pH.

Seeing the

coordination environment at both physiologically relevant and more extreme pHs would
enable a better understanding of the coordination states that are available to Hg(II), a
model for Cu(I), and may suggest a mechanism by which copper can be transferred from
HAH1 to other proteins (or may suggest intermediates that are formed when Cu(I) is
transferred from HAH1 to WLN or MNK).

5.1

Introduction
HAH1 is a small, single domain metallochaperone that possesses a ferredoxin fold

and can ligate a single atom of Cu(I) via two cysteines that are located in a solvent
exposed loop (1, 2). This protein, also known as Atox1, delivers cytosolic copper to the
trans-Golgi network for incorporation into cuproproteins such as ceruloplasmin. HAH1
delivers the copper to a membrane-embedded ATPase that pumps the copper across the
membrane into the interior of the trans-Golgi network. There are two ATPases that
accept the copper, each being expressed in different locations: in liver cells, the ATPase
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is Wilson disease protein while the ATPase in other tissues is Menkes protein (also
known as ATP7A).
Experimental evidence has shown that the transfer of copper from HAH1 to both
the Wilson disease protein and the Menkes protein involves the formation of a
heterodimer in which the copper is ligated by both HAH1 and one of the metal-binding
domains of the target protein (2–4). The nature of the intermediate that is formed during
copper transfer is not well characterized. The intermediate could be a two-, three-, or
four-coordinate structure, as each metal-binding domain and HAH1 possesses two
cysteines in the metal-binding loop.

Computation analysis suggests that a three-

coordinate intermediate is most energetically favored, with two three-coordinate
intermediates occurring during copper transfer (5). In this scheme, two ligands initially
come from HAH1 and one from the metal-binding domain; in the second of the
intermediates, two ligands come from the metal-binding domain and one comes from
HAH1.
The NMR solution structures of apo- and Cu(I)-HAH1 have been solved and the
structures indicate that the copper is ligated by two cysteines from a single molecule of
HAH1 and that no homodimers were detected (1). It seems probable that a higher order
intermediate would be formed, however, as the copper is transferred.
Crystal structures for HAH1 complexed with Cd(II), Hg(II) or Cu(I) have been
determined (2).

In these crystals, HAH1 formed a three-coordinate homodimeric

complex in the presence of Hg(II) and a 4-coordinate homodimeric complex in the
presence of Cd(II). The Cu(I)-HAH1 crystals were also homodimeric as well, with the
Cu(I) found in either a 3- or 4-coordinate state; the resolution could not unambiguously
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determine whether or not a fourth ligand was present, though if it were it would be close
to the limit of known copper-sulfur bond lengths. The presence of the higher coordinated
copper center in the crystals provides evidence that such a coordination state is possible.
Such a state may only be an artifact of the crystal packing, however, and not necessarily
indicative of a physiologically relevant state. The quest for experimental evidence of a
higher coordinated intermediate state was the impetus for this study.
To study the coordination of metals in proteins in a simplified system, Pecoraro
and his group have designed a metallopeptide that contains a metal-binding site in the
interior of an α-helical coiled coil (6). In the presence of Hg(II), the metallopeptides selfassemble into dimers and trimers. Each metallopeptide contributes one metal-binding
site to coordinate the Hg(II) atom in the hydrophobic interior of the coil. Physiological
pH favors a two-coordinate dimer while a pH of 8.5 favors the formation of a 3coordintate trimer. Variations of the peptide have been used to study the coordination
states and binding geometries of Cd(II) and As(III), as well as to further study Hg(II) (7,
8).
Both Cu(I) and Hg(II) are soft acids and have

similar preferences for

coordination geometries. Since Hg(II) will bind to HAH1 and there is an isotope of
Hg(II),
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Hg that is amenable to techniques such as NMR and perturbed angular

correlation (PAC), Hg(II) was used as a model for Cu(I) to investigate the possible
coordinate environments that could exist for Cu(I). Using Hg(II) as a model was further
validated by the fact the yeast Atx(I) can transfer Hg(II) to the Ccc2, the yeast homologue
of Wilson disease protein; this suggests that Hg(II) and Cu(I) are transported by similar
mechanisms and may form similar intermediates during copper transfer (9).
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5.2

Analytical Gel Filtration
Analytical gel filtration experiments were done to determine how pH and Hg(II)

changed the association state of HAH1, which was expressed and purified as discussed in
Section 2.4.5.4. The procedure outlined below was developed by Dr. Brian Zeider
during the course of his PhD dissertation (10).
A Superdex 75 16/600 column was equilibrated with 1 CV (120 mL) of buffer
using a flow rate of 1.0 mL/min. Three buffers were used: 100 mM sodium phosphate
(pH 7.5), 100 mM sodium phosphate (pH 8.5), and 100 mM CHES (pH 9.4); each buffer
also contained 200 mM NaCl and 1 mM TCEP (to prevent the oxidation of cysteines at
elevated pHs); DTT was not used because it is a ligand for Hg(II). As the gel filtration
experiments were run at 4ºC, the buffers were prepared at room temperature such that
they would have the desired pH at 4ºC. Hg(II)-HAH1 samples were freshly prepared by
adding 0.5 equivalents of Hg(II) (from HgCl2) to HAH1 that was in the desired buffer.
Duplicate injections of apo- and Hg(II)-HAH1 as well as the protein standards were
analyzed for each buffer. The elution volumes, taken at the peak apex, were determined
by using the Unicorn Software that was supplied with the ӒKTA FPLC and are shown in
Tables 5.1-5.3 below.
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Table 5.1: Table of protein standards and HAH1 elution volumes at pH 7.5.
Protein
MW (Daltons)
Log MW
Aprotinin
6,500
3.81
Ribonuclease A
13,700
4.14
Carbonic
Anhydrase
29,000
4.46
Ovalbumin
43,000
4.63
Apo-HAH1
9,500*
N/A
Hg(II)-HAH1
9,700*
N/A
*The MW that was calculated from the standard curve. The
Hg(II)-HAH1 are 7,341 and 7,351 Daltons, respectively.

Ve
91.43
78.94

Kav
0.62
0.45

65.56
0.27
57.64
0.16
85.30
0.53
84.65
0.53
actual MW for apo- and

Table 5.2: Table of protein standards and HAH1 elution volumes at pH 8.5.
Protein
MW (Daltons)
Log MW
Aprotinin
6,500
3.81
Ribonuclease A
13,700
4.14
Carbonic
Anhydrase
29,000
4.46
Ovalbumin
43,000
4.63
Apo-HAH1
9,500*
N/A
Hg(II)-HAH1
10,500*
N/A
*The MW that was calculated from the standard curve. The
Hg(II)-HAH1 are 7,341 and 7,351 Daltons, respectively.

Ve
91.48
78.79

Kav
0.62
0.45

65.72
0.27
57.52
0.16
84.94
0.53
83.15
0.51
actual MW for apo- and

Table 5.3: Table of protein standards and HAH1 elution volumes at pH 9.4.
Protein
MW (Daltons)
Log MW
Aprotinin
6,500
3.81
Ribonuclease A
13,700
4.14
Carbonic
Anhydrase
29,000
4.46
Ovalbumin
43,000
4.63
Apo-HAH1
8,400*
N/A
Hg(II)-HAH1
11,500*
N/A
*The MW that was calculated from the standard curve. The
Hg(II)-HAH1 are 7,341 and 7,351 Daltons, respectively.
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Ve
90.29
78.32

Kav
0.60
0.44

67.34
0.29
59.39
0.19
84.94
0.53
83.15
0.51
actual MW for apo- and

Figure 5.1: Chromatograms of apo-HAH1 at various pHs (11). Equal amounts of each
sample were injected onto a Superdex 75 16/600 column and eluted using an isocratic
gradient. Apo-HAH1 was a monomer at pHs 7.5 and 8.5, though the mass of the protein
decreased slightly at pH 9.4; this decrease may be due to the protein adopting a molten
globule structure. Figure used by permission of John Wiley and Sons.

Figure 5.2: Chromatograms of Hg(II)-HAH1 at various pHs (11). Equal amounts of
each sample (the same amounts as used in Figure 5.1) were injected onto a Superdex 75
16/600 column and eluted using an isocratic gradient. As the pH increases, the apparent
mass of Hg(II)-HAH1 increases, as evidenced by smaller elution volumes. The shoulder
at ~85 mL at pH 9.4 was likely apo-HAH1, as that was the elution volume for the protein
at this pH. Figure used by permission of John Wiley and Sons.
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As the chromatograms in Figure 5.1 show, apo-HAH1 existed as a monomer at
pHs 7.5 and 8.5. At pH 9.4 there was a slight decrease in the apparent molecular weight
and an increase in A254. The decrease in molecular weight may be due to HAH1 adopting
a molten globule structure at this pH. CD confirmed that there were no significant
alterations to the secondary structure in the far-UV region (see A2 in the Appendix).
This was consistent with the presence of a molten globule, which possesses the correct
secondary structure but lacks the correct tertiary structure and appropriate side chain
packing of the properly folded protein. The increase in A254 may be explained by the
partial deprotonation of the two tyrosine residues (12). The pKa for the side chain of the
free amino acid in solution is 10.4, and at a pH of 9.4, the side chain would be 9%
deprotonated, assuming that the pkas were not significantly altered by an extreme
microenvironment in HAH1.
In the presence of Hg(II), HAH1 began to dimerize as the pH increased; this is
shown in Figure 5.2. This behavior is in contrast to what occurred for apo-HAH1, which
remained monomeric at each pH tested. The apparent molecular weights are summarized
in Table 5.4. While equal amounts of protein was injected for all of the apo- and Hg(II)
runs, the signal intensity increased in the Hg(II) samples due to ligand-to-metal charge
transfer.
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Table 5.4: Summary of the masses of apo- and Hg(II)-HAH1 at various pHs. As the pH
increases, HAH1 begins to dimerize in the presence of Hg(II).
pH
7.5
8.5
9.4

Apo-HAH1
9,500 Da
9,500 Da
8,400 Da

Hg(II)-HAH1
9,700 Da
10,500 Da
11,500 Da

Actual MW

7,341 Da

7,541 Da

While these gel filtration studies provided evidence for a dimeric association state
for HAH1 in the presence of Hg(II), information regarding the nature of the coordination
state could not be deduced.

To investigate the coordination states,

199

Hg NMR and

199m

Hg PAC experiments were performed.

5.3

Discussion
Analytical gel filtration results showed that in the presence of Hg(II), HAH1

began to dimerize as the pH increased. Investigation of the coordination states of the
Hg(II) at the various pHs was carried out using 199Hg NMR and 199mHg PAC (11).
The

199

Hg NMR spectra shown in Figure 5.3 has a single signal at -819 ppm for

the pH 7.5 sample (10, 11). This is consistent with the chemical shift of -821 ppm that
O’Halloran’s group observed for a 2-coordinate Hg(II) thiolate species of Cu(I)-Atx1, the
yeast homologue of HAH1 (13). At pH 8.5, two signals appear – one at -806 ppm and
the other at -348 ppm. The former signal was still consistent with a HgS2 species. The
signal at -348 ppm could be two possible structures - either a T-shaped 3-coordinate HgS3
species or a 4-coordinate HgS4 species (13–15). At pH 9.4, the signal at ~800 ppm
disappeared, leaving only the signal at -348 nm. From the NMR experiments it was
concluded that at physiological pH a 2-coordinate HgS2 species was present; as the pH
increased, the concentration of this species decreased and a species that was either 3- or
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4- coordinate appeared. Since NMR could not be used to distinguish between the 3- and
4-coordinate structures, 199mHg PAC was used.

Figure 5.3: 199Hg NMR of Hg(II)-HAH1 at various pHs (11). The signal at -819 ppm is
consistent with a 2-coordinate Hg(II) thiolate species while the signal at -348 ppm could
be attributed to either a T-shaped 3-coordinate HgS3 species or a 4-coordinate HgS4
species (11). Figure used by permission of John Wiley and Sons.

The

199m

Hg PAC data is shown below in Figure 5.4. At physiological pH (solid

line), the peak labeled with the down arrow dominated the spectra and was consistent
with HgS2 (16). As the pH was increased to 8.5 (dashed line), the amplitude of that peak
decreased by one third and a new peak, labeled with the up arrow, began to emerge; this
new peak was consistent with a distorted HgS4 structure (17) . Increasing the pH to 9.4
further reduced the amplitude of the signal for the HgS2 species while the amplitude for
the distorted HgS4 increased.

The signal complexity increased at pH 9.4, which

complicated the analysis since there were several satisfactory models that could fit the
data; one of the models that fit best was a T-shaped HgS3 species. It was concluded that
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at pH 9.4 an equilibrium of several species was present, including HgS2, a distorted HgS4
structure, and possibly a T-shaped HgS3 species.
The

199

Hg NMR data indicated only a single peak in the spectra, which

corresponded to either a 3- or 4-coordinate species while the 199mHg PAC data was more
complex and indicated a the presence of multiple species. The authors pointed out that
this may be due to the exchange rate of the species relative to the time scale of the
technique. NMR operates on the millisecond time scale, and an exchange rate that is
faster than this will produce only one peak in the spectra. In contrast, PAC operates on a
faster time scale: microseconds-nanoseconds (µs-ns).

Since there was a mixture of

higher coordinate species present at pH 9.4 in the PAC experiments but not the NMR
experiment, the exchange rate for the speciation must be on the µs-ns timescale.

Figure 5.4: 199mHg PAC results for HAH. The solid line is at pH 7.5, the dashed line is
at pH 8.5, and the dotted line is at pH 9.4. The down arrow denotes a species consistent
with HgS2 while the up arrow denotes species that are consistent with a distorted HgS4
structure (11). Figure used by permission of John Wiley and Sons.
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5.4

Conclusion
These experiments gave insight into the association and coordinate states Hg(II)-

HAH1.

Analytical gel filtration experiments showed that Hg(II)-HAH1 began to

dimerize as the pH increased while apo-HAH1 remained monomeric.

199

Hg NMR

revealed the presence of a 2-coordinate HgS2 species at physiological pH, a combination
of 2-coordinate and 3- and/or 4-coordinate species at pH 8.5, and only a 3- and/or 4coordinate species at pH 9.4.

199m

Hg data confirmed the presence of a 2-coordinate HgS2

species at pH 7.5 while at pH 8.5 there was a 2-coordinate HgS2 species and a distorted
HgS4 species. The signal at pH 9.4 was more complex and could not be unambiguously
deconvoluted. What was apparent, however, was that multiple species were present. The
models that best fit the spectra are a T-shaped HgS3 species and a distorted HgS4 species.
The presence of multiple species in the PAC data and only a single signal in the NMR
spectra provided information regarding the exchange rate of the complex. The exchange
rate had to be faster than the NMR timescale (ms) since only one peak was seen in that
spectra, but slower than the PAC timescale (µs-ns) since multiple peaks were observed.
Overall, the experiments showed that higher coordination states could be achieved for
mercury-thiolate compounds, some of which may mimic the intermediates that are
formed during copper transfer from HAH1 to the metal-binding domains of Wilson
disease proteins and Menkes protein.
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APPENDIX

Figure A.1: Thermal unfolding of WLN1-6. The data is plotted at 222 nm. As with
WLN1-4, no discernible unfolding transition is observed for WLN1-6. Additionally, the
slight decrease in CD signal is likely due to the same structural rearrangement was
observed with WLN1-4 that resulted in the formation of soluble aggregates. Gel
filtration experiments were not done with WLN1-6 to confirm this, however.
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Figure A.2: CD spectra of HAH1 at pH 9.4. Data was collected at 4˚C in a 1 mm
cuvette. HAH1 maintained its secondary structure after 24 hours at pH 9.4. Adding
Hg(II) did not immediately produce significant changes in the region of 200-250 nm,
though after 24 hours the signal became less negative in this area.
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Figure A.3: CD spectra of HAH1 at pH 8.5. Data was collected at 4˚C in a 1 mm
cuvette.
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Table A.1: 1H, 15N, and 13C resonance assignments for apoWLN4 at 37˚C.
Residue
G1
T2
C3
S4
T5
T6
L7
I8
A9
I10
A11
G12
M13
T14
C15
A16
S17
C18
V19
H20
S21
I22
E23
G24
M25
I26
S27
Q28
L29
E30
G31
V32
Q33
Q34
I35
S36
V37

HN

N

CA

CB

8.657
8.438
9.260
8.172
9.174
9.377
8.509
9.291
8.517
8.767
9.158

120.172
116.047
122.985
129.923
125.235
131.610
122.610
131.610
107.487
119.985
113.988

57.536
61.366
60.076
53.587
59.255
51.672
60.663
50.968
45.261
56.988
62.079

65.510
71.061
69.849
45.143
41.742
19.225
41.039
20.945

8.282
8.047
8.650
8.368
7.687
8.462
7.899
7.015
7.554
8.579
8.595
7.742
9.205
7.891
8.790
8.319
9.894

116.422
122.797
117.36
106.109
119.61
118.86
110.797
116.422
121.297
125.235
109.859
121.110
128.423
116.422
121.11
120.41
129.548

61.836
66.058
60.467
47.059
58.161
61.523
61.523
55.542
54.877
58.004
45.105
64.181
56.597
55.777
58.395
56.128
61.288
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34.315
71.407

62.657
38.693
29.428
32.752
35.097
63.165
29.624
41.352
28.998
31.735
29.936
32.869
40.257
64.963
32.360

Table A.1—Continued
Residue
S38
L39
A40
E41
G42
T43
A44
T45
V46
L47
Y48
N49
P50
A51
V52
I53
S54
P55
E56
E57
L58
R59
A60
A61
I62
E63
D64
M65
G66
F67
E68
A69
S70
V71
V72
S73
E74

HN
8.877
8.915
8.392
7.711
8.024
7.468
9.674
8.822
9.158
9.072
9.362
8.939

N
120.922
131.223
119.435
112.297
109.672
106.859
122.235
119.985
127.673
130.485
123.735
119.047

CA
54.955
57.848
54.916
56.128
46.825
58.943
50.186
62.383
60.898
54.095
55.229
49.013

CB
63.477
41.899
18.561
30.562

7.961
7.922
8.321
7.554

119.985
115.86
121.297
116.61

53.157
62.618
60.311
55.190

18.834
35.332
42.329
65.979

8.298
7.594
7.578
8.431
8.337
7.703
7.570
8.384
8.431
7.617
8.133
6.905
8.024
9.041
8.759
9.111
8.947
8.141
8.235

115.297
119.422
121.11
119.235
120.36
120.36
118.86
122.047
120.735
116.235
105.359
118.485
119.985
127.673
114.735
126.173
128.985
117.922
128.61

58.865
59.332
57.927
59.881
54.955
54.902
65.589
58.982
56.793

28.451
30.250
42.212
29.311
18.053
17.842
38.146
29.272
40.843
33.690
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44.714
56.832
56.011
50.655
56.91
64.259
63.165
57.966

73.563
22.118
69.576
33.846
43.384
41.547
39.162

41.273
30.718
23.134
65.745
31.969
64.611
31.422

Figure A.4: Project approval certification.
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Figure A.5: Permission from John Wiley for use of Figures 5.1 – 5.4.
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Figure A.6: Permission from Nature Publishing Group for use of Figure 1.4.
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Figure A.7: Permission from Springer for use of Figure 1.7.
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